Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Neoplasms of the CNS

  Free Subscription


Articles published in J Neurooncol

Retrieve available abstracts of 932 articles:
HTML format



Single Articles


    May 2024
  1. COVELL MM, Roy JM, Gupta N, Raihane AS, et al
    Frailty in intracranial meningioma resection: the risk analysis index demonstrates strong discrimination for predicting non-home discharge and in-hospital mortality.
    J Neurooncol. 2024 May 7. doi: 10.1007/s11060-024-04703.
    PubMed     Abstract available


  2. OTTENHAUSEN M, Renovanz M, Bartz I, Poplawski A, et al
    Use of complementary therapies and supportive measures of patients with intracranial gliomas-a prospective evaluation in an outpatient clinic.
    J Neurooncol. 2024 May 6. doi: 10.1007/s11060-024-04696.
    PubMed     Abstract available


  3. SHIN I, Sim Y, Choi SH, Park YW, et al
    Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas.
    J Neurooncol. 2024 May 3. doi: 10.1007/s11060-024-04656.
    PubMed     Abstract available


  4. BAQRI W, Rzadki K, Habbous S, Das S, et al
    Treatment, healthcare utilization and outcomes in patients with glioblastoma in Ontario: a 10-year cohort study.
    J Neurooncol. 2024 May 3. doi: 10.1007/s11060-024-04690.
    PubMed     Abstract available


    April 2024
  5. LI G, Tian Q, Wang S, Li K, et al
    Superficial meningioma with bone involvement: surgical strategies and clinical outcomes.
    J Neurooncol. 2024 Apr 30. doi: 10.1007/s11060-024-04604.
    PubMed     Abstract available


  6. BASREE MM, Li C, Um H, Bui AH, et al
    Leveraging radiomics and machine learning to differentiate radiation necrosis from recurrence in patients with brain metastases.
    J Neurooncol. 2024 Apr 30. doi: 10.1007/s11060-024-04669.
    PubMed     Abstract available


  7. DORON O, Wong T, Ablyazova F, Singha S, et al
    Results from a first-in-human phase i safety trial to evaluate the use of a vascularized pericranial/temporoparietal fascial flap to line the resection cavity following resection of newly diagnosed glioblastoma.
    J Neurooncol. 2024 Apr 26. doi: 10.1007/s11060-024-04647.
    PubMed     Abstract available


  8. WANG S, Zhang D, Wang J, Peng X, et al
    PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor.
    J Neurooncol. 2024 Apr 25. doi: 10.1007/s11060-024-04655.
    PubMed     Abstract available


  9. PARKER M, Kazemi F, Ahmed AK, Kuo CC, et al
    Exploring the impact of primary care utilization and health information exchange upon treatment patterns and clinical outcomes of glioblastoma patients.
    J Neurooncol. 2024 Apr 25. doi: 10.1007/s11060-024-04677.
    PubMed     Abstract available


  10. JOST J, Volker K, Brandt R, Stummer W, et al
    Correction to: Maximal cardiopulmonary exercise testing in glioblastoma patients undergoing chemotherapy: assessment of feasibility, safety, and physical fitness status.
    J Neurooncol. 2024 Apr 24. doi: 10.1007/s11060-024-04686.
    PubMed    


  11. MAIURI F, Corvino S, Corazzelli G, Del Basso De Caro M, et al
    Single versus multiple reoperations for recurrent intracranial meningiomas.
    J Neurooncol. 2024 Apr 24. doi: 10.1007/s11060-024-04673.
    PubMed     Abstract available


  12. OKAMOTO T, Mizuta R, Takahashi Y, Otani Y, et al
    Genomic landscape of glioblastoma without IDH somatic mutation in 42 cases: a comprehensive analysis using RNA sequencing data.
    J Neurooncol. 2024 Apr 23. doi: 10.1007/s11060-024-04628.
    PubMed     Abstract available


  13. SUN T, Liu B, Cai L, Zhou Y, et al
    Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy.
    J Neurooncol. 2024 Apr 23. doi: 10.1007/s11060-024-04689.
    PubMed     Abstract available


  14. KOIDE Y, Nagai N, Adachi S, Ito M, et al
    Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study.
    J Neurooncol. 2024 Apr 22. doi: 10.1007/s11060-024-04681.
    PubMed     Abstract available


  15. CZARNOTA GJ
    Comment in reply to Chen et al. Journal of Neuro-Oncology (2023) 165:535-545 "Focused ultrasound combined with radiotherapy for malignant brain tumor: a preclinical and clinical study".
    J Neurooncol. 2024 Apr 19. doi: 10.1007/s11060-024-04675.
    PubMed    


  16. CONRAD K, Lober-Handwerker R, Hazaymeh M, Rohde V, et al
    Personalized prognosis stratification of newly diagnosed glioblastoma applying a statistical decision tree model.
    J Neurooncol. 2024 Apr 19. doi: 10.1007/s11060-024-04683.
    PubMed     Abstract available


  17. DESAI J, Rajkumar S, Shepard MJ, Herbst J, et al
    National trends in the treatment of adult diffuse midline gliomas: a rare clinical scenario.
    J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04663.
    PubMed     Abstract available


  18. SALAME AAM, Charchar HLS, de Oliveira Dourado JP, Mendonca B, et al
    Neuroradiological features of patients with bilateral macronodular adrenocortical disease and meningiomas associated or not with genetic variants of ARMC5- a case series.
    J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04680.
    PubMed     Abstract available


  19. MASHIACH E, Alzate JD, De Nigris Vasconcellos F, Adams S, et al
    Improved outcomes for triple negative breast cancer brain metastases patients after stereotactic radiosurgery and new systemic approaches.
    J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04651.
    PubMed     Abstract available


  20. GATELY L, Mesia C, Sepulveda JM, Del Barco S, et al
    Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM).
    J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04668.
    PubMed     Abstract available


  21. KOCHER D, Cao L, Guiho R, Langhammer M, et al
    Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines.
    J Neurooncol. 2024 Apr 17. doi: 10.1007/s11060-024-04672.
    PubMed     Abstract available


  22. WILSON L, Atallah A, Romero JM
    Preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed and resectable glioblastoma.
    J Neurooncol. 2024 Apr 15. doi: 10.1007/s11060-024-04666.
    PubMed    


  23. SHEEHAN JP, Trifiletti DM, Lehrer EJ
    Tissue biopsy before resection in glioblastoma: is there an opportunity to improve outcomes with liquid biopsies and pre-operative stereotactic radiosurgery?
    J Neurooncol. 2024 Apr 11. doi: 10.1007/s11060-024-04678.
    PubMed    


  24. CHEN KT, Huang CY, Pai PC, Yang WC, et al
    Correction to: Focused ultrasound combined with radiotherapy for malignant brain tumor: a preclinical and clinical study.
    J Neurooncol. 2024 Apr 10. doi: 10.1007/s11060-024-04671.
    PubMed    


  25. KONDO N, Kinouchi T, Natsumeda M, Matsuzaki J, et al
    Profile of miRNAs in small extracellular vesicles released from glioblastoma cells treated by boron neutron capture therapy.
    J Neurooncol. 2024 Apr 10. doi: 10.1007/s11060-024-04649.
    PubMed     Abstract available


  26. MIRZAYEVA L, Ucar M, Kaymaz AM, Temel E, et al
    Intraoperative magnetic resonance imaging in glioma surgery: a single-center experience.
    J Neurooncol. 2024 Apr 3. doi: 10.1007/s11060-024-04660.
    PubMed     Abstract available


  27. MAHMOODIFAR S, Pangal DJ, Neman J, Zada G, et al
    Comparative analysis of the spatial distribution of brain metastases across several primary cancers using machine learning and deep learning models.
    J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04630.
    PubMed     Abstract available


  28. DMUKAUSKAS M, Cioffi G, Waite KA, Sloan AE, et al
    Sex differences in adverse events in Medicare individuals >/= 66 years of age post glioblastoma treatment.
    J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04652.
    PubMed     Abstract available


  29. LU VM, Brun JD, Niazi TN, Brun JD, et al
    Pediatric neurosurgical medulloblastoma outcomes in La Paz, Bolivia: How a Lower Middle-Income Country (LMIC) institution in South America compares to the United States.
    J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04664.
    PubMed     Abstract available


  30. XIANG Y, Chen Y, Xu Z, Zhou S, et al
    Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.
    J Neurooncol. 2024 Apr 2. doi: 10.1007/s11060-024-04662.
    PubMed     Abstract available


  31. JOST J, Volker K, Brandt R, Stummer W, et al
    Maximal cardiopulmonary exercise testing in glioblastoma patients undergoing chemotherapy: assessment of feasibility, safety, and physical fitness status.
    J Neurooncol. 2024 Apr 1. doi: 10.1007/s11060-024-04629.
    PubMed     Abstract available


  32. ROGERS JL, Wall T, Acquaye-Mallory AA, Boris L, et al
    Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors.
    J Neurooncol. 2024;167:349-359.
    PubMed     Abstract available


    March 2024
  33. TONG E, Horsley P, Wheeler H, Wong M, et al
    Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
    J Neurooncol. 2024 Mar 29. doi: 10.1007/s11060-024-04643.
    PubMed     Abstract available


  34. FLORES-PACO P, Vargas-Aliaga A, Guevara MG, Lopera I, et al
    A new updated prognostic index for patients with brain metastases (BMs) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology. METASNCore project.
    J Neurooncol. 2024 Mar 27. doi: 10.1007/s11060-024-04618.
    PubMed     Abstract available


  35. WATANABE G, Young K, Rauber E, Khan MF, et al
    A systematic review of extraneural meningioma metastasis: timing, evolution and outlook.
    J Neurooncol. 2024 Mar 26. doi: 10.1007/s11060-024-04659.
    PubMed     Abstract available


  36. STRAUBE C, Combs SE, Bernhardt D, Gempt J, et al
    Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers.
    J Neurooncol. 2024 Mar 23. doi: 10.1007/s11060-024-04633.
    PubMed     Abstract available


  37. ANDREWS CE, Zilberberg J, Perez-Olle R, Exley MA, et al
    Correction to: Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy.
    J Neurooncol. 2024 Mar 22. doi: 10.1007/s11060-024-04635.
    PubMed    


  38. ZAKI PG, Herr S, Shepard MJ
    Letter to the editor: Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis.
    J Neurooncol. 2024 Mar 22. doi: 10.1007/s11060-024-04602.
    PubMed    


  39. FINK L, van Oorschot B, von Sass C, Dibue M, et al
    Palliative care for in-patient malignant glioma patients in Germany.
    J Neurooncol. 2024 Mar 20. doi: 10.1007/s11060-024-04611.
    PubMed     Abstract available


  40. GEENS W, Vanlaer N, Nijland L, Van Laere S, et al
    Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition.
    J Neurooncol. 2024 Mar 19. doi: 10.1007/s11060-024-04646.
    PubMed     Abstract available


  41. BOBHOLZ SA, Hoefs A, Hamburger J, Lowman AK, et al
    Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response.
    J Neurooncol. 2024 Mar 18. doi: 10.1007/s11060-024-04641.
    PubMed    


  42. ZHU P, Pichardo-Rojas PS, Dono A, Tandon N, et al
    The detrimental effect of biopsy preceding resection in surgically accessible glioblastoma: results from the national cancer database.
    J Neurooncol. 2024 Mar 16. doi: 10.1007/s11060-024-04644.
    PubMed     Abstract available


  43. CHAKRAVARTI S, Kuo CC, Kazemi F, Kang A, et al
    Correction to: Preoperative patient-reported physical health-related quality of life predicts short-term postoperative outcomes in brain tumor patients.
    J Neurooncol. 2024 Mar 15. doi: 10.1007/s11060-024-04640.
    PubMed    


  44. JIANG J, Li WB, Xiao SW
    Correction to: Prognostic factors analysis of diffuse midline glioma.
    J Neurooncol. 2024 Mar 15. doi: 10.1007/s11060-024-04634.
    PubMed    


  45. PALAVANI LB, Silva GM, Borges PGLB, Ferreira MY, et al
    Fractionated stereotactic radiotherapy in craniopharyngiomas: A systematic review and single arm meta-analysis.
    J Neurooncol. 2024 Mar 8. doi: 10.1007/s11060-024-04621.
    PubMed     Abstract available


  46. DI NUNNO V, Lombardi G, Simonelli M, Minniti G, et al
    The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study.
    J Neurooncol. 2024 Mar 8. doi: 10.1007/s11060-024-04589.
    PubMed     Abstract available


  47. GRAILLON T, Salgues B, Horowitz T, Padovani L, et al
    Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis.
    J Neurooncol. 2024 Mar 7. doi: 10.1007/s11060-024-04622.
    PubMed     Abstract available


  48. SINGH E, Gurses ME, Costello MC, Berke C, et al
    Correction to: Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review.
    J Neurooncol. 2024 Mar 6. doi: 10.1007/s11060-024-04619.
    PubMed    


  49. YOKOGAMI K, Watanabe T, Yamashita S, Mizuguchi A, et al
    Inhibition of BMP signaling pathway induced senescence and calcification in anaplastic meningioma.
    J Neurooncol. 2024 Mar 6. doi: 10.1007/s11060-024-04625.
    PubMed     Abstract available


  50. CHAKRAVARTI S, Kuo CC, Kazemi F, Kang A, et al
    Preoperative patient-reported physical health-related quality of life predicts short-term postoperative outcomes in brain tumor patients.
    J Neurooncol. 2024 Mar 4. doi: 10.1007/s11060-024-04627.
    PubMed     Abstract available


  51. LIM MJR, Zhang Z, Zheng Y, Khoo IWL, et al
    Effect of sarcopenia and frailty on outcomes among patients with brain metastases.
    J Neurooncol. 2024 Mar 2. doi: 10.1007/s11060-023-04542.
    PubMed     Abstract available


  52. CHEN Y, Ning J, Shu L, Wen L, et al
    CPLX2 is a novel tumor suppressor and improves the prognosis in glioma.
    J Neurooncol. 2024 Mar 1. doi: 10.1007/s11060-023-04548.
    PubMed     Abstract available


  53. KEGOYA Y, Otani Y, Inoue Y, Mizuta R, et al
    Midline invasion predicts poor prognosis in diffuse hemispheric glioma, H3 G34-mutant: an individual participant data review.
    J Neurooncol. 2024 Mar 1. doi: 10.1007/s11060-024-04587.
    PubMed     Abstract available


  54. SHEEHAN JP, Singh R, Trifiletti DM
    Stereotactic radiosurgery for intracranial adenoid cystic carcinoma.
    J Neurooncol. 2024;167:229-230.
    PubMed    


  55. WILSON JS, Main C, Thorp N, Taylor RE, et al
    The effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic review.
    J Neurooncol. 2024;167:1-34.
    PubMed     Abstract available


  56. RANADE M, Epari S, Shetty O, Dhanavade S, et al
    CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization.
    J Neurooncol. 2024;167:189-198.
    PubMed     Abstract available


    February 2024
  57. YU M, Ge Y, Wang Z, Zhang Y, et al
    The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study.
    J Neurooncol. 2024 Feb 29. doi: 10.1007/s11060-024-04609.
    PubMed     Abstract available


  58. CEPEDA S, Garcia-Garcia S, Arrese I, Sarabia R, et al
    Non-navigated 2D intraoperative ultrasound: An unsophisticated surgical tool to achieve high standards of care in glioma surgery.
    J Neurooncol. 2024 Feb 28. doi: 10.1007/s11060-024-04614.
    PubMed     Abstract available


  59. JALLOH M, Kankam SB
    Harnessing imaging biomarkers for glioblastoma metastasis diagnosis: a correspondence.
    J Neurooncol. 2024 Feb 23. doi: 10.1007/s11060-024-04606.
    PubMed    


  60. YILMAZ MT, Kahvecioglu A, Yazici G, Mohammadipour S, et al
    Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years' experience of a single center.
    J Neurooncol. 2024 Feb 22. doi: 10.1007/s11060-024-04607.
    PubMed     Abstract available


  61. JIANG J, Li WB, Xiao SW
    Prognostic factors analysis of diffuse midline glioma.
    J Neurooncol. 2024 Feb 21. doi: 10.1007/s11060-024-04605.
    PubMed     Abstract available


  62. EHRET F, Zuhlke O, Schweizer L, Kahn J, et al
    Validation of a methylation-based signature for subventricular zone involvement in glioblastoma.
    J Neurooncol. 2024 Feb 20. doi: 10.1007/s11060-024-04570.
    PubMed     Abstract available


  63. DASGUPTA P, Ou A, Lin H, Gregory T, et al
    The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab.
    J Neurooncol. 2024 Feb 19. doi: 10.1007/s11060-023-04551.
    PubMed     Abstract available


  64. BACCILI CURY MEGID T, Baskurt Z, Ma LX, Barron CC, et al
    Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes.
    J Neurooncol. 2024 Feb 19. doi: 10.1007/s11060-024-04576.
    PubMed     Abstract available


  65. BOBHOLZ SA, Hoefs A, Hamburger J, Lowman AK, et al
    Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response.
    J Neurooncol. 2024 Feb 19. doi: 10.1007/s11060-024-04593.
    PubMed     Abstract available


  66. UMEKAWA M, Shinya Y, Hasegawa H, Morshed RA, et al
    Ki-67 labeling index predicts tumor progression patterns and survival in patients with atypical meningiomas following stereotactic radiosurgery.
    J Neurooncol. 2024 Feb 18. doi: 10.1007/s11060-023-04537.
    PubMed     Abstract available


  67. ARNOLD LM, Hoshina Y, Lee H, Colman H, et al
    Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors.
    J Neurooncol. 2024 Feb 16. doi: 10.1007/s11060-024-04588.
    PubMed     Abstract available


  68. SHEEHAN JP, Mantziaris G, Bunevicius A
    Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma.
    J Neurooncol. 2024 Feb 16. doi: 10.1007/s11060-024-04592.
    PubMed    


  69. SHIRAI Y, Ueno T, Kojima S, Ikeuchi H, et al
    The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.
    J Neurooncol. 2024 Feb 16. doi: 10.1007/s11060-024-04563.
    PubMed     Abstract available


  70. WASILEWSKI D, Onken J, Horicke P, Bukatz J, et al
    Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection.
    J Neurooncol. 2024 Feb 15. doi: 10.1007/s11060-024-04590.
    PubMed     Abstract available


  71. DONO A, Torres J, Nunez L, Arevalo O, et al
    Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype.
    J Neurooncol. 2024 Feb 13. doi: 10.1007/s11060-024-04575.
    PubMed     Abstract available


  72. KOAY JM, Michaelides L, Moniz-Garcia DP, Quinones-Hinojosa A, et al
    Repeated surgical resections for management of high-grade glioma and its impact on quality of life.
    J Neurooncol. 2024 Feb 13. doi: 10.1007/s11060-024-04600.
    PubMed     Abstract available


  73. ANGELOVA P, Gicheva M
    Comment: Additional factors affecting cognitive function in low grade glioma patients.
    J Neurooncol. 2024 Feb 13. doi: 10.1007/s11060-024-04598.
    PubMed    


  74. WATANABE G, Wong JM, Estes B, Khan MF, et al
    Diffuse Midline H3K27-Altered Gliomas in the Spinal Cord: A Systematic Review.
    J Neurooncol. 2024 Feb 12. doi: 10.1007/s11060-024-04584.
    PubMed     Abstract available


  75. FAIRCHILD A, Salama JK, Godfrey D, Wiggins WF, et al
    Incidence and imaging characteristics of difficult to detect retrospectively identified brain metastases in patients receiving repeat courses of stereotactic radiosurgery.
    J Neurooncol. 2024 Feb 10. doi: 10.1007/s11060-024-04594.
    PubMed     Abstract available


  76. MIRIAN C, Jensen LR, Juratli TA, Maier AD, et al
    The importance of considering competing risks in recurrence analysis of intracranial meningioma.
    J Neurooncol. 2024 Feb 10. doi: 10.1007/s11060-024-04572.
    PubMed     Abstract available


  77. ALHALABI OT, Dao Trong P, Kaes M, Jakobs M, et al
    Repeat surgery of recurrent glioma for molecularly informed treatment in the age of precision oncology: A risk-benefit analysis.
    J Neurooncol. 2024 Feb 9. doi: 10.1007/s11060-024-04595.
    PubMed     Abstract available


  78. KERIC N, Krenzlin H, Kalasauskas D, Freyschlag CF, et al
    Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
    J Neurooncol. 2024 Feb 7. doi: 10.1007/s11060-024-04585.
    PubMed     Abstract available


  79. AVERBUCH I, Tschernichovsky R, Yust-Katz S, Rotem O, et al
    Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment.
    J Neurooncol. 2024 Feb 7. doi: 10.1007/s11060-024-04562.
    PubMed     Abstract available


  80. TRAN S, Lapidus A, Neal A, Peters KB, et al
    A systematic review of the impact of brain tumours on risk of motor vehicle crashes.
    J Neurooncol. 2024 Feb 6. doi: 10.1007/s11060-024-04586.
    PubMed     Abstract available


  81. SALANS M, Ni L, Morin O, Ziemer B, et al
    Adverse radiation effect versus tumor progression following stereotactic radiosurgery for brain metastases: Implications of radiologic uncertainty.
    J Neurooncol. 2024 Feb 5. doi: 10.1007/s11060-024-04578.
    PubMed     Abstract available


  82. TANG JD, Mills MN, Nakashima J, Dohm AE, et al
    Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
    J Neurooncol. 2024 Feb 3. doi: 10.1007/s11060-023-04543.
    PubMed     Abstract available


  83. ZIMMERMANN MLM, Breedt LC, Centeno EGZ, Reijneveld JC, et al
    The relationship between pathological brain activity and functional network connectivity in glioma patients.
    J Neurooncol. 2024 Feb 3. doi: 10.1007/s11060-024-04577.
    PubMed     Abstract available


  84. HAMMER Y, Najjar W, Kahanov L, Joskowicz L, et al
    Two is better than one: longitudinal detection and volumetric evaluation of brain metastases after Stereotactic Radiosurgery with a deep learning pipeline.
    J Neurooncol. 2024 Feb 1. doi: 10.1007/s11060-024-04580.
    PubMed     Abstract available


  85. WANG B, Liu Y, Zhang J, Yin S, et al
    Evaluating contouring accuracy and dosimetry impact of current MRI-guided adaptive radiation therapy for brain metastases: a retrospective study.
    J Neurooncol. 2024 Feb 1. doi: 10.1007/s11060-024-04583.
    PubMed     Abstract available


  86. KHOWAL S, Zhang D, Yong WH, Heaney AP, et al
    Whole-exome sequencing reveals genetic variants that may play a role in neurocytomas.
    J Neurooncol. 2024;166:471-483.
    PubMed     Abstract available


    January 2024
  87. SINGH E, Gurses ME, Costello MC, Lu VM, et al
    Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review.
    J Neurooncol. 2024 Jan 31. doi: 10.1007/s11060-024-04582.
    PubMed     Abstract available


  88. TANAKA T, Tamura R, Takei J, Morimoto Y, et al
    An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma.
    J Neurooncol. 2024 Jan 31. doi: 10.1007/s11060-023-04544.
    PubMed     Abstract available


  89. GATELY L, Mesia C, Sepulveda JM, Del Barco S, et al
    Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.
    J Neurooncol. 2024 Jan 30. doi: 10.1007/s11060-024-04581.
    PubMed    


  90. DASGUPTA P, Rousseau JF
    Clinical and molecular determinants of bleeding-related adverse outcomes in high-grade glioma.
    J Neurooncol. 2024 Jan 29. doi: 10.1007/s11060-024-04574.
    PubMed     Abstract available


  91. PETRONEK MS, Bodeker KL, Lee CY, Teferi N, et al
    Iron-based biomarkers for personalizing pharmacological ascorbate therapy in glioblastoma: insights from a phase 2 clinical trial.
    J Neurooncol. 2024 Jan 29. doi: 10.1007/s11060-024-04571.
    PubMed     Abstract available


  92. VAN OPIJNEN MP, Broekman MLD, Cuppen E, Dubbink HJ, et al
    Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting.
    J Neurooncol. 2024 Jan 29. doi: 10.1007/s11060-024-04568.
    PubMed     Abstract available


  93. YEKULA A, Gessler DJ, Ferreira C, Shah R, et al
    GammaTile((R)) (GT) as a brachytherapy platform for rapidly proliferating glioblastomas: from case series to clinical trials.
    J Neurooncol. 2024 Jan 28. doi: 10.1007/s11060-023-04545.
    PubMed     Abstract available


  94. GONZALEZ-APONTE MF, Damato AR, Trebucq LL, Simon T, et al
    Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma.
    J Neurooncol. 2024 Jan 26. doi: 10.1007/s11060-023-04535.
    PubMed     Abstract available


  95. KREATSOULAS D, Damante M, Cua S, Lonser RR, et al
    Adjuvant convection-enhanced delivery for the treatment of brain tumors.
    J Neurooncol. 2024 Jan 23. doi: 10.1007/s11060-023-04552.
    PubMed     Abstract available


  96. MULLER SJ, Khadhraoui E, Ganslandt O, Henkes H, et al
    MRI Treatment Response Assessment Maps (TRAMs) for differentiating recurrent glioblastoma from radiation necrosis.
    J Neurooncol. 2024 Jan 23. doi: 10.1007/s11060-024-04573.
    PubMed     Abstract available


  97. GARCIA MA, Turner A, Brachman DG
    The role of GammaTile in the treatment of brain tumors: a technical and clinical overview.
    J Neurooncol. 2024 Jan 23. doi: 10.1007/s11060-023-04523.
    PubMed     Abstract available


  98. REESE JC, Fadel HA, Pawloski JA, Samir M, et al
    Laser interstitial thermal therapy for deep-seated perivascular brain tumors is not associated with distal ischemia.
    J Neurooncol. 2024 Jan 19. doi: 10.1007/s11060-023-04546.
    PubMed     Abstract available


  99. RYNDA AY, Rostovthev DM, Zabrodskaya YM, Olyushin VE, et al
    Immunotherapy with autologous dendritic cells in the complex treatment of malignant gliomas - results.
    J Neurooncol. 2024 Jan 16. doi: 10.1007/s11060-023-04559.
    PubMed     Abstract available


  100. ON J, Natsumeda M, Takahashi H, Koyama A, et al
    Reliable detection of genetic alterations in cyst fluid DNA for the diagnosis of brain tumors.
    J Neurooncol. 2024 Jan 16. doi: 10.1007/s11060-023-04555.
    PubMed     Abstract available


  101. ZAPANTA RINONOS S, Li T, Pianka ST, Prins TJ, et al
    dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma.
    J Neurooncol. 2024 Jan 15. doi: 10.1007/s11060-023-04531.
    PubMed     Abstract available


  102. KUAH XYC, Lucas-Herald AK, McCarrison S, Boyle R, et al
    Presentation and outcomes of paediatric craniopharyngioma in the west of Scotland: a 25 year experience.
    J Neurooncol. 2024 Jan 15. doi: 10.1007/s11060-023-04490.
    PubMed     Abstract available


  103. DOGAN E, Yildirim Z, Akalin T, Ozgiray E, et al
    Investigating the effects of PTEN mutations on cGAS-STING pathway in glioblastoma tumours.
    J Neurooncol. 2024 Jan 12. doi: 10.1007/s11060-023-04556.
    PubMed     Abstract available


  104. DAGHER R, Gad M, da Silva de Santana P, Sadeghi MA, et al
    Umbrella review and network meta-analysis of diagnostic imaging test accuracy studies in Differentiating between brain tumor progression versus pseudoprogression and radionecrosis.
    J Neurooncol. 2024 Jan 11. doi: 10.1007/s11060-023-04528.
    PubMed     Abstract available


  105. MIYAKOSHI A, Ubukata N, Miyake H, Shoji-Asahina A, et al
    Risk factors for glioblastoma in adults in Japan: an exploratory cohort study based on the Shizuoka Kokuho Database, the Shizuoka study.
    J Neurooncol. 2024 Jan 11. doi: 10.1007/s11060-024-04566.
    PubMed     Abstract available


  106. BERGER A, Mullen R, Bernstein K, Mashiach E, et al
    Volumetric growth rate of incidentally found meningiomas on immunotherapy.
    J Neurooncol. 2024 Jan 9. doi: 10.1007/s11060-023-04558.
    PubMed     Abstract available


  107. HUDSON K, Mondia MW, Zhang Y, Saha S, et al
    The role of microRNAs in brain metastasis.
    J Neurooncol. 2024 Jan 9. doi: 10.1007/s11060-023-04541.
    PubMed     Abstract available


  108. ZHANG Q, Dai Z, Chen Y, Li Q, et al
    Endosome associated trafficking regulator 1 promotes tumor growth and invasion of glioblastoma multiforme via inhibiting TNF signaling pathway.
    J Neurooncol. 2024 Jan 8. doi: 10.1007/s11060-023-04527.
    PubMed     Abstract available


  109. ZEUNER S, Vollmer J, Sigaud R, Oppermann S, et al
    Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.
    J Neurooncol. 2024 Jan 7. doi: 10.1007/s11060-023-04526.
    PubMed     Abstract available


  110. YADAV N, Purow BW
    Understanding current experimental models of glioblastoma-brain microenvironment interactions.
    J Neurooncol. 2024 Jan 5. doi: 10.1007/s11060-023-04536.
    PubMed     Abstract available


  111. ZHANG JF, Okai B, Iovoli A, Goulenko V, et al
    Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma.
    J Neurooncol. 2024 Jan 4. doi: 10.1007/s11060-023-04524.
    PubMed     Abstract available


  112. KAMBE A, Kitao S, Ochiai R, Hosoya T, et al
    The utility of arterial spin labeling imaging for predicting prognosis after a recurrence of high-grade glioma in patients under bevacizumab treatment.
    J Neurooncol. 2024 Jan 2. doi: 10.1007/s11060-023-04550.
    PubMed     Abstract available


  113. HESHAM D, On J, Alshahaby N, Amer N, et al
    Multi-omics analyses of choroid plexus carcinoma cell lines reveal potential targetable pathways and alterations.
    J Neurooncol. 2024;166:27-38.
    PubMed     Abstract available


  114. FADUL CE, Thakur A, Kim J, Kassay-McAllister J, et al
    Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide.
    J Neurooncol. 2024;166:321-330.
    PubMed     Abstract available


  115. OBRECHT-STURM D, Pfaff E, Mynarek M, Bison B, et al
    Pineal anlage tumor: clinical and diagnostic features, and rationales for treatment.
    J Neurooncol. 2024;166:359-368.
    PubMed     Abstract available


  116. EBADI M, Morse M, Gooley T, Ermoian R, et al
    Craniospinal irradiation for CNS leukemia: rates of response and durability of CNS control.
    J Neurooncol. 2024;166:351-357.
    PubMed     Abstract available


  117. SHEEHAN JP, Michalopoulos GD, Katsos K, Bydon M, et al
    The NeuroPoint alliance SRS & tumor QOD registries.
    J Neurooncol. 2024;166:257-264.
    PubMed     Abstract available


  118. FENG J, Zhang J, Chen L, Li C, et al
    Treatment outcomes and risk factors of patients with intracranial germ cell tumour with choriocarcinoma element or beta-HCG level higher than 500 IU/L.
    J Neurooncol. 2024;166:331-339.
    PubMed     Abstract available


  119. HONG S, Garces YI, Price KA, Shinya Y, et al
    Treatment outcomes of single-fraction stereotactic radiosurgery for adenoid cystic carcinoma: a case series of 55 patients.
    J Neurooncol. 2024;166:369-376.
    PubMed     Abstract available


    December 2023
  120. NORIKANE T, Mitamura K, Yamamoto Y, Manabe Y, et al
    Comparative evaluation of (11)C-methionine and (18)F-fluorodeoxyglucose positron emission tomography for distinguishing between primary central nervous system lymphoma and isocitrate dehydrogenase-wildtype glioblastoma.
    J Neurooncol. 2023 Dec 31. doi: 10.1007/s11060-023-04534.
    PubMed     Abstract available


  121. GATELY L, Mesia C, Sepulveda JM, Del Barco S, et al
    A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.
    J Neurooncol. 2023 Dec 28. doi: 10.1007/s11060-023-04513.
    PubMed     Abstract available


  122. ARORA H, Mammi M, Patel NM, Zyfi D, et al
    Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis.
    J Neurooncol. 2023 Dec 27. doi: 10.1007/s11060-023-04549.
    PubMed     Abstract available


  123. YANG ZC, Yin CD, Yeh FC, Xue BW, et al
    Exploring MGMT methylation-driven structural connectivity changes in insular gliomas: a tractography and graph theoretical analysis.
    J Neurooncol. 2023 Dec 27. doi: 10.1007/s11060-023-04539.
    PubMed     Abstract available


  124. BENNEBROEK CA, Schouten CR, Montauban-van Swijndregt MC, Saeed P, et al
    Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components.
    J Neurooncol. 2023 Dec 27. doi: 10.1007/s11060-023-04516.
    PubMed     Abstract available


  125. REN L, Chen J, Deng J, Qing X, et al
    The development of a combined clinico-radiomics model for predicting post-operative recurrence in atypical meningiomas: a multicenter study.
    J Neurooncol. 2023 Dec 26. doi: 10.1007/s11060-023-04511.
    PubMed     Abstract available


  126. CHOU CJ, Yang HC, Chang PY, Chen CJ, et al
    Automated identification and quantification of metastatic brain tumors and perilesional edema based on a deep learning neural network.
    J Neurooncol. 2023 Dec 22. doi: 10.1007/s11060-023-04540.
    PubMed     Abstract available


  127. MIJAJLOVIC V, Miler M, Ilic R, Rasic D, et al
    Oncogene-induced senescence in meningiomas-an immunohistochemical study.
    J Neurooncol. 2023 Dec 20. doi: 10.1007/s11060-023-04532.
    PubMed     Abstract available


  128. KINSLOW CJ, Siegelin MD, Iwamoto FM, Gallitto M, et al
    MGMT promoter methylation in 1p19q-intact gliomas.
    J Neurooncol. 2023 Dec 20. doi: 10.1007/s11060-023-04515.
    PubMed     Abstract available


  129. LU VM, Khalafallah AM, Jaman E, Gurses ME, et al
    Clinical course of ventriculoperitoneal shunting for hydrocephalus following glioblastoma surgery: a systematic review and meta-analysis.
    J Neurooncol. 2023 Dec 19. doi: 10.1007/s11060-023-04538.
    PubMed     Abstract available


  130. ABETE-FORNARA G, Bintintan Socaciu P, Fanizzi C, Fiore G, et al
    Neuropsychological functioning during chemotherapy with temozolomide in high-grade glioma patients: a retrospective single centre study.
    J Neurooncol. 2023 Dec 18. doi: 10.1007/s11060-023-04533.
    PubMed     Abstract available


  131. CHEN Q, Wang K, Ren X, Zhao X, et al
    Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [(11)C]methionine PET.
    J Neurooncol. 2023 Dec 14. doi: 10.1007/s11060-023-04529.
    PubMed     Abstract available


  132. CHANG CT, Chen HH, Chuang CC, Chang SH, et al
    Ganciclovir as a potential treatment for glioma: a systematic review and meta-analysis.
    J Neurooncol. 2023 Dec 8. doi: 10.1007/s11060-023-04503.
    PubMed     Abstract available


  133. CHEN KT, Huang CY, Pai PC, Yang WC, et al
    Focused ultrasound combined with radiotherapy for malignant brain tumor: a preclinical and clinical study.
    J Neurooncol. 2023 Dec 7. doi: 10.1007/s11060-023-04517.
    PubMed     Abstract available


  134. MIAO Q, Zheng X, Li L, Zheng X, et al
    Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.
    J Neurooncol. 2023;165:517-525.
    PubMed     Abstract available


  135. WILLEMS YCP, Vaassen F, Zegers CML, Postma AA, et al
    Anatomical changes in resection cavity during brain radiotherapy.
    J Neurooncol. 2023;165:479-486.
    PubMed     Abstract available


  136. RAMMELOO E, Schouten JW, Krikour K, Bos EM, et al
    Preoperative assessment of eloquence in neurosurgery: a systematic review.
    J Neurooncol. 2023;165:413-430.
    PubMed     Abstract available


  137. SHEN CI, Chiang CL, Huang HC, Tseng YH, et al
    Management strategies for intracranial progression in ALK-positive non-small cell lung cancer: a real-world cohort study.
    J Neurooncol. 2023;165:459-465.
    PubMed     Abstract available


  138. WIJAYA JH, Patel UD, Quintero-Consuegra MD, Aguilera-Pena MP, et al
    Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis.
    J Neurooncol. 2023;165:431-438.
    PubMed     Abstract available


  139. LYNES J, Khan I, Aguilera C, Rubino S, et al
    Development of a "Geo-Tagged" tumor sample registry: intra-operative linkage of sample location to imaging.
    J Neurooncol. 2023;165:449-458.
    PubMed     Abstract available


  140. SELT F, El Damaty A, Schuhmann MU, Sigaud R, et al
    Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow.
    J Neurooncol. 2023;165:467-478.
    PubMed     Abstract available


    November 2023
  141. SHEEHAN J, Mantziaris G, Dumont C, Pikis S, et al
    Incidental meningiomas: a current and increasingly common challenge.
    J Neurooncol. 2023 Nov 30. doi: 10.1007/s11060-023-04525.
    PubMed    


  142. BAUMGARTEN P, Prange G, Kamp MA, Monden D, et al
    Treatment of very elderly glioblastoma patients >/= 75 years of age: whom to treat.
    J Neurooncol. 2023 Nov 30. doi: 10.1007/s11060-023-04518.
    PubMed     Abstract available


  143. ANDREWS CE, Zilberberg J, Perez-Olle R, Exley MA, et al
    Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy.
    J Neurooncol. 2023 Nov 29. doi: 10.1007/s11060-023-04491.
    PubMed     Abstract available


  144. KLEINBERG L, Ye X, Supko J, Stevens GHJ, et al
    A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM).
    J Neurooncol. 2023 Nov 28. doi: 10.1007/s11060-023-04514.
    PubMed     Abstract available


  145. YAVUZ BB, Kilinc F, Kanyilmaz G, Aktan M, et al
    Pyruvate kinase M2 (PKM-2) expression and prognostic significance in glioblastoma patients.
    J Neurooncol. 2023 Nov 27. doi: 10.1007/s11060-023-04521.
    PubMed     Abstract available


  146. CHIANG CL, Yang HC, Liao YT, Luo YH, et al
    Treatment and survival of patients with small cell lung cancer and brain metastasis.
    J Neurooncol. 2023 Nov 20. doi: 10.1007/s11060-023-04512.
    PubMed     Abstract available


  147. QIU X, Gao J, Hu J, Yang J, et al
    Particle beam radiotherapy in the treatment of WHO grade 2 and 3 meningiomas: an early experience from Shanghai Proton and Heavy Ion Center.
    J Neurooncol. 2023 Nov 17. doi: 10.1007/s11060-023-04401.
    PubMed     Abstract available


  148. QIN N, Paisana E, Picard D, Leprivier G, et al
    The long non-coding RNA OTX2-AS1 promotes tumor growth and predicts response to BCL-2 inhibition in medulloblastoma.
    J Neurooncol. 2023 Nov 17. doi: 10.1007/s11060-023-04508.
    PubMed     Abstract available


  149. VOGLIS S, Padevit L, van Niftrik CHB, Kalin V, et al
    Safety of microneurosurgical interventions for superficial and deep-seated brain metastases: single-center cohort study of 637 consecutive cases.
    J Neurooncol. 2023 Nov 10. doi: 10.1007/s11060-023-04478.
    PubMed     Abstract available


  150. KHAN AB, Dang HQ, Gopakumar S, Lazaro T, et al
    Clinical outcomes of stereotactic biopsy on children with pontine diffuse midline glioma.
    J Neurooncol. 2023 Nov 9. doi: 10.1007/s11060-023-04475.
    PubMed     Abstract available


  151. KIM N, Lee J, Nam DH, Lee JI, et al
    Correction to: Impact of boost sequence in concurrent chemo-radiotherapy on newly diagnosed IDH-wildtype glioblastoma multiforme.
    J Neurooncol. 2023 Nov 8. doi: 10.1007/s11060-023-04498.
    PubMed    


  152. NASLUND O, Strand PS, Solheim O, Al Masri M, et al
    Incidence, management, and outcome of incidental meningioma: what has happened in 10 years?
    J Neurooncol. 2023 Nov 8. doi: 10.1007/s11060-023-04482.
    PubMed     Abstract available


  153. YAMAMOTO S, Okita Y, Arita H, Sanada T, et al
    Qualitative MR features to identify non-enhancing tumors within glioblastoma's T2-FLAIR hyperintense lesions.
    J Neurooncol. 2023 Nov 2. doi: 10.1007/s11060-023-04454.
    PubMed     Abstract available


  154. LIN HT, Lin CM, Wu YY, Chang WH, et al
    Predictors for delayed awakening in adult glioma patients receiving awake craniotomy under monitored anesthesia care.
    J Neurooncol. 2023 Nov 2. doi: 10.1007/s11060-023-04494.
    PubMed     Abstract available


  155. CHEN YH, Moore D, Lee CC, Su YH, et al
    Focused ultrasound for brain metastases: an update on global clinical trials.
    J Neurooncol. 2023 Nov 1. doi: 10.1007/s11060-023-04492.
    PubMed     Abstract available


  156. HONG Y, Miao Q, Zheng X, Xu Y, et al
    Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis.
    J Neurooncol. 2023;165:301-312.
    PubMed     Abstract available


  157. PRICE M, Neff C, Kruchko C, Barnholtz-Sloan JS, et al
    Capturing evolving definitions of 12 select rare CNS tumors: a timely report from CBTRUS and NCI-CONNECT.
    J Neurooncol. 2023;165:279-290.
    PubMed     Abstract available


  158. KO MK, Kwak YK, Choi BO, Jeun SS, et al
    Is reduced-dose whole-brain radiotherapy also feasible in primary CNS lymphoma for curative or salvage purpose?
    J Neurooncol. 2023;165:321-328.
    PubMed     Abstract available


  159. ZAMARUD A, Marianayagam NJ, Park DJ, Yener U, et al
    The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience.
    J Neurooncol. 2023;165:373-379.
    PubMed     Abstract available


    October 2023
  160. KRASSNIG S, Leber SL, Orthmann A, Golob-Schwarzl N, et al
    Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
    J Neurooncol. 2023 Oct 31. doi: 10.1007/s11060-023-04451.
    PubMed     Abstract available


  161. LEHRER EJ, Khosla AA, Ozair A, Gurewitz J, et al
    Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395 patients.
    J Neurooncol. 2023 Oct 27. doi: 10.1007/s11060-023-04413.
    PubMed     Abstract available


  162. MOHAMMAD AH, Jatana S, Ruiz-Barerra MA, Khalaf R, et al
    Metformin use is associated with longer survival in glioblastoma patients with MGMT gene silencing.
    J Neurooncol. 2023 Oct 27. doi: 10.1007/s11060-023-04485.
    PubMed     Abstract available


  163. MA S, Lee H, Jo WY, Byun YH, et al
    The Warburg effect in patients with brain tumors: a comprehensive analysis of clinical significance.
    J Neurooncol. 2023 Oct 27. doi: 10.1007/s11060-023-04486.
    PubMed     Abstract available


  164. CROMPTON D, Koffler D, Fekrmandi F, Lehrer EJ, et al
    Preoperative stereotactic radiosurgery as neoadjuvant therapy for resectable brain tumors.
    J Neurooncol. 2023 Oct 27. doi: 10.1007/s11060-023-04466.
    PubMed     Abstract available


  165. GROB ST, Miller KR, Sanford B, Donson AM, et al
    Genetic predictors of neurocognitive outcomes in survivors of pediatric brain tumors.
    J Neurooncol. 2023 Oct 25. doi: 10.1007/s11060-023-04472.
    PubMed     Abstract available


  166. ELLIS EM, Drumm MR, Rai SM, Huang J, et al
    Long-term antiseizure medication use in patients after meningioma resection: identifying predictors for successful weaning and failures.
    J Neurooncol. 2023 Oct 24. doi: 10.1007/s11060-023-04481.
    PubMed     Abstract available


  167. STROWD R, Ellingson B, Raymond C, Yao J, et al
    Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
    J Neurooncol. 2023 Oct 21. doi: 10.1007/s11060-023-04456.
    PubMed     Abstract available


  168. KIM N, Lee J, Nam DH, Lee JI, et al
    Impact of boost sequence in concurrent chemo-radiotherapy on newly diagnosed IDH-wildtype glioblastoma multiforme.
    J Neurooncol. 2023 Oct 20. doi: 10.1007/s11060-023-04465.
    PubMed     Abstract available


  169. YU Y, Chen H, Tian Z, Zhang Q, et al
    Improved survival outcome with not-delayed radiotherapy and immediate PD-1/PD-L1 inhibitor for non-small-cell lung cancer patients with brain metastases.
    J Neurooncol. 2023 Oct 17. doi: 10.1007/s11060-023-04459.
    PubMed     Abstract available


  170. NAKAJIMA R, Kinoshita M, Okita H, Nakada M, et al
    Glioblastomas at the white matter of temporo-parietal junction cause a poor postoperative independence level.
    J Neurooncol. 2023 Oct 17. doi: 10.1007/s11060-023-04479.
    PubMed     Abstract available


  171. HOU C, Shi S, Gao M, Ji J, et al
    Targeting TNFAIP2 induces immunogenic cell death and sensitizes glioblastoma multiforme to anti-PD-1 therapy.
    J Neurooncol. 2023 Oct 11. doi: 10.1007/s11060-023-04449.
    PubMed     Abstract available


  172. DEJONCKHEERE CS, Layer JP, Hamed M, Layer K, et al
    Intraoperative or postoperative stereotactic radiotherapy for brain metastases: time to systemic treatment onset and other patient-relevant outcomes.
    J Neurooncol. 2023 Oct 9. doi: 10.1007/s11060-023-04464.
    PubMed     Abstract available


  173. BORST GR, Post R
    Letter to the editor: the impact of systemic treatment on brain metastases should be considered in clinical outcome analysis.
    J Neurooncol. 2023 Oct 9. doi: 10.1007/s11060-023-04457.
    PubMed    


  174. PANDYA SHESH B, Walter V, Palsa K, Slagle-Webb B, et al
    Sexually dimorphic effect of H-ferritin genetic manipulation on survival and tumor microenvironment in a mouse model of glioblastoma.
    J Neurooncol. 2023 Oct 9. doi: 10.1007/s11060-023-04415.
    PubMed     Abstract available


  175. ERNSTER AE, Body A, Deleyrolle P, St Clair J, et al
    Patterns and predictors of anxiety and depression symptom trajectories in patients diagnosed with primary brain tumors.
    J Neurooncol. 2023 Oct 7. doi: 10.1007/s11060-023-04469.
    PubMed     Abstract available


  176. KOTCH C, Si SJ, Desai K, Caminada P, et al
    The impact of changes in gadolinium-enhancement on disease progression in children with neurofibromatosis type 1-associated optic pathway glioma: a retrospective analysis.
    J Neurooncol. 2023 Oct 7. doi: 10.1007/s11060-023-04468.
    PubMed     Abstract available


  177. DADEY DYA, Medress ZA, Sharma M, Ugiliweneza B, et al
    Risk of developing glioblastoma following non-CNS primary cancer: a SEER analysis between 2000 and 2018.
    J Neurooncol. 2023 Oct 4. doi: 10.1007/s11060-023-04460.
    PubMed     Abstract available


  178. COVELL MM, Warrier A, Rumalla KC, Dehney CM, et al
    RAI-measured frailty predicts non-home discharge following metastatic brain tumor resection: national inpatient sample analysis of 20,185 patients.
    J Neurooncol. 2023 Oct 3. doi: 10.1007/s11060-023-04461.
    PubMed     Abstract available


  179. WELLER J, Zeyen T, Schafer N, Schaub C, et al
    The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.
    J Neurooncol. 2023 Oct 3. doi: 10.1007/s11060-023-04470.
    PubMed     Abstract available


  180. VOLLMER J, Ecker J, Hielscher T, Valinciute G, et al
    Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.
    J Neurooncol. 2023 Oct 3. doi: 10.1007/s11060-023-04445.
    PubMed     Abstract available


  181. QUE T, Huang G, Tan JE, Zhang P, et al
    Supramaximal resection based on en-bloc technique reduces tumor burden and prolongs survival in primary supratentorial lobar glioblastoma.
    J Neurooncol. 2023 Oct 2. doi: 10.1007/s11060-023-04399.
    PubMed     Abstract available


  182. STOCKDILL ML, Mendoza T, Armstrong TS, Miaskowski C, et al
    Identification of health-related quality of life profiles among long-term survivors of primary central nervous system tumors.
    J Neurooncol. 2023;165:181-190.
    PubMed     Abstract available


  183. BAI K, Chen X, Qi X, Zhang Y, et al
    Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases.
    J Neurooncol. 2023;165:149-160.
    PubMed     Abstract available


  184. ONISHI S, Yamasaki F, Amatya VJ, Takayasu T, et al
    Residual diffusion-weighted imaging hyperintense signal in primary central nervous system lymphoma can predict early recurrence.
    J Neurooncol. 2023;165:171-179.
    PubMed     Abstract available


  185. GUTIERREZ-VALENCIA E, Sanchez I, Valles A, Diaz O, et al
    Pachymeningeal disease: a systematic review and metanalysis.
    J Neurooncol. 2023;165:29-39.
    PubMed     Abstract available


    September 2023
  186. VAN T HEK R, Ortiz-Herrera JL, Salazar-Pigeon A, Ramirez-Loera C, et al
    Age and sex disparities in Latin-American adults with gliomas: a systematic review and meta-analysis.
    J Neurooncol. 2023 Sep 29. doi: 10.1007/s11060-023-04448.
    PubMed     Abstract available


  187. KARABACAK M, Jagtiani P, Carrasquilla A, Shrivastava RK, et al
    Advancing personalized prognosis in atypical and anaplastic meningiomas through interpretable machine learning models.
    J Neurooncol. 2023 Sep 28. doi: 10.1007/s11060-023-04463.
    PubMed     Abstract available


  188. VAN DER MEER PB, Dirven L, Fiocco M, Vos MJ, et al
    Impact of timing of antiseizure medication withdrawal on seizure recurrence in glioma patients: a retrospective observational study.
    J Neurooncol. 2023 Sep 27. doi: 10.1007/s11060-023-04450.
    PubMed     Abstract available


  189. LI L, Shao MY, Zou SC, Xiao ZF, et al
    Correction to: MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44.
    J Neurooncol. 2023 Sep 22. doi: 10.1007/s11060-023-04429.
    PubMed    


  190. MARWAH R, Xing D, Squire T, Soon YY, et al
    Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity.
    J Neurooncol. 2023 Sep 21. doi: 10.1007/s11060-023-04441.
    PubMed     Abstract available


  191. SHEEHAN JP, Trifiletti DM
    Comments: neurosurgery and radiation oncology advances have improved visual outcomes for skull base meningioma patients.
    J Neurooncol. 2023 Sep 18. doi: 10.1007/s11060-023-04400.
    PubMed    


  192. KUAN AS, Chiang CL, Wu HM, Yang HC, et al
    Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses.
    J Neurooncol. 2023 Sep 18. doi: 10.1007/s11060-023-04452.
    PubMed     Abstract available


  193. FURUTA T, Negoto T, Miyoshi H, Moritsubo M, et al
    Intratumoral thrombosis as a histological biomarker for predicting epidermal growth factor receptor alteration and poor prognosis in patients with glioblastomas.
    J Neurooncol. 2023 Sep 14. doi: 10.1007/s11060-023-04447.
    PubMed     Abstract available


  194. IGLSEDER S, Iglseder A, Beliveau V, Heugenhauser J, et al
    Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.
    J Neurooncol. 2023 Sep 14. doi: 10.1007/s11060-023-04414.
    PubMed     Abstract available


  195. KATLOWITZ KA, Athukuri P, Sharma H, Dang H, et al
    Seizure outcomes after resection of primary brain tumors in pediatric patients: a systematic review and meta-analysis.
    J Neurooncol. 2023 Sep 14. doi: 10.1007/s11060-023-04446.
    PubMed     Abstract available


  196. JABEHDAR MARALANI P, Stewart J, Hiremath S, Lawrence L, et al
    Relationship between apparent diffusion coefficient and survival as a function of distance from gross tumor volume on radiation planning MRI in newly diagnosed glioblastoma.
    J Neurooncol. 2023 Sep 14. doi: 10.1007/s11060-023-04440.
    PubMed     Abstract available


  197. DIMOV D, Brainman D, Berger B, Coras R, et al
    The role of cytoreductive surgery in multifocal/multicentric glioblastomas.
    J Neurooncol. 2023 Sep 12. doi: 10.1007/s11060-023-04410.
    PubMed     Abstract available


  198. NINATTI G, Pini C, Bono BC, Gelardi F, et al
    The prognostic power of [(11)C]methionine PET in IDH-wildtype diffuse gliomas with lower-grade histological features: venturing beyond WHO classification.
    J Neurooncol. 2023 Sep 11. doi: 10.1007/s11060-023-04438.
    PubMed     Abstract available


  199. ALZATE JD, Mullen R, Mashiach E, Bernstein K, et al
    EGFR-mutated non-small lung cancer brain metastases and radiosurgery outcomes with a focus on leptomeningeal disease.
    J Neurooncol. 2023 Sep 10. doi: 10.1007/s11060-023-04442.
    PubMed     Abstract available


  200. SOHN B, Park K, Ahn SS, Park YW, et al
    Dynamic contrast-enhanced MRI radiomics model predicts epidermal growth factor receptor amplification in glioblastoma, IDH-wildtype.
    J Neurooncol. 2023 Sep 10. doi: 10.1007/s11060-023-04435.
    PubMed     Abstract available


  201. HOU Z, Hu J, Liu X, Yan Z, et al
    Decision system for extent of resection in WHO grade 3 gliomas: a Chinese Glioma Genome Atlas database analysis.
    J Neurooncol. 2023 Sep 5. doi: 10.1007/s11060-023-04420.
    PubMed     Abstract available


  202. WU YY, Chen KT, Chu YC, Yeh CC, et al
    Neuropsychological impairment in primary malignant brain tumor patients with awake craniotomy: a hospital-based registration study.
    J Neurooncol. 2023 Sep 5. doi: 10.1007/s11060-023-04431.
    PubMed     Abstract available


  203. MURTHA AN, Zaki PG, Shepard MJ
    Letter to the editor: outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis.
    J Neurooncol. 2023 Sep 5. doi: 10.1007/s11060-023-04434.
    PubMed    


  204. LUCKETT PH, Olufawo M, Lamichhane B, Park KY, et al
    Predicting survival in glioblastoma with multimodal neuroimaging and machine learning.
    J Neurooncol. 2023 Sep 5. doi: 10.1007/s11060-023-04439.
    PubMed     Abstract available


  205. HUNG JS, Su YH, Chen CJ, Chiang CL, et al
    Is it advisable to perform radiosurgery for EGFR-TKI-controlled brain metastases? A retrospective study of the role of radiosurgery in lung cancer treatment.
    J Neurooncol. 2023 Sep 1. doi: 10.1007/s11060-023-04425.
    PubMed     Abstract available


  206. CIFARELLI CP, Vargo JA, Sener U, Cifarelli DT, et al
    Intracranial intraoperative radiotherapy (IORT): evaluation of electrocorticography and peri-operative seizure risk.
    J Neurooncol. 2023;164:423-430.
    PubMed     Abstract available


  207. MINNITI G, Paolini S, Antonelli M, Gianno F, et al
    Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma.
    J Neurooncol. 2023;164:331-339.
    PubMed     Abstract available


  208. HOU L, Chen X, Qiu G, Qi X, et al
    Cerebrospinal fluid exosomal protein alterations via proteomic analysis of NSCLC with leptomeningeal carcinomatosis.
    J Neurooncol. 2023;164:367-376.
    PubMed     Abstract available


  209. FIGUEREDO LF, Shelton WJ, Tagle-Vega U, Sanchez E, et al
    The state of art of awake craniotomy in Latin American countries: a scoping review.
    J Neurooncol. 2023;164:287-298.
    PubMed     Abstract available


  210. ID SAID B, Soliman H, Moravan V, Myrehaug S, et al
    Patterns of treatment and outcomes of patients with brain-only metastatic breast cancer.
    J Neurooncol. 2023;164:437-445.
    PubMed     Abstract available


  211. ZENG C, Yang Q, Li Z, Wei Z, et al
    Treatment outcomes for response-based radiotherapy in children and adolescents with central nervous system germinoma: a prospective study.
    J Neurooncol. 2023;164:643-653.
    PubMed     Abstract available


  212. ZEYEN T, Paech D, Weller J, Schafer N, et al
    Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
    J Neurooncol. 2023;164:607-616.
    PubMed     Abstract available


    August 2023
  213. PERTZ M, Schlomer S, Seidel C, Hentschel B, et al
    Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up.
    J Neurooncol. 2023 Aug 30. doi: 10.1007/s11060-023-04419.
    PubMed     Abstract available


  214. JIA W, Zhai X, Jing X, Bao Q, et al
    Prognostic value of cranial radiotherapy and optimal timing stratified by lung-molGPA for NSCLC patients with brain metastases.
    J Neurooncol. 2023 Aug 30. doi: 10.1007/s11060-023-04426.
    PubMed     Abstract available


  215. WAGENER K, Beckhaus J, Boekhoff S, Friedrich C, et al
    Publisher Correction to: Sporadic and neurofibromatosis type 2-associated meningioma in children and adolescents.
    J Neurooncol. 2023 Aug 29. doi: 10.1007/s11060-023-04424.
    PubMed    


  216. QURESHI HM, Tabor JK, Pickens K, Lei H, et al
    Frailty and postoperative outcomes in brain tumor patients: a systematic review subdivided by tumor etiology.
    J Neurooncol. 2023 Aug 25. doi: 10.1007/s11060-023-04416.
    PubMed     Abstract available


  217. DE PIETRO R, Zaccaro L, Marampon F, Tini P, et al
    The evolving role of reirradiation in the management of recurrent brain tumors.
    J Neurooncol. 2023 Aug 25. doi: 10.1007/s11060-023-04407.
    PubMed     Abstract available


  218. LEHRER EJ, Trifiletti DM, Sheehan JP
    Stereotactic radiosurgery in patients with extensive brain metastases - supporting evidence and knowledge gaps.
    J Neurooncol. 2023 Aug 21. doi: 10.1007/s11060-023-04422.
    PubMed    


  219. EBIKO Y, Tamura K, Hara S, Inaji M, et al
    T2-FLAIR mismatch sign correlates with (11)C-methionine uptake in lower-grade diffuse gliomas.
    J Neurooncol. 2023 Aug 17. doi: 10.1007/s11060-023-04417.
    PubMed     Abstract available


  220. GURRIERI L, Mercatali L, Ibrahim T, Fausti V, et al
    Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series.
    J Neurooncol. 2023 Aug 16. doi: 10.1007/s11060-023-04357.
    PubMed     Abstract available


  221. LAWSON MCLEAN A
    Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib.
    J Neurooncol. 2023 Aug 10. doi: 10.1007/s11060-023-04408.
    PubMed    


  222. MIER-GARCIA JF, Ospina-Santa S, Orozco-Mera J, Ma R, et al
    Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis.
    J Neurooncol. 2023 Aug 10. doi: 10.1007/s11060-023-04409.
    PubMed     Abstract available


  223. JABLONSKA PA, Muniz T, Ribeiro M, Liu ZA, et al
    Toxicity and outcomes of melanoma brain metastases treated with stereotactic radiosurgery: the risk of subsequent symptomatic intralesional hemorrhage exceeds that of radiation necrosis.
    J Neurooncol. 2023 Aug 8. doi: 10.1007/s11060-023-04404.
    PubMed     Abstract available


  224. OTANI R, Ikegami M, Yamada R, Yajima H, et al
    PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort.
    J Neurooncol. 2023 Aug 8. doi: 10.1007/s11060-023-04411.
    PubMed     Abstract available


  225. HOLDAWAY M, Ablyazova F, Huda S, D'Amico RS, et al
    First in-human intrathecal delivery of bevacizumab for leptomeningeal spread from recurrent glioblastoma: rationale for a dose escalation trial.
    J Neurooncol. 2023 Aug 7. doi: 10.1007/s11060-023-04412.
    PubMed     Abstract available


  226. LANG A, Jeron RL, Lontzek B, Kiesel B, et al
    Mapping high-grade glioma immune infiltration to 5-ALA fluorescence levels: TCGA data computation, classical histology, and digital image analysis.
    J Neurooncol. 2023 Aug 6. doi: 10.1007/s11060-023-04406.
    PubMed     Abstract available


  227. NEUMANN B, Onken J, Konig N, Stetefeld H, et al
    Outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis.
    J Neurooncol. 2023 Aug 2. doi: 10.1007/s11060-023-04403.
    PubMed     Abstract available


  228. AKINDURO OO, Ghaith AK, El-Hajj VG, Ghanem M, et al
    Effect of race, sex, and socioeconomic factors on overall survival following the resection of intramedullary spinal cord tumors.
    J Neurooncol. 2023;164:75-85.
    PubMed     Abstract available


  229. NETH BJ, Webb MJ, White J, Uhm JH, et al
    Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience.
    J Neurooncol. 2023;164:239-247.
    PubMed     Abstract available


    July 2023
  230. NODA R, Kawashima M, Segawa M, Tsunoda S, et al
    Fractionated versus staged gamma knife radiosurgery for mid-to-large brain metastases: a propensity score-matched analysis.
    J Neurooncol. 2023 Jul 31. doi: 10.1007/s11060-023-04374.
    PubMed     Abstract available


  231. HU T, Xuan R, Han E, Cai L, et al
    SPOPL induces tumorigenicity and stemness in glioma stem cells by activating Notch signaling.
    J Neurooncol. 2023 Jul 31. doi: 10.1007/s11060-023-04394.
    PubMed     Abstract available


  232. MANTICA M, Drappatz J, Lieberman F, Hadjipanayis CG, et al
    Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme.
    J Neurooncol. 2023 Jul 29. doi: 10.1007/s11060-023-04398.
    PubMed     Abstract available


  233. VIOZZI I, Overduin CG, Rijpma A, Rovers MM, et al
    MR-guided LITT therapy in patients with primary irresectable glioblastoma: a prospective, controlled pilot study.
    J Neurooncol. 2023 Jul 28. doi: 10.1007/s11060-023-04371.
    PubMed     Abstract available


  234. BALLO MT, Conlon P, Lavy-Shahaf G, Kinzel A, et al
    Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
    J Neurooncol. 2023 Jul 26. doi: 10.1007/s11060-023-04348.
    PubMed     Abstract available


  235. RAVIN R, Suarez-Meade P, Busse B, Blank PS, et al
    Perivascular invasion of primary human glioblastoma cells in organotypic human brain slices: human cells migrating in human brain.
    J Neurooncol. 2023 Jul 25. doi: 10.1007/s11060-023-04349.
    PubMed     Abstract available


  236. KHATRI VM, Mills MN, Oliver DE, Yu HM, et al
    Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases.
    J Neurooncol. 2023 Jul 25. doi: 10.1007/s11060-023-04402.
    PubMed     Abstract available


  237. SPILLE DC, Thomas C, Wagner A, Grauer OM, et al
    Molecular predictors for decitabine efficacy in meningiomas - a pilot study.
    J Neurooncol. 2023 Jul 21. doi: 10.1007/s11060-023-04379.
    PubMed     Abstract available


  238. LAYER JP, Hamed M, Potthoff AL, Dejonckheere CS, et al
    Outcome assessment of intraoperative radiotherapy for brain metastases: results of a prospective observational study with comparative matched-pair analysis.
    J Neurooncol. 2023 Jul 21. doi: 10.1007/s11060-023-04380.
    PubMed     Abstract available


  239. BUYUKTEPE M, Kaplan I, Bayatli E, Dogan H, et al
    Significance of O6-methyl guanine methyltransferase promoter methylation in high grade glioma patients: optimal cutoff point, CpG locus, and genetic assay.
    J Neurooncol. 2023 Jul 20. doi: 10.1007/s11060-023-04397.
    PubMed     Abstract available


  240. ZHANG YT, Wang Y, Zhong XD, Chang J, et al
    Efficacy of intrathecal methotrexate in children with high-risk medulloblastoma over three years: a retrospective study from a single center.
    J Neurooncol. 2023 Jul 20. doi: 10.1007/s11060-023-04388.
    PubMed     Abstract available


  241. TAORI S, Wei Z, Deng H, Hadjipanayis CG, et al
    Stereotactic radiosurgery for patients with brain metastases from gastroesophageal cancers.
    J Neurooncol. 2023 Jul 20. doi: 10.1007/s11060-023-04392.
    PubMed     Abstract available


  242. YANG X, Ji C, Qi Y, Huang J, et al
    Signal-transducing adaptor protein 1 (STAP1) in microglia promotes the malignant progression of glioma.
    J Neurooncol. 2023 Jul 18. doi: 10.1007/s11060-023-04390.
    PubMed     Abstract available


  243. CHOJAK R, Fares J, Petrosyan E, Lesniak MS, et al
    Cellular senescence in glioma.
    J Neurooncol. 2023 Jul 17. doi: 10.1007/s11060-023-04387.
    PubMed     Abstract available


  244. MALLICK S, Gupta S, Amariyil A, Kunhiparambath H, et al
    Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial.
    J Neurooncol. 2023 Jul 15. doi: 10.1007/s11060-023-04391.
    PubMed     Abstract available


  245. ONYIAH C, Shepard MJ
    Letter: are there incidences of clinically relevant psychiatric symptoms during glioblastoma treatment?
    J Neurooncol. 2023 Jul 13. doi: 10.1007/s11060-023-04376.
    PubMed    


  246. MATSUI JK, Allen PK, Perlow HK, Johnson JM, et al
    Prognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience.
    J Neurooncol. 2023 Jul 13. doi: 10.1007/s11060-023-04386.
    PubMed     Abstract available


  247. OTANI R, Sadato D, Yamada R, Yajima H, et al
    CHD5 gene variant predicts leptomeningeal metastasis after surgical resection of brain metastases of breast cancer.
    J Neurooncol. 2023 Jul 13. doi: 10.1007/s11060-023-04381.
    PubMed     Abstract available


  248. LEI H, Tabor JK, O'Brien J, Qin R, et al
    Associations of race and socioeconomic status with outcomes after intracranial meningioma resection: a systematic review and meta-analysis.
    J Neurooncol. 2023 Jul 13. doi: 10.1007/s11060-023-04393.
    PubMed     Abstract available


  249. INDHARTY RS, Japardi I, Irina RS, Tandean S, et al
    Comparison of direct cortical stimulation and transcranial magnetic stimulation in brain tumor surgery: systematic review and meta analyses.
    J Neurooncol. 2023 Jul 12. doi: 10.1007/s11060-023-04378.
    PubMed     Abstract available


  250. YADAV N, Babu D, Madigubba S, Panigrahi M, et al
    Tyrphostin A9 attenuates glioblastoma growth by suppressing PYK2/EGFR-ERK signaling pathway.
    J Neurooncol. 2023 Jul 6. doi: 10.1007/s11060-023-04383.
    PubMed     Abstract available


  251. MISHRA A, Koffler D, Calugaru E, Rowe N, et al
    Let's make size not matter: tumor control and toxicity outcomes of hypofractionated Gamma Knife radiosurgery for large brain metastases.
    J Neurooncol. 2023 Jul 6. doi: 10.1007/s11060-023-04365.
    PubMed     Abstract available


  252. TANRIKULU B, Yasar AH, Canpolat C, Corapcioglu F, et al
    Preliminary findings of German-sourced ONC201 treatment in H3K27 altered pediatric pontine diffuse midline gliomas.
    J Neurooncol. 2023 Jul 4. doi: 10.1007/s11060-023-04347.
    PubMed     Abstract available


  253. WAGENER K, Beckhaus J, Boekhoff S, Friedrich C, et al
    Sporadic and neurofibromatosis type 2-associated meningioma in children and adolescents.
    J Neurooncol. 2023 Jul 4. doi: 10.1007/s11060-023-04344.
    PubMed     Abstract available


  254. LUO M, Tang R, Wang H
    Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
    J Neurooncol. 2023;163:663-674.
    PubMed     Abstract available


  255. LESKINEN S, Shah HA, Yaffe B, Schneider SJ, et al
    Hippocampal avoidance in whole brain radiotherapy and prophylactic cranial irradiation: a systematic review and meta-analysis.
    J Neurooncol. 2023;163:515-527.
    PubMed     Abstract available


    June 2023
  256. JONNAKUTI VS, Ji P, Gao Y, Lin A, et al
    NUDT21 alters glioma migration through differential alternative polyadenylation of LAMC1.
    J Neurooncol. 2023 Jun 30. doi: 10.1007/s11060-023-04370.
    PubMed     Abstract available


  257. MEISSNER AK, Gutsche R, Galldiks N, Kocher M, et al
    Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancer.
    J Neurooncol. 2023 Jun 29. doi: 10.1007/s11060-023-04367.
    PubMed     Abstract available


  258. MOORE-PALHARES D, Chen H, Keith J, Wang M, et al
    Correction to: Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis.
    J Neurooncol. 2023 Jun 28. doi: 10.1007/s11060-023-04364.
    PubMed    


  259. ADILE AA, Bakhshinyan D, Suk Y, Uehling D, et al
    An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma.
    J Neurooncol. 2023 Jun 24. doi: 10.1007/s11060-023-04372.
    PubMed     Abstract available


  260. HOLDAWAY M, Starner J, Patel RR, Salama J, et al
    Improvement in visual outcomes of patients with base of skull meningioma as a result of evolution in the treatment techniques in the last three decades: a systematic review.
    J Neurooncol. 2023 Jun 24. doi: 10.1007/s11060-023-04366.
    PubMed     Abstract available


  261. CHEN J, Li T, Zhou N, He Y, et al
    Engineered Salmonella inhibits GPX4 expression and induces ferroptosis to suppress glioma growth in vitro and in vivo.
    J Neurooncol. 2023 Jun 23. doi: 10.1007/s11060-023-04369.
    PubMed     Abstract available


  262. TOM MC, DiFilippo FP, Jones SE, Suh JH, et al
    (18)F-fluciclovine PET/CT to distinguish radiation necrosis from tumor progression for brain metastases treated with radiosurgery: results of a prospective pilot study.
    J Neurooncol. 2023 Jun 21. doi: 10.1007/s11060-023-04377.
    PubMed     Abstract available


  263. MASSIMINO M, Vennarini S, Buttarelli FR, Antonelli M, et al
    Optimizing reirradiation for relapsed medulloblastoma: identifying the ideal patient and tumor profiles.
    J Neurooncol. 2023 Jun 16. doi: 10.1007/s11060-023-04361.
    PubMed     Abstract available


  264. KHAN AB, Patel R, McDonald MF, Goethe E, et al
    Integrated clinical genomic analysis reveals xenobiotic metabolic genes are downregulated in meningiomas of current smokers.
    J Neurooncol. 2023 Jun 15. doi: 10.1007/s11060-023-04359.
    PubMed     Abstract available


  265. JOST J, Muther M, Brandt R, Altuner U, et al
    Conceptual development of an intensive exercise program for glioma patients (ActiNO): summary of clinical experience.
    J Neurooncol. 2023 Jun 12. doi: 10.1007/s11060-023-04354.
    PubMed     Abstract available


  266. MERENZON MA, Levy AS, Bhatia S, Rivera C, et al
    Towards the definition of progressive disease in brain metastasis treated with laser ablation: an evidence-based study.
    J Neurooncol. 2023 Jun 12. doi: 10.1007/s11060-023-04360.
    PubMed     Abstract available


  267. CHO NS, Sanvito F, Thakuria S, Wang C, et al
    Multi-nuclear sodium, diffusion, and perfusion MRI in human gliomas.
    J Neurooncol. 2023 Jun 9. doi: 10.1007/s11060-023-04363.
    PubMed     Abstract available


  268. WELLER J, Katzendobler S, Niedermeyer S, Harter PN, et al
    Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status.
    J Neurooncol. 2023 Jun 8. doi: 10.1007/s11060-023-04362.
    PubMed     Abstract available


  269. NAGAI N, Koide Y, Shindo Y, Hashimoto S, et al
    Retrospective non-inferiority study of stereotactic radiosurgery for more than ten brain metastases.
    J Neurooncol. 2023 Jun 7. doi: 10.1007/s11060-023-04358.
    PubMed     Abstract available


  270. TOKLU S, Kemerdere R, Kacira T, Gurses MS, et al
    Tissue and plasma free amino acid detection by LC-MS/MS method in high grade glioma patients.
    J Neurooncol. 2023 Jun 6. doi: 10.1007/s11060-023-04329.
    PubMed     Abstract available


  271. MA J, Li D, Hong Y, Zhang Y, et al
    Different clinical and cytogenetic features of primary skull base meningiomas and non-skull base meningiomas.
    J Neurooncol. 2023 Jun 2. doi: 10.1007/s11060-023-04351.
    PubMed     Abstract available


  272. VAN SCHIE P, Rijksen BLT, Bot M, Wiersma T, et al
    Optimizing treatment of brain metastases in an era of novel systemic treatments: a single center consecutive series.
    J Neurooncol. 2023 Jun 2. doi: 10.1007/s11060-023-04343.
    PubMed     Abstract available


  273. CACCESE M, Desideri I, Padovan M, Bruno F, et al
    Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study.
    J Neurooncol. 2023 Jun 1. doi: 10.1007/s11060-023-04356.
    PubMed     Abstract available


  274. BISWAS A, Salvucci M, Connor K, Dussmann H, et al
    Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors.
    J Neurooncol. 2023;163:327-338.
    PubMed     Abstract available


    May 2023
  275. MOORE-PALHARES D, Chen H, Keith J, Wang M, et al
    Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis.
    J Neurooncol. 2023 May 31. doi: 10.1007/s11060-023-04340.
    PubMed     Abstract available


  276. BANDER ED, Kelly A, Ma X, Christos PJ, et al
    Safety and efficacy of Cesium-131 brachytherapy for brain tumors.
    J Neurooncol. 2023 May 30. doi: 10.1007/s11060-023-04352.
    PubMed     Abstract available


  277. MCLAUGHLIN LA, Yildirim O, Rosenblum MK, Imber BS, et al
    Identification of incidental brain tumors in prostate cancer patients via PSMA PET/CT.
    J Neurooncol. 2023 May 29. doi: 10.1007/s11060-023-04355.
    PubMed     Abstract available


  278. SHEEHAN J, Cifarelli CP, Fadul C
    Contemporary care for brain metastasis patients: multidisciplinary approaches and the role of prospective national registries.
    J Neurooncol. 2023 May 25. doi: 10.1007/s11060-023-04350.
    PubMed    


  279. BUSCH N, Wegner RE, Shepard MJ
    Letter to the editor: neurocognitive functioning after Gamma Knife and LINAC stereotactic radiosurgery in patients with brain metastases.
    J Neurooncol. 2023 May 25. doi: 10.1007/s11060-023-04345.
    PubMed    


  280. TINI P, Yavoroska M, Mazzei MA, Miracco C, et al
    Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status.
    J Neurooncol. 2023 May 25. doi: 10.1007/s11060-023-04342.
    PubMed     Abstract available


  281. JURATLI TA, Jungk C, Miller JJ
    Journal of Neuro Oncology: Diagnostic and therapeutic implications of IDH mutations in gliomas following the 2021 World Health Organization classification of CNS tumors.
    J Neurooncol. 2023 May 22. doi: 10.1007/s11060-023-04317.
    PubMed    


  282. CROOMS RC, Taylor JW, Jette N, Morgenstern R, et al
    Palliative care referral across the disease trajectory in high-grade glioma.
    J Neurooncol. 2023 May 20. doi: 10.1007/s11060-023-04338.
    PubMed     Abstract available


  283. FENG X, Zhu F, Dai L, Liu X, et al
    Caspase-3 in glioma indicates an unfavorable prognosis by involving surrounding angiogenesis and tumor cell repopulation.
    J Neurooncol. 2023 May 17. doi: 10.1007/s11060-023-04339.
    PubMed     Abstract available


  284. KNIGHT A, Horsley P, Yuile A, Yim J, et al
    Volumetric response and pattern of failure of histone altered high grade glioma in adults following management with radiation therapy.
    J Neurooncol. 2023 May 15. doi: 10.1007/s11060-023-04332.
    PubMed     Abstract available


  285. VALINCIUTE G, Ecker J, Selt F, Hielscher T, et al
    Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells.
    J Neurooncol. 2023 May 15. doi: 10.1007/s11060-023-04319.
    PubMed     Abstract available


  286. BONOSI L, Marino S, Benigno UE, Musso S, et al
    Sonodynamic therapy and magnetic resonance-guided focused ultrasound: new therapeutic strategy in glioblastoma.
    J Neurooncol. 2023 May 14. doi: 10.1007/s11060-023-04333.
    PubMed     Abstract available


  287. ZILIOLI A, Misirocchi F, Mutti C, Pancaldi B, et al
    Volumetric hippocampal changes in glioblastoma: a biomarker for neuroplasticity?
    J Neurooncol. 2023 May 13. doi: 10.1007/s11060-023-04315.
    PubMed     Abstract available


  288. MA Y, Shi F, Sun T, Chen H, et al
    Histopathological auxiliary system for brain tumour (HAS-Bt) based on weakly supervised learning using a WHO CNS5-style pipeline.
    J Neurooncol. 2023 May 13. doi: 10.1007/s11060-023-04306.
    PubMed     Abstract available


  289. MERLIN MS, Schmitt E, Mezloy-Destracque M, Dufour C, et al
    Neurocognitive and radiological follow-up of children under 5 years of age treated for medulloblastoma according to the HIT-SKK protocol.
    J Neurooncol. 2023 May 12. doi: 10.1007/s11060-023-04328.
    PubMed     Abstract available


  290. PADILLA CS, Ho VKY, Mooijenkind TWAN, Louwman MWJ, et al
    Brain metastases in adult patients with melanoma of unknown primary in the Netherlands (2011-2020).
    J Neurooncol. 2023 May 12. doi: 10.1007/s11060-023-04335.
    PubMed     Abstract available


  291. ZABEK T, Szmatola T, Adamczyk-Grochala J, Lewinska A, et al
    Knockout of TRDMT1 methyltransferase affects DNA methylome in glioblastoma cells.
    J Neurooncol. 2023 May 11. doi: 10.1007/s11060-023-04304.
    PubMed     Abstract available


  292. KALYVAS A, Gutierrez-Valencia E, Lau R, Ye XY, et al
    Anatomical and surgical characteristics correlate with pachymeningeal failure in patients with brain metastases after neurosurgical resection and adjuvant stereotactic radiosurgery.
    J Neurooncol. 2023 May 10. doi: 10.1007/s11060-023-04325.
    PubMed     Abstract available


  293. REGLI LKP, Huijs SMH, Pasmans RCOS, Leue C, et al
    Incidence of clinically relevant psychiatric symptoms during glioblastoma treatment: an exploratory study.
    J Neurooncol. 2023 May 10. doi: 10.1007/s11060-023-04326.
    PubMed     Abstract available


  294. SAUNDERS JT, Kumar S, Benavides-Serrato A, Holmes B, et al
    Translation of circHGF RNA encodes an HGF protein variant promoting glioblastoma growth through stimulation of c-MET.
    J Neurooncol. 2023 May 10. doi: 10.1007/s11060-023-04331.
    PubMed     Abstract available


  295. LAZZARINI E, Silvestris DA, Benvenuto G, Osti D, et al
    Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors.
    J Neurooncol. 2023 May 4. doi: 10.1007/s11060-023-04287.
    PubMed     Abstract available


  296. ZUO P, Li Y, Wang T, Lin X, et al
    A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma.
    J Neurooncol. 2023 May 3. doi: 10.1007/s11060-023-04323.
    PubMed     Abstract available


  297. FISHMAN H, Monin R, Dor-On E, Kinzel A, et al
    Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
    J Neurooncol. 2023 May 2. doi: 10.1007/s11060-023-04308.
    PubMed     Abstract available


  298. TRAVERS SS, Fisher CM, Kabos P, Cittelly DM, et al
    Breast cancer brain metastases localization and risk of hydrocephalus: a single institution experience.
    J Neurooncol. 2023 May 2. doi: 10.1007/s11060-023-04314.
    PubMed     Abstract available


  299. DE GODOY LL, Chawla S, Brem S, Wang S, et al
    Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.
    J Neurooncol. 2023 May 2. doi: 10.1007/s11060-023-04324.
    PubMed     Abstract available


  300. YE L, Wu BS, Xu ZA, Ji XF, et al
    Evidence for an intra-tumoral microbiome in pituitary neuroendocrine tumors with different clinical phenotypes.
    J Neurooncol. 2023;163:133-142.
    PubMed     Abstract available


  301. DEWAN MC, Isaacs AM, Cools MJ, Yengo-Kahn A, et al
    Treatment of hydrocephalus following posterior fossa tumor resection: a multicenter collaboration from the Hydrocephalus Clinical Research Network.
    J Neurooncol. 2023;163:123-132.
    PubMed     Abstract available


  302. LI Q, Ma Y, Lin Z, Ma J, et al
    A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.
    J Neurooncol. 2023;163:39-46.
    PubMed     Abstract available


    April 2023
  303. AMELOT A, Terrier LM, Cognacq G, Jecko V, et al
    Correction to: Natural history of spinal cord metastasis from brain glioblastomas.
    J Neurooncol. 2023 Apr 26. doi: 10.1007/s11060-023-04320.
    PubMed    


  304. SENGUPTA S
    Integrative neuro-oncology for brain tumor patients.
    J Neurooncol. 2023 Apr 25. doi: 10.1007/s11060-023-04309.
    PubMed    


  305. CHANG WH, Wei KC, Chen PY, Chen YC, et al
    The impact of patient factors and tumor characteristics on language neuroplasticity in left hemispheric diffuse gliomas prior to surgical resection.
    J Neurooncol. 2023 Apr 24. doi: 10.1007/s11060-023-04311.
    PubMed     Abstract available


  306. TRACZ JA, Donnelly BM, Ngu S, Vojnic M, et al
    The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma.
    J Neurooncol. 2023 Apr 22. doi: 10.1007/s11060-023-04312.
    PubMed     Abstract available


  307. SYED HR, Kilburn L, Fonseca A, Nazarian J, et al
    First-in-human sonodynamic therapy with ALA for pediatric diffuse intrinsic pontine glioma: a phase 1/2 study using low-intensity focused ultrasound : Technical communication.
    J Neurooncol. 2023 Apr 12. doi: 10.1007/s11060-023-04269.
    PubMed    


  308. DEMETZ M, Krigers A, Moser P, Kerschbaumer J, et al
    Same but different. Incidental and symptomatic lower grade gliomas show differences in molecular features and survival.
    J Neurooncol. 2023 Apr 12. doi: 10.1007/s11060-023-04301.
    PubMed     Abstract available


  309. ALTIERI R, Certo F, Pacella D, Cammarata G, et al
    Metabolic delineation of IDH1 wild-type glioblastoma surgical anatomy: how to plan the tumor extent of resection.
    J Neurooncol. 2023 Apr 11. doi: 10.1007/s11060-023-04305.
    PubMed     Abstract available


  310. VOON NS, Manan HA, Yahya N
    Remote assessment of cognition and quality of life following radiotherapy for glioma: deep-learning-based predictive models and MRI correlates.
    J Neurooncol. 2023 Apr 4:1-9. doi: 10.1007/s11060-023-04303.
    PubMed     Abstract available


  311. DINCER A, Morales-Valero SF, Robert SM, Tabor JK, et al
    Surgical strategies for intracranial meningioma in the molecular era.
    J Neurooncol. 2023 Apr 3. doi: 10.1007/s11060-023-04272.
    PubMed     Abstract available


  312. YAMASHITA S, Takeshima H, Hata N, Uchida H, et al
    Clinicopathologic analysis of pineal parenchymal tumors of intermediate differentiation: a multi-institutional cohort study by the Kyushu Neuro-Oncology Study Group.
    J Neurooncol. 2023;162:425-433.
    PubMed     Abstract available


  313. FOO JC, Yaman Bajin I, Marushchak O, McKeown T, et al
    Time to dismiss boost? Outcomes of children with localized and metastatic germinoma.
    J Neurooncol. 2023;162:443-448.
    PubMed     Abstract available


  314. ROEHRIG A, Indelicato DJ, Paulino AC, Ermoian R, et al
    Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR).
    J Neurooncol. 2023;162:353-362.
    PubMed     Abstract available


  315. KEARNS K, Shepard MJ, Sheehan JP
    Social media and the Journal of Neuro-Oncology.
    J Neurooncol. 2023;162:453-454.
    PubMed    


    March 2023
  316. AYMERIC A, Louis-Marie T, Gabrielle C, Vincent J, et al
    Natural history of spinal cord metastasis from brain glioblastomas.
    J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04298.
    PubMed     Abstract available


  317. QUAN G, Wang T, Ren JL, Xue X, et al
    Prognostic and predictive impact of abnormal signal volume evolution early after chemoradiotherapy in glioblastoma.
    J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04299.
    PubMed     Abstract available


  318. CHAMPEAUX-DEPOND C, Jecko V, Weller J, Constantinou P, et al
    Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study.
    J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04295.
    PubMed     Abstract available


  319. OZKARA BB, Federau C, Dagher SA, Pattnaik D, et al
    Correlating volumetric and linear measurements of brain metastases on MRI scans using intelligent automation software: a preliminary study.
    J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04297.
    PubMed     Abstract available


  320. ZHA B, Yang J, Dang Q, Li P, et al
    A phase I clinical trial of sonodynamic therapy combined with temozolomide in the treatment of recurrent glioblastoma.
    J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04292.
    PubMed     Abstract available


  321. POPPE JP, Schwartz C
    In reply to the letter to the editor by Busch et al. regarding "Surgeon experience in glioblastoma surgery of the elderly-a multicenter, retrospective cohort study".
    J Neurooncol. 2023 Mar 29. doi: 10.1007/s11060-023-04302.
    PubMed    


  322. KIMURA K, Deguchi S, Mitsuya K, Mamesaya N, et al
    Validation of the initial brain metastasis velocity in non-small cell lung cancer at a single cancer center.
    J Neurooncol. 2023 Mar 28. doi: 10.1007/s11060-023-04300.
    PubMed     Abstract available


  323. WAMELINK IJHG, Hempel HL, van de Giessen E, Vries MHM, et al
    The patients' experience of neuroimaging of primary brain tumors: a cross-sectional survey study.
    J Neurooncol. 2023 Mar 28. doi: 10.1007/s11060-023-04290.
    PubMed     Abstract available


  324. IUS T, Sabatino G, Panciani PP, Fontanella MM, et al
    Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch(R)): a systematic review.
    J Neurooncol. 2023 Mar 24. doi: 10.1007/s11060-023-04274.
    PubMed     Abstract available


  325. PARSONS MW, Sabsevitz DS
    Cognitive issues in patients with IDH mutant gliomas: from neuroscience to clinical neuropsychology.
    J Neurooncol. 2023 Mar 20. doi: 10.1007/s11060-023-04289.
    PubMed     Abstract available


  326. LIANG L, Wen L, Qin S, He Z, et al
    Poor Karnofsky performance status is not a contraindication for neurosurgical resection in patients with lung cancer brain metastases: a multicenter, retrospective PSM-IPTW cohort study.
    J Neurooncol. 2023 Mar 20. doi: 10.1007/s11060-023-04293.
    PubMed     Abstract available


  327. SHAH DS, Reddy RV, Dogruel Y, Asfour MZ, et al
    Calcified spinal meningiomas: a systematic review of clinical characteristics, treatment strategies, and outcomes.
    J Neurooncol. 2023 Mar 17. doi: 10.1007/s11060-023-04291.
    PubMed     Abstract available


  328. QUACH S, Schwartz C, Aumiller M, Foglar M, et al
    Interstitial photodynamic therapy for newly diagnosed glioblastoma.
    J Neurooncol. 2023 Mar 16. doi: 10.1007/s11060-023-04284.
    PubMed     Abstract available


  329. BLEEKER L, Kouwenhoven MCM, de Heer I, Lissenberg-Witte BI, et al
    Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol.
    J Neurooncol. 2023 Mar 15. doi: 10.1007/s11060-023-04285.
    PubMed     Abstract available


  330. YAN M, Lee M, Myrehaug S, Tseng CL, et al
    Hypofractionated stereotactic radiosurgery (HSRS) as a salvage treatment for brain metastases failing prior stereotactic radiosurgery (SRS).
    J Neurooncol. 2023 Mar 13. doi: 10.1007/s11060-023-04265.
    PubMed     Abstract available


  331. DUFFAU H
    Occurrence of non-central nervous system cancers during postoperative follow-up of patients who underwent surgery for a WHO grade II glioma: implications for therapeutic management.
    J Neurooncol. 2023 Mar 13. doi: 10.1007/s11060-023-04288.
    PubMed     Abstract available


  332. KING AL, Roche KN, Leeper HE, Vera E, et al
    Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trial.
    J Neurooncol. 2023 Mar 8:1-9. doi: 10.1007/s11060-023-04271.
    PubMed     Abstract available


  333. JUSINO S, Fadul CE, Dillon P
    Systematic review of the management of brain metastases from hormone receptor positive breast cancer.
    J Neurooncol. 2023 Mar 8. doi: 10.1007/s11060-023-04276.
    PubMed     Abstract available


  334. TRIFILETTI DM, Akinyelu T, Burri SH, Jeudy A, et al
    Glioma inadvertently treated with preoperative stereotactic radiosurgery: focusing on safety.
    J Neurooncol. 2023 Mar 6. doi: 10.1007/s11060-023-04278.
    PubMed    


  335. MARTIN JA, Hart NH, Bradford N, Naumann F, et al
    Prevalence and management of sleep disturbance in adults with primary brain tumours and their caregivers: a systematic review.
    J Neurooncol. 2023 Mar 2. doi: 10.1007/s11060-023-04270.
    PubMed     Abstract available


  336. LI C, Guan N, Liu F
    T7 peptide-decorated exosome-based nanocarrier system for delivery of Galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma.
    J Neurooncol. 2023 Mar 1. doi: 10.1007/s11060-023-04257.
    PubMed     Abstract available


  337. THIERHEIMER M, Cioffi G, Waite KA, Kruchko C, et al
    Mortality trends in primary malignant brain and central nervous system tumors vary by histopathology, age, race, and sex.
    J Neurooncol. 2023;162:167-177.
    PubMed     Abstract available


  338. SHARMA M, Do TH, Palzer EF, Huling JD, et al
    Comparable safety profile between neuro-oncology procedures involving stereotactic needle biopsy (SNB) followed by laser interstitial thermal therapy (LITT) and LITT alone procedures.
    J Neurooncol. 2023;162:147-156.
    PubMed     Abstract available


  339. WEI Z, Pease M, Tang LW, Deng H, et al
    Radiosurgery outcomes in infratentorial juvenile pilocytic astrocytomas.
    J Neurooncol. 2023;162:157-165.
    PubMed     Abstract available


  340. CACCIOTTI C, Chua IS, Cuadra J, Ullrich NJ, et al
    Pediatric central nervous system tumor survivor and caregiver experiences with multidisciplinary telehealth.
    J Neurooncol. 2023;162:191-198.
    PubMed     Abstract available


  341. WESSELS PH, Boelens MC, Monkhorst K, Sonke GS, et al
    A review on genetic alterations in CNS metastases related to breast cancer treatment. Is there a role for liquid biopsies in CSF?
    J Neurooncol. 2023;162:1-13.
    PubMed     Abstract available


    February 2023
  342. TRINGALE KR, Wolden SL, Karajannis M, Haque S, et al
    Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma.
    J Neurooncol. 2023 Feb 28. doi: 10.1007/s11060-022-04235.
    PubMed     Abstract available


  343. MOLITERNO J, Brastianos PK
    Journal of Neuro-Oncology, Meningioma issue.
    J Neurooncol. 2023 Feb 27. doi: 10.1007/s11060-023-04251.
    PubMed    


  344. PARK YW, Han K, Kim S, Kwon H, et al
    Revisiting prognostic factors in glioma with leptomeningeal metastases: a comprehensive analysis of clinical and molecular factors and treatment modalities.
    J Neurooncol. 2023 Feb 25. doi: 10.1007/s11060-022-04233.
    PubMed     Abstract available


  345. WANG JZ, Nassiri F, Landry AP, Patil V, et al
    The multiomic landscape of meningiomas: a review and update.
    J Neurooncol. 2023 Feb 25. doi: 10.1007/s11060-023-04253.
    PubMed     Abstract available


  346. DE CASTRO DG, Sanematsu PI Jr, Pellizzon ACA, Suzuki SH, et al
    Intraoperative radiotherapy for brain metastases: first-stage results of a single-arm, open-label, phase 2 trial.
    J Neurooncol. 2023 Feb 24. doi: 10.1007/s11060-023-04266.
    PubMed     Abstract available


  347. PEI J, Li P, Gao YH, Tian BG, et al
    Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography-mass spectrometry (LC-MS/MS).
    J Neurooncol. 2023 Feb 22. doi: 10.1007/s11060-023-04256.
    PubMed     Abstract available


  348. UHLMANN EJ, Mackel CE, Deforzh E, Rabinovsky R, et al
    Inhibition of the epigenetically activated miR-483-5p/IGF-2 pathway results in rapid loss of meningioma tumor cell viability.
    J Neurooncol. 2023 Feb 21. doi: 10.1007/s11060-023-04264.
    PubMed     Abstract available


  349. BUSCH N, Zaki PG, Shepard MJ
    Letter to the editor: surgeon experience in glioblastoma surgery of the elderly-a multicenter, retrospective cohort study.
    J Neurooncol. 2023 Feb 21. doi: 10.1007/s11060-023-04267.
    PubMed    


  350. NASRALLAH MP, Aldape KD
    Molecular classification and grading of meningioma.
    J Neurooncol. 2023 Feb 18. doi: 10.1007/s11060-022-04228.
    PubMed     Abstract available


  351. ORTIZ-RIVERA J, Nunez R, Kucheryavykh Y, Kucheryavykh L, et al
    The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model.
    J Neurooncol. 2023 Feb 15. doi: 10.1007/s11060-023-04260.
    PubMed     Abstract available


  352. GHODRATI F, Mekonnen M, Mahgerefteh N, Zhang AB, et al
    Preoperative meningioma vascularity index is associated with significantly increased intraoperative blood loss and greater risk of subtotal resection.
    J Neurooncol. 2023 Feb 14. doi: 10.1007/s11060-023-04259.
    PubMed     Abstract available


  353. HUYNH KA, Coopmans EC, Zamanipoor Najafabadi AH, Dirven L, et al
    Correction to: Healthcare utilization and costs among intracranial meningioma patients during long-term follow-up.
    J Neurooncol. 2023 Feb 13. doi: 10.1007/s11060-023-04255.
    PubMed    


  354. SCHRAMM MWJ, Currie S, Lee MT, Livermore LJ, et al
    Do animal models of brain tumors replicate human peritumoral edema? a systematic literature search.
    J Neurooncol. 2023 Feb 9. doi: 10.1007/s11060-023-04246.
    PubMed     Abstract available


  355. HEINZEL A, Mottaghy FM, Filss C, Stoffels G, et al
    The impact of brain lesions on health-related quality of life in patients with WHO CNS grade 3 or 4 glioma: a lesion-function and resting-state fMRI analysis.
    J Neurooncol. 2023 Feb 7. doi: 10.1007/s11060-023-04254.
    PubMed     Abstract available


  356. MELHEM JM, Tahir A, Calabrese E, Granovskaya I, et al
    Dose-dependent efficacy of bevacizumab in recurrent glioblastoma.
    J Neurooncol. 2023 Feb 7. doi: 10.1007/s11060-023-04248.
    PubMed     Abstract available


  357. FUKUYA Y, Tamura M, Nitta M, Saito T, et al
    Tumor volume and calcifications as indicators for preoperative differentiation of grade II/III diffuse gliomas.
    J Neurooncol. 2023 Feb 7. doi: 10.1007/s11060-023-04244.
    PubMed     Abstract available


  358. WITTEN AJ, Ben-Shalom N, Ellis JA, Boockvar JA, et al
    Optimization of novel exoscopic blue light filter during fluorescence-guided resection of Glioblastoma.
    J Neurooncol. 2023 Feb 6. doi: 10.1007/s11060-022-04231.
    PubMed     Abstract available


  359. SPECKTER H, Palque-Santos S, Mota-Gonzalez R, Bido J, et al
    Can Apparent Diffusion Coefficient (ADC) maps replace Diffusion Tensor Imaging (DTI) maps to predict the volumetric response of meningiomas to Gamma Knife Radiosurgery?
    J Neurooncol. 2023 Feb 6. doi: 10.1007/s11060-023-04243.
    PubMed     Abstract available


  360. PERWEIN T, Giese B, Nussbaumer G, von Bueren AO, et al
    How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
    J Neurooncol. 2023 Feb 1. doi: 10.1007/s11060-023-04241.
    PubMed     Abstract available


  361. PATEL Z, Cho M, Das S
    The role of immune checkpoint inhibitors in patients with intracranial metastatic disease.
    J Neurooncol. 2023;161:469-478.
    PubMed     Abstract available


  362. AK M, Lf N, Gm I, Av K, et al
    Outcomes following management of relapsed pediatric posterior fossa ependymoma in the molecular era.
    J Neurooncol. 2023;161:573-582.
    PubMed     Abstract available


    January 2023
  363. POPPE JP, Machegger L, Steinbacher J, Stefanits H, et al
    Surgeon experience in glioblastoma surgery of the elderly-a multicenter, retrospective cohort study.
    J Neurooncol. 2023 Jan 31. doi: 10.1007/s11060-023-04252.
    PubMed     Abstract available


  364. DADARIO NB, Ivan M, Sughrue ME
    Standardizing connectome-based brain tumor surgery through a network-based surgical nomenclature.
    J Neurooncol. 2023 Jan 31. doi: 10.1007/s11060-023-04249.
    PubMed    


  365. REUSS DE
    Updates on the WHO diagnosis of IDH-mutant glioma.
    J Neurooncol. 2023 Jan 30. doi: 10.1007/s11060-023-04250.
    PubMed     Abstract available


  366. POTTHOFF AL, Heimann M, Lehmann F, Ilic I, et al
    Survival after resection of brain metastasis: impact of synchronous versus metachronous metastatic disease.
    J Neurooncol. 2023 Jan 25. doi: 10.1007/s11060-023-04242.
    PubMed     Abstract available


  367. COPPIETERS N, Scalisi J, Digregorio M, Leparc L, et al
    Study of Strawberry Notch homolog 1 and 2 expression in human glioblastoma.
    J Neurooncol. 2023 Jan 25. doi: 10.1007/s11060-023-04240.
    PubMed     Abstract available


  368. HOLTZMAN AL, Glassman GE, Dagan R, Rao D, et al
    Long-term outcomes of fractionated proton beam therapy for benign or radiographic intracranial meningioma.
    J Neurooncol. 2023 Jan 24. doi: 10.1007/s11060-022-04207.
    PubMed     Abstract available


  369. GIUSSANI C, Carrabba G, Rui CB, Chiarello G, et al
    Perilesional resection technique of glioblastoma: intraoperative ultrasound and histological findings of the resection borders in a single center experience.
    J Neurooncol. 2023 Jan 23. doi: 10.1007/s11060-022-04232.
    PubMed     Abstract available


  370. HALKETT GKB, Lobb EA, Phillips JL, McDougall E, et al
    Carer preparedness improved by providing a supportive educational intervention for carers of patients with high-grade glioma: RCT results.
    J Neurooncol. 2023 Jan 19. doi: 10.1007/s11060-023-04239.
    PubMed     Abstract available


  371. DAO TRONG P, Gluszak M, Reuss D, von Deimling A, et al
    Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort.
    J Neurooncol. 2023 Jan 17. doi: 10.1007/s11060-022-04230.
    PubMed     Abstract available


  372. ELSAMADICY AA, Reeves BC, Craft S, Sherman JJZ, et al
    A current review of spinal meningiomas: epidemiology, clinical presentation and management.
    J Neurooncol. 2023 Jan 13. doi: 10.1007/s11060-023-04238.
    PubMed     Abstract available


  373. WIJAYA JH, July J, Quintero-Consuegra M, Chadid DP, et al
    A systematic review and meta-analysis of the effects of tranexamic acid in surgical procedure for intracranial meningioma.
    J Neurooncol. 2023 Jan 12. doi: 10.1007/s11060-023-04237.
    PubMed     Abstract available


  374. SILVERSTEIN JW, Shah HA, Unadkat P, Vilaysom S, et al
    Short and long-term prognostic value of intraoperative motor evoked potentials in brain tumor patients: a case series of 121 brain tumor patients.
    J Neurooncol. 2023 Jan 11. doi: 10.1007/s11060-022-04229.
    PubMed     Abstract available


  375. HUYNH KA, Coopmans EC, Najafabadi AHZ, Dirven L, et al
    Healthcare utilization and costs among intracranial meningioma patients during long-term follow-up.
    J Neurooncol. 2023 Jan 10. doi: 10.1007/s11060-022-04223.
    PubMed     Abstract available


  376. LEHMAN NL
    Early ependymal tumor with MN1-BEND2 fusion: a mostly cerebral tumor of female children with a good prognosis that is distinct from classical astroblastoma.
    J Neurooncol. 2023 Jan 6. doi: 10.1007/s11060-022-04222.
    PubMed     Abstract available


  377. EICHKORN T, Lischalk JW, Horner-Rieber J, Deng M, et al
    Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3.
    J Neurooncol. 2023 Jan 4. doi: 10.1007/s11060-022-04217.
    PubMed     Abstract available


  378. SUAREZ-MEADE P, Watanabe F, Ruiz-Garcia H, Rafferty SB, et al
    SARS-CoV2 entry factors are expressed in primary human glioblastoma and recapitulated in cerebral organoid models.
    J Neurooncol. 2023 Jan 3:1-10. doi: 10.1007/s11060-022-04205.
    PubMed     Abstract available


  379. MAYO ZS, Halima A, Broughman JR, Smile TD, et al
    Radiation necrosis or tumor progression? A review of the radiographic modalities used in the diagnosis of cerebral radiation necrosis.
    J Neurooncol. 2023;161:23-31.
    PubMed     Abstract available


  380. LIN YY, Wu HM, Yang HC, Chen CJ, et al
    Stereotactic radiosurgery for pituitary and cavernous sinus metastases.
    J Neurooncol. 2023;161:175-184.
    PubMed     Abstract available


  381. JOHNSON KJ, Barnes JM, Delavar A, O'Connell CP, et al
    Facility patient volume and survival among individuals diagnosed with malignant central nervous system tumors.
    J Neurooncol. 2023;161:117-126.
    PubMed     Abstract available


  382. WELLER J, Schafer N, Schaub C, Tzaridis T, et al
    Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
    J Neurooncol. 2023;161:147-153.
    PubMed     Abstract available


  383. KUMAR S, Islim AI, Moon R, Millward CP, et al
    Long term quality of life outcomes following surgical resection alone for benign paediatric intracranial tumours.
    J Neurooncol. 2023;161:77-84.
    PubMed     Abstract available


  384. BUTENSCHOEN VM, Schwendner M, Hubertus V, Onken J, et al
    Preoperative angiographic considerations and neurological outcome after surgical treatment of intradural spinal hemangioblastoma: a multicenter retrospective case series.
    J Neurooncol. 2023;161:107-115.
    PubMed     Abstract available


  385. CARLOS-ESCALANTE JA, Mejia-Perez SI, Soto-Reyes E, Guerra-Calderas L, et al
    Deep DNA sequencing of MGMT, TP53 and AGT in Mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker.
    J Neurooncol. 2023;161:165-174.
    PubMed     Abstract available


    December 2022
  386. QIU X, Gao J, Hu J, Yang J, et al
    Proton radiotherapy in the treatment of IDH-mutant diffuse gliomas: an early experience from shanghai proton and heavy ion center.
    J Neurooncol. 2022 Dec 30. doi: 10.1007/s11060-022-04202.
    PubMed     Abstract available


  387. SLOAN AE, Nock CJ, Ye X, Buerki R, et al
    ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449.
    J Neurooncol. 2022 Dec 29. doi: 10.1007/s11060-022-04193.
    PubMed     Abstract available


  388. SOMMA T, Bove I, Vitulli F, Cappabianca P, et al
    Management and treatment of brain tumors during pregnancy: an Italian survey.
    J Neurooncol. 2022 Dec 29. doi: 10.1007/s11060-022-04215.
    PubMed     Abstract available


  389. WOLLRING MM, Werner JM, Ceccon G, Lohmann P, et al
    Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.
    J Neurooncol. 2022 Dec 29. doi: 10.1007/s11060-022-04218.
    PubMed     Abstract available


  390. HOPPER A, Salans M, Karunamuni R, Hattangadi-Gluth JA, et al
    Neurocognitive considerations in the treatment of meningioma with radiation therapy: applications for quantitative neuroimaging and precision radiation medicine.
    J Neurooncol. 2022 Dec 26. doi: 10.1007/s11060-022-04175.
    PubMed     Abstract available


  391. ENTENMANN CJ, Bubenikova A, Blazkova J Jr, Zapotocky M, et al
    Evaluation of the growth rates and related prognostic factors in radiation-induced meningiomas.
    J Neurooncol. 2022 Dec 24. doi: 10.1007/s11060-022-04209.
    PubMed     Abstract available


  392. SINGH J, Sharma R, Shukla N, Narwal P, et al
    DNA methylation profiling of meningiomas highlights clinically distinct molecular subgroups.
    J Neurooncol. 2022 Dec 24. doi: 10.1007/s11060-022-04220.
    PubMed     Abstract available


  393. USUZAKI T, Takahashi K
    Comment on "Sex as a prognostic factor in adult‑type diffuse gliomas: an integrated clinical and molecular analysis according to 2021 WHO classification".
    J Neurooncol. 2022 Dec 22. doi: 10.1007/s11060-022-04224.
    PubMed    


  394. LIU CW, Yang HC, Chiang CL, Shen CI, et al
    Leukoencephalopathy in patients with brain metastases who received radiosurgery with or without whole brain radiotherapy.
    J Neurooncol. 2022 Dec 22. doi: 10.1007/s11060-022-04210.
    PubMed     Abstract available


  395. KESHWARA SM, Gillespie CS, Mustafa MA, George AM, et al
    Quality of life outcomes in incidental and operated meningiomas (QUALMS): a cross-sectional cohort study.
    J Neurooncol. 2022 Dec 16. doi: 10.1007/s11060-022-04198.
    PubMed     Abstract available


  396. SHI W, Wang Y, Xia W, Liu B, et al
    Brain metastases from small cell lung cancer and non-small cell lung cancer: comparison of spatial distribution and identification of metastatic risk regions.
    J Neurooncol. 2022 Dec 15. doi: 10.1007/s11060-022-04211.
    PubMed     Abstract available


  397. STEINER G, Galli R, Preusse G, Michen S, et al
    A new approach for clinical translation of infrared spectroscopy: exploitation of the signature of glioblastoma for general brain tumor recognition.
    J Neurooncol. 2022 Dec 12. doi: 10.1007/s11060-022-04204.
    PubMed     Abstract available


  398. THOMMEN R, Kazim SF, Rumalla K, Kassicieh AJ, et al
    Correction to: Preoperative frailty measured by risk analysis index predicts complications and poor discharge outcomes after Brain Tumor Resection in a large multi-center analysis.
    J Neurooncol. 2022 Dec 12. doi: 10.1007/s11060-022-04212.
    PubMed    


  399. SINGNURKAR A, Poon R, Detsky J
    18F-FET-PET imaging in high-grade gliomas and brain metastases: a systematic review and meta-analysis.
    J Neurooncol. 2022 Dec 11. doi: 10.1007/s11060-022-04201.
    PubMed     Abstract available


  400. CHEN YC, Yang HC, Chiang CL, Chen CJ, et al
    Natural history of lung squamous cell brain metastases in patients treated with radiosurgery: a thirty-year experience at a tertiary medical center.
    J Neurooncol. 2022 Dec 5. doi: 10.1007/s11060-022-04153.
    PubMed     Abstract available


  401. KIM D, Chang WI, Byun HK, Kim IA, et al
    Dose-response relationship in patients with newly diagnosed atypical meningioma treated with adjuvant radiotherapy.
    J Neurooncol. 2022 Dec 5. doi: 10.1007/s11060-022-04206.
    PubMed     Abstract available


  402. ALBERS EAC, de Ruiter MB, van de Poll-Franse LV, Merckel LG, et al
    Neurocognitive functioning after Gamma Knife and LINAC stereotactic radiosurgery in patients with brain metastases.
    J Neurooncol. 2022 Dec 1. doi: 10.1007/s11060-022-04185.
    PubMed     Abstract available


  403. CHOJAK R, Kozba-Gosztyla M, Polanska K, Rojek M, et al
    Surgical resection versus biopsy in the treatment of primary central nervous system lymphoma: a systematic review and meta-analysis.
    J Neurooncol. 2022;160:753-761.
    PubMed     Abstract available


  404. PENNINGTON Z, Mikula AL, Lakomkin N, Meyer FB, et al
    Impact of tumor-associated syrinx on outcomes following resection of primary ependymomas of the spinal cord.
    J Neurooncol. 2022;160:725-733.
    PubMed     Abstract available


  405. TOMASINO B, Guarracino I, Pauletto G, Pez S, et al
    Performing real time neuropsychological testing during awake craniotomy: are dexmedetomidine or propofol the same? A preliminary report.
    J Neurooncol. 2022;160:707-716.
    PubMed     Abstract available


  406. SLEURS C, Zegers CML, Compter I, Dijkstra J, et al
    Neurocognition in adults with intracranial tumors: does location really matter?
    J Neurooncol. 2022;160:619-629.
    PubMed     Abstract available


    November 2022
  407. KIM W, Ghodrati F, Mozaffari K, Samarage HM, et al
    Endoscopic endonasal approach for resection of a recurrent spheno-orbital meningioma resulting in complete resolution of visual symptoms: A case report and review of literature.
    J Neurooncol. 2022 Nov 29. doi: 10.1007/s11060-022-04141.
    PubMed     Abstract available


  408. KHRISTOV V, Nesterova D, Trifoi M, Clegg T, et al
    Plasma IL13Ralpha2 as a novel liquid biopsy biomarker for glioblastoma.
    J Neurooncol. 2022 Nov 27. doi: 10.1007/s11060-022-04196.
    PubMed     Abstract available


  409. VASAN V, Dullea JT, Devarajan A, Ali M, et al
    NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.
    J Neurooncol. 2022 Nov 27. doi: 10.1007/s11060-022-04197.
    PubMed     Abstract available


  410. SVENJEBY C, Carstam L, Werlenius K, Bontell TO, et al
    Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period.
    J Neurooncol. 2022 Nov 25. doi: 10.1007/s11060-022-04136.
    PubMed     Abstract available


  411. ROACH JR, Plaha P, McGowan DR, Higgins GS, et al
    The role of [(18)F]fluorodopa positron emission tomography in grading of gliomas.
    J Neurooncol. 2022 Nov 24. doi: 10.1007/s11060-022-04177.
    PubMed     Abstract available


  412. MIYAGISHIMA DF, Moliterno J, Claus E, Gunel M, et al
    Hormone therapies in meningioma-where are we?
    J Neurooncol. 2022 Nov 23. doi: 10.1007/s11060-022-04187.
    PubMed     Abstract available


  413. ELSHEIKH M, Bridgman E, Lavrador JP, Lammy S, et al
    Association of extent of resection and functional outcomes in diffuse low-grade glioma: systematic review & meta-analysis.
    J Neurooncol. 2022 Nov 21. doi: 10.1007/s11060-022-04192.
    PubMed     Abstract available


  414. KIM SJ, Park SJ, Park J, Cho HJ, et al
    Dual inhibition of CPT1A and G6PD suppresses glioblastoma tumorspheres.
    J Neurooncol. 2022 Nov 17. pii: 10.1007/s11060-022-04189.
    PubMed     Abstract available


  415. GAMBOA NT, Crabb B, Henson JC, Cole KL, et al
    High-grade glioma imaging volumes and survival: a single-institution analysis of 101 patients after resection using intraoperative MRI.
    J Neurooncol. 2022 Nov 17. pii: 10.1007/s11060-022-04159.
    PubMed     Abstract available


  416. TEN CATE C, Huijs SMH, Willemsen ACH, Pasmans RCOS, et al
    Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients.
    J Neurooncol. 2022 Nov 17. pii: 10.1007/s11060-022-04180.
    PubMed     Abstract available


  417. ISLIM AI, Lee JX, Mustafa MA, Millward CP, et al
    Sporadic multiple intracranial meningioma does not infer worse patient outcomes: results from a case control study.
    J Neurooncol. 2022 Nov 15. pii: 10.1007/s11060-022-04184.
    PubMed     Abstract available


  418. RAJKUMAR S, Liang Y, Wegner RE, Shepard MJ, et al
    Utilization of neoadjuvant stereotactic radiosurgery for the treatment of brain metastases requiring surgical resection: a topic review.
    J Neurooncol. 2022 Nov 14. pii: 10.1007/s11060-022-04190.
    PubMed     Abstract available


  419. SHAH HA, Leskinen S, Khilji H, Narayan V, et al
    Utility of 5-ALA for fluorescence-guided resection of brain metastases: a systematic review.
    J Neurooncol. 2022 Nov 12. pii: 10.1007/s11060-022-04188.
    PubMed     Abstract available


  420. SATRAGNO C, Verrico A, Giannelli F, Ferrero A, et al
    High dose craniospinal irradiation as independent risk factor of permanent alopecia in childhood medulloblastoma survivors: cohort study and literature review.
    J Neurooncol. 2022 Nov 12. pii: 10.1007/s11060-022-04186.
    PubMed     Abstract available


  421. WANG J, Huang Y, Zhao F, Chen J, et al
    Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
    J Neurooncol. 2022 Nov 10. pii: 10.1007/s11060-022-04162.
    PubMed     Abstract available


  422. CHIDLEY P, Shanker M, Phillips C, Haghighi N, et al
    Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature.
    J Neurooncol. 2022 Nov 10. pii: 10.1007/s11060-022-04151.
    PubMed     Abstract available


  423. ALI AS, Lombardo J, Niazi MZ, Miller RC, et al
    Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.
    J Neurooncol. 2022 Nov 10. pii: 10.1007/s11060-022-04146.
    PubMed     Abstract available


  424. QUIJANO-RUBIO C, Silginer M, Weller M
    CRISPR/Cas9-mediated abrogation of CD95L/CD95 signaling-induced glioma cell growth and immunosuppression increases survival in murine glioma models.
    J Neurooncol. 2022 Nov 10. pii: 10.1007/s11060-022-04137.
    PubMed     Abstract available


  425. SHI DD, Anand S, Abdullah KG, McBrayer SK, et al
    DNA damage in IDH-mutant gliomas: mechanisms and clinical implications.
    J Neurooncol. 2022 Nov 9. pii: 10.1007/s11060-022-04172.
    PubMed     Abstract available


  426. ZHOU S, Ren F, Li C, Jiang L, et al
    Efficacy and safety of immune checkpoint inhibitors plus anlotinib in small cell lung cancer with brain metastases: a retrospective, multicentre study.
    J Neurooncol. 2022 Nov 8. pii: 10.1007/s11060-022-04182.
    PubMed     Abstract available


  427. MADER MM, Deuter D, Sauvigny T, Borchert P, et al
    Diffusion tensor imaging changes in patients with glioma-associated seizures.
    J Neurooncol. 2022 Nov 7. pii: 10.1007/s11060-022-04139.
    PubMed     Abstract available


  428. ROY LO, Lemelin M, Blanchette M, Poirier MB, et al
    Expression of ABCB1, ABCC1 and 3 and ABCG2 in glioblastoma and their relevance in relation to clinical survival surrogates.
    J Neurooncol. 2022 Nov 7. pii: 10.1007/s11060-022-04179.
    PubMed     Abstract available


  429. LANIER CM, Pearce J, Isom S, Xing F, et al
    Long term survivors of stereotactic radiosurgery for brain metastases: do distant brain failures reach a plateau and what factors are associated with a brain metastasis velocity of zero?
    J Neurooncol. 2022 Nov 6. pii: 10.1007/s11060-022-04183.
    PubMed     Abstract available


  430. HUA L, Ren L, Wu Q, Deng J, et al
    Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk.
    J Neurooncol. 2022 Nov 3. pii: 10.1007/s11060-022-04169.
    PubMed     Abstract available


  431. BRAUCHITSCH SV, Strzelczyk A, Rosenow F, Neuhaus E, et al
    High end-of-life incidence of seizures and status epilepticus in patients with primary and secondary brain tumors.
    J Neurooncol. 2022 Nov 3. pii: 10.1007/s11060-022-04133.
    PubMed     Abstract available


  432. GALLET C, Clavreul A, Morandi X, Delion M, et al
    What surgical approach for left-sided eloquent glioblastoma: biopsy, resection under general anesthesia or awake craniotomy?
    J Neurooncol. 2022 Nov 3. pii: 10.1007/s11060-022-04163.
    PubMed     Abstract available


  433. CHOTAI S, Tang AR, Gupta R, Guidry BS, et al
    Matched case-control analysis of outcomes following surgical resection of incidental meningioma.
    J Neurooncol. 2022 Nov 3. pii: 10.1007/s11060-022-04167.
    PubMed     Abstract available


  434. ZENG L, Li H, Chen R, Yang H, et al
    Integration of molecular pathology with histopathology to accurately evaluate the biological behaviour of WHO grade 2 meningiomas and patient prognosis.
    J Neurooncol. 2022 Nov 2. pii: 10.1007/s11060-022-04170.
    PubMed     Abstract available


  435. GORODEZKI D, Zipfel J, Queudeville M, Sosa J, et al
    Resection extent and BRAF V600E mutation status determine postoperative tumor growth velocity in pediatric low-grade glioma: results from a single-center cohort analysis.
    J Neurooncol. 2022 Nov 1. pii: 10.1007/s11060-022-04176.
    PubMed     Abstract available


  436. MCKENZIE G, Gaskins J, Rattani A, Oliver A, et al
    Radiosurgery fractionation and post-treatment hemorrhage development for intact melanoma brain metastases.
    J Neurooncol. 2022 Nov 1. pii: 10.1007/s11060-022-04178.
    PubMed     Abstract available


  437. JIA H, Zhang P, Gu G, Li T, et al
    Brainstem tumors may increase the impairment of behavioral emotional cognition in children.
    J Neurooncol. 2022;160:423-432.
    PubMed     Abstract available


  438. IGLESIAS P, Biagetti B, Araujo-Castro M, Alcazar V, et al
    Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma.
    J Neurooncol. 2022;160:351-359.
    PubMed     Abstract available


  439. RAGHIB MF, Salim A, Angez M, Ghazi SM, et al
    Prognostic implication of size on outcomes of pituitary macroadenoma: a comparative analysis of giant adenoma with non-giant macroadenoma.
    J Neurooncol. 2022;160:491-496.
    PubMed     Abstract available


  440. SHE L, Deng D, Su L, Liu C, et al
    Comparison of surgery with or without adjuvant radiotherapy in treating central neurocytoma: a single-center retrospective real-world study.
    J Neurooncol. 2022;160:455-462.
    PubMed     Abstract available


  441. WEBB M, Johnson DR, Mahajan A, Brown P, et al
    Clinical experience and outcomes in patients with pineal parenchymal tumor of intermediate differentiation (PPTID): a single-institution analysis.
    J Neurooncol. 2022;160:527-534.
    PubMed     Abstract available


    October 2022
  442. THOMMEN R, Kazim SF, Rumalla K, Kassicieh AJ, et al
    Preoperative frailty measured by risk analysis index predicts complications and poor discharge outcomes after Brain Tumor Resection in a large multi-center analysis.
    J Neurooncol. 2022 Oct 31. pii: 10.1007/s11060-022-04135.
    PubMed     Abstract available


  443. CHEN WC, Perlow HK, Choudhury A, Nguyen MP, et al
    Radiotherapy for meningiomas.
    J Neurooncol. 2022 Oct 31. pii: 10.1007/s11060-022-04171.
    PubMed     Abstract available


  444. RUDA R, Bruno F, Pellerino A, Pronello E, et al
    Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?
    J Neurooncol. 2022 Oct 30. pii: 10.1007/s11060-022-04155.
    PubMed     Abstract available


  445. TSUJI S, Nakamura S, Shoda K, Yamada T, et al
    NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells.
    J Neurooncol. 2022 Oct 29. pii: 10.1007/s11060-022-04154.
    PubMed     Abstract available


  446. SHARMA M, Wang D, Palmisciano P, Ugiliweneza B, et al
    Is intraoperative MRI use in malignant brain tumor surgery a health care burden? A matched analysis of MarketScan Database.
    J Neurooncol. 2022 Oct 26. pii: 10.1007/s11060-022-04142.
    PubMed     Abstract available


  447. OHNO M, Kitano S, Satomi K, Yoshida A, et al
    Assessment of radiographic and prognostic characteristics of programmed death-ligand 1 expression in high-grade gliomas.
    J Neurooncol. 2022 Oct 25. pii: 10.1007/s11060-022-04165.
    PubMed     Abstract available


  448. BATTISTA F, Muscas G, Dinoi F, Gadda D, et al
    Ventricular entry during surgical resection is associated with intracranial leptomeningeal dissemination in glioblastoma patients.
    J Neurooncol. 2022 Oct 23. pii: 10.1007/s11060-022-04166.
    PubMed     Abstract available


  449. CARSTAM L, Ryden I, Jakola AS
    Seizures in patients with IDH-mutated lower grade gliomas.
    J Neurooncol. 2022 Oct 18. pii: 10.1007/s11060-022-04158.
    PubMed     Abstract available


  450. MAHMOODIFAR S, Pangal DJ, Cardinal T, Craig D, et al
    A quantitative characterization of the spatial distribution of brain metastases from breast cancer and respective molecular subtypes.
    J Neurooncol. 2022 Oct 16. pii: 10.1007/s11060-022-04147.
    PubMed     Abstract available


  451. PEASE M, Gersey ZC, Ak M, Elakkad A, et al
    Pre-operative MRI radiomics model non-invasively predicts key genomic markers and survival in glioblastoma patients.
    J Neurooncol. 2022 Oct 14. pii: 10.1007/s11060-022-04150.
    PubMed     Abstract available


  452. HUI C, Qu V, Wang JY, von Eyben R, et al
    Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.
    J Neurooncol. 2022 Oct 13. pii: 10.1007/s11060-022-04145.
    PubMed     Abstract available


  453. MARQUEZ J, Schmidt M, Bowers CA
    Letter: Does the "hospital frailty risk score" measure preoperative frailty for craniopharyngioma surgery?
    J Neurooncol. 2022 Oct 12. pii: 10.1007/s11060-022-04157.
    PubMed    


  454. RAZAVIAN NB, Helis CA, Laxton A, Tatter S, et al
    Outcomes of radiation-induced meningiomas treated with stereotactic radiosurgery.
    J Neurooncol. 2022 Oct 12. pii: 10.1007/s11060-022-04156.
    PubMed     Abstract available


  455. LU G, Zhu P, Rao M, Linendoll N, et al
    Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
    J Neurooncol. 2022 Oct 6. pii: 10.1007/s11060-022-04144.
    PubMed     Abstract available


  456. MAIR MJ, Berghoff AS, Brastianos PK, Preusser M, et al
    Emerging systemic treatment options in meningioma.
    J Neurooncol. 2022 Oct 1. pii: 10.1007/s11060-022-04148.
    PubMed     Abstract available


  457. CIOFFI G, Waite KA, Edelson JL, Kruchko C, et al
    Changes in survival over time for primary brain and other CNS tumors in the United States, 2004-2017.
    J Neurooncol. 2022;160:209-219.
    PubMed     Abstract available


  458. WELLER J, Katzendobler S, Blobner J, Thiele F, et al
    Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3.
    J Neurooncol. 2022;160:149-158.
    PubMed     Abstract available


  459. SURUGA Y, Satomi K, Otani Y, Fujii K, et al
    The utility of DNA methylation analysis in elderly patients with pilocytic astrocytoma morphology.
    J Neurooncol. 2022;160:179-189.
    PubMed     Abstract available


  460. MALAIZE H, Laigle-Donadey F, Riche M, Marijon P, et al
    Roles and outcomes of stereotactic biopsy for adult patients with brainstem lesion.
    J Neurooncol. 2022;160:159-170.
    PubMed     Abstract available


  461. HONG KT, Han JW, Fuji H, Byun HK, et al
    Outcomes of intracranial non-germinomatous germ cell tumors: a retrospective Asian multinational study on treatment strategies and prognostic factors.
    J Neurooncol. 2022;160:41-53.
    PubMed     Abstract available


  462. PALMISCIANO P, Watanabe G, Conching A, Ogasawara C, et al
    Intrathecal therapy for the management of leptomeningeal metastatic disease: a scoping review of the current literature and ongoing clinical trials.
    J Neurooncol. 2022;160:79-100.
    PubMed     Abstract available


    September 2022
  463. ABDALLAH HM, Mallela AN, Wei Z, Abou-Al-Shaar H, et al
    Gamma Knife radiosurgery for meningiomas of the confluence of the falx and tentorium.
    J Neurooncol. 2022 Sep 20. pii: 10.1007/s11060-022-04125.
    PubMed     Abstract available


  464. KOIDE Y, Nagai N, Miyauchi R, Kitagawa T, et al
    Radiotherapy or systemic therapy versus combined therapy in patients with brain metastases: a propensity-score matched study.
    J Neurooncol. 2022 Sep 16. pii: 10.1007/s11060-022-04132.
    PubMed     Abstract available


  465. SCHACKERT G, Lenk M, Kirsch M, Hennig S, et al
    Surgical results of 158 petroclival meningiomas with special focus on standard craniotomies.
    J Neurooncol. 2022 Sep 14. pii: 10.1007/s11060-022-04105.
    PubMed     Abstract available


  466. SU H, Hailin Z, Dongdong L, Jiang Y, et al
    Long non-coding RNA LINC01018 inhibits human glioma cell proliferation and metastasis by directly targeting miRNA-182-5p.
    J Neurooncol. 2022 Sep 12. pii: 10.1007/s11060-022-04113.
    PubMed     Abstract available


  467. LU VM, Niazi TN
    Racial disparities in pediatric malignant glioma management: current state of affairs in the United States.
    J Neurooncol. 2022 Sep 8. pii: 10.1007/s11060-022-04130.
    PubMed     Abstract available


  468. ABDELRAHMAN A, Negroni C, Sahm F, Adams CL, et al
    miR-497 and 219 in blood aid meningioma classification.
    J Neurooncol. 2022 Sep 8. pii: 10.1007/s11060-022-04126.
    PubMed     Abstract available


  469. SAMOYEAU T, Provost C, Roux A, Legrand L, et al
    Meningioma in patients exposed to progestin drugs: results from a real-life screening program.
    J Neurooncol. 2022 Sep 6. pii: 10.1007/s11060-022-04124.
    PubMed     Abstract available


  470. DOS SANTOS SILVA J, Schreiner CA, de Lima L, Brigido CEPL, et al
    Volumetric measurement of intracranial meningiomas: a comparison between linear, planimetric, and machine learning with multiparametric voxel-based morphometry methods.
    J Neurooncol. 2022 Sep 5. pii: 10.1007/s11060-022-04127.
    PubMed     Abstract available


  471. SHIDOH S, Savjani RR, Cho NS, Ullman HE, et al
    Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation.
    J Neurooncol. 2022 Sep 2. pii: 10.1007/s11060-022-04123.
    PubMed     Abstract available


  472. TAKAMI H, Graffeo CS, Perry A, Brown DA, et al
    Presentation, imaging, patterns of care, growth, and outcome in sporadic and von Hippel-Lindau-associated central nervous system hemangioblastomas.
    J Neurooncol. 2022;159:221-231.
    PubMed     Abstract available


  473. SHIBAHARA I, Shibahara Y, Hagiwara H, Watanabe T, et al
    Ventricular opening and cerebrospinal fluid circulation accelerate the biodegradation process of carmustine wafers suggesting their immunomodulation potential in the human brain.
    J Neurooncol. 2022;159:425-435.
    PubMed     Abstract available


  474. GELHARD S, Maxwell A, Colman H, Cohen AL, et al
    Consolidation regimens in primary central nervous system lymphoma: a single-center retrospective cohort evaluating survival outcomes and cost-benefit analysis.
    J Neurooncol. 2022;159:293-300.
    PubMed     Abstract available


  475. ALIOUAT I, Moiraghi A, Simboli GA, Birsen R, et al
    Accuracy and safety of 101 consecutives neurosurgical procedures for newly diagnosed central nervous system lymphomas: a single-institution experience.
    J Neurooncol. 2022;159:347-358.
    PubMed     Abstract available


  476. GARZIO K, McElroy K, Grossman S, Holdhoff M, et al
    Safety of temozolomide use in adult patients with renal dysfunction.
    J Neurooncol. 2022;159:591-596.
    PubMed     Abstract available


  477. KALAWI AZ, Malicki DM, Abdullaev Z, Pratt DW, et al
    The role of methylation profiling in histologically diagnosed neurocytoma: a case series.
    J Neurooncol. 2022;159:725-733.
    PubMed     Abstract available


  478. PLANT-FOX AS, Suzuki T, Diaz Coronado RY, Epelman S, et al
    An international study evaluating the epidemiology of intracranial germ cell tumors in the native versus immigrant Japanese populations: the need for an international registry.
    J Neurooncol. 2022;159:563-570.
    PubMed     Abstract available


    August 2022
  479. KUMAR TS, Afnan WM, Chan CY, Audrey C, et al
    Impact of seizures and antiseizure medication on survival in patients with glioma.
    J Neurooncol. 2022 Aug 29. pii: 10.1007/s11060-022-04108.
    PubMed     Abstract available


  480. SAGBERG LM, Fyllingen EH, Hansen TI, Strand PS, et al
    Is intracranial volume a risk factor for IDH-mutant low-grade glioma? A case-control study.
    J Neurooncol. 2022 Aug 27. pii: 10.1007/s11060-022-04120.
    PubMed     Abstract available


  481. YAN M, Holden L, Wang M, Soliman H, et al
    Gamma knife icon based hypofractionated stereotactic radiosurgery (GKI-HSRS) for brain metastases: impact of dose and volume.
    J Neurooncol. 2022 Aug 24. pii: 10.1007/s11060-022-04115.
    PubMed     Abstract available


  482. IMBER BS, Young RJ, Beal K, Reiner AS, et al
    Correction to: Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastases.
    J Neurooncol. 2022 Aug 23. pii: 10.1007/s11060-022-04121.
    PubMed    


  483. WANG M, Zhang Y, Shi W, Zhu R, et al
    Frameless robot-assisted stereotactic biopsy: an effective and minimally invasive technique for pediatric diffuse intrinsic pontine gliomas.
    J Neurooncol. 2022 Aug 23. pii: 10.1007/s11060-022-04122.
    PubMed     Abstract available


  484. GUNJUR A, Balasubramanian A, Hafeez U, Menon S, et al
    Correction to: Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review.
    J Neurooncol. 2022 Aug 22. pii: 10.1007/s11060-022-04119.
    PubMed    


  485. KIM M, Kim S, Park YW, Han K, et al
    Sex as a prognostic factor in adult-type diffuse gliomas: an integrated clinical and molecular analysis according to the 2021 WHO classification.
    J Neurooncol. 2022 Aug 21. pii: 10.1007/s11060-022-04114.
    PubMed     Abstract available


  486. PARTIN RE, Wogksch MD, Dhaduk R, Ashford JM, et al
    Physical function, body mass index, and fitness outcomes in children, adolescents, and emerging adults with craniopharyngioma from proton therapy through five years of follow-up.
    J Neurooncol. 2022 Aug 20. pii: 10.1007/s11060-022-04116.
    PubMed     Abstract available


  487. SIMOES PADILLA C, Ho VKY, van der Strate IH, Leenders WPJ, et al
    Prognostic factors among patients with brain metastases from cancer of unknown primary site.
    J Neurooncol. 2022 Aug 17. pii: 10.1007/s11060-022-04106.
    PubMed     Abstract available


  488. MA J, Tian Y, Hao S, Zheng L, et al
    Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis.
    J Neurooncol. 2022 Aug 17. pii: 10.1007/s11060-022-04111.
    PubMed     Abstract available


  489. BIN-ALAMER O, Alnefaie N, Qedair J, Chaudhary A, et al
    Single session versus multisession stereotactic radiosurgery for the management of intracranial meningiomas: a systematic review and meta-analysis.
    J Neurooncol. 2022 Aug 17. pii: 10.1007/s11060-022-04112.
    PubMed     Abstract available


  490. LIAO HR, Chiang CL, Shen CI, Chen CJ, et al
    EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases.
    J Neurooncol. 2022 Aug 17. pii: 10.1007/s11060-022-04110.
    PubMed     Abstract available


  491. LI S, Wu B, Xiao Y, Wu J, et al
    Exploring the pathological relationships between adamantinomatous craniopharyngioma and contiguous structures with tumor origin.
    J Neurooncol. 2022 Aug 8. pii: 10.1007/s11060-022-04084.
    PubMed     Abstract available


  492. HOLLINGWORTH M, Zacharoulis S
    Infusion-related side-effects during convection enhanced delivery for brainstem-diffuse midline glioma/diffuse intrinsic pontine glioma.
    J Neurooncol. 2022 Aug 6. pii: 10.1007/s11060-022-04077.
    PubMed     Abstract available


  493. GUNJUR A, Balasubramanian A, Hafeez U, Menon S, et al
    Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review.
    J Neurooncol. 2022 Aug 6. pii: 10.1007/s11060-022-04092.
    PubMed     Abstract available


  494. CLIMANS SA, Mason WP, Grunfeld E, Chan K, et al
    Clinical features of glioma patients who develop pneumocystis pneumonia with temozolomide chemoradiotherapy.
    J Neurooncol. 2022 Aug 6. pii: 10.1007/s11060-022-04109.
    PubMed     Abstract available


  495. PONTORIERO A, Critelli P, Conti A, Cardali S, et al
    The "Combo" radiotherapy treatment for high-risk grade 2 meningiomas: dose escalation and initial safety and efficacy analysis.
    J Neurooncol. 2022 Aug 4. pii: 10.1007/s11060-022-04107.
    PubMed     Abstract available


  496. LOHKAMP LN, Kulkarni AV, Drake JM, Rutka JT, et al
    Preservation of endocrine function after Ommaya reservoir insertion in children with cystic craniopharyngioma.
    J Neurooncol. 2022 Aug 4. pii: 10.1007/s11060-022-04099.
    PubMed     Abstract available


  497. ONISHI S, Yamasaki F, Amatya VJ, Takayasu T, et al
    Characteristics and therapeutic strategies of radiation-induced glioma: case series and comprehensive literature review.
    J Neurooncol. 2022 Aug 3. pii: 10.1007/s11060-022-04090.
    PubMed     Abstract available


  498. TANG AR, Chotai S, Grisham CJ, Guidry BS, et al
    Outcomes following surgical resection of cystic intracranial meningiomas.
    J Neurooncol. 2022 Aug 3. pii: 10.1007/s11060-022-04096.
    PubMed     Abstract available


  499. VUONG HG, Dunn IF
    Primary versus secondary gliosarcoma: a systematic review and meta-analysis.
    J Neurooncol. 2022;159:195-200.
    PubMed     Abstract available


  500. DESJARDINS C, Larrieu-Ciron D, Choquet S, Mokhtari K, et al
    Chemotherapy is an efficient treatment in primary CNS MALT lymphoma.
    J Neurooncol. 2022;159:151-161.
    PubMed     Abstract available


  501. ID SAID B, Chen H, Jerzak KJ, Warner E, et al
    Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2 + breast cancer.
    J Neurooncol. 2022;159:177-183.
    PubMed     Abstract available


  502. RAKOVEC M, Khalafallah AM, Wei O, Day D, et al
    A consensus definition of supratotal resection for anatomically distinct primary glioblastoma: an AANS/CNS Section on Tumors survey of neurosurgical oncologists.
    J Neurooncol. 2022 Aug 1. pii: 10.1007/s11060-022-04048.
    PubMed     Abstract available


    July 2022
  503. IMBER BS, Young RJ, Beal K, Reiner AS, et al
    Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastases.
    J Neurooncol. 2022 Jul 27. pii: 10.1007/s11060-022-04101.
    PubMed     Abstract available


  504. DAZA-OVALLE A, Bin-Alamer O, Flickinger J, Niranjan A, et al
    Outcomes after gamma knife radiosurgery for intraventricular meningiomas.
    J Neurooncol. 2022 Jul 26. pii: 10.1007/s11060-022-04091.
    PubMed     Abstract available


  505. DO TH, Howard MA, Palzer EF, Huling JD, et al
    Readmission risk of malignant brain tumor patients undergoing laser interstitial thermal therapy (LITT) and stereotactic needle biopsy (SNB): a covariate balancing weights analysis of the National Readmissions Database (NRD).
    J Neurooncol. 2022 Jul 23. pii: 10.1007/s11060-022-04093.
    PubMed     Abstract available


  506. LUGER AL, Konig S, Samp PF, Urban H, et al
    Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.
    J Neurooncol. 2022 Jul 21. pii: 10.1007/s11060-022-04049.
    PubMed     Abstract available


  507. YOGENDRAN LV, Kalelioglu T, Donahue JH, Ahmad H, et al
    The landscape of brain tumor mimics in neuro-oncology practice.
    J Neurooncol. 2022 Jul 20. pii: 10.1007/s11060-022-04087.
    PubMed     Abstract available


  508. MENDEZ VALDEZ MJ, Lu VM, Kim E, Rivas SR, et al
    Glioblastoma multiforme in patients with human immunodeficiency virus: an integrated review and analysis.
    J Neurooncol. 2022 Jul 20. pii: 10.1007/s11060-022-04095.
    PubMed     Abstract available


  509. MOASSEFI M, Faghani S, Conte GM, Kowalchuk RO, et al
    A deep learning model for discriminating true progression from pseudoprogression in glioblastoma patients.
    J Neurooncol. 2022 Jul 19. pii: 10.1007/s11060-022-04080.
    PubMed     Abstract available


  510. MULLER M, Winz O, Gutsche R, Leijenaar RTH, et al
    Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression.
    J Neurooncol. 2022 Jul 19. pii: 10.1007/s11060-022-04089.
    PubMed     Abstract available


  511. HAGIWARA A, Schlossman J, Shabani S, Raymond C, et al
    Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation.
    J Neurooncol. 2022 Jul 17. pii: 10.1007/s11060-022-04088.
    PubMed     Abstract available


  512. MELNICK KF, Miller P, Carmichael E, McGrath K, et al
    The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival.
    J Neurooncol. 2022 Jul 15. pii: 10.1007/s11060-022-04083.
    PubMed     Abstract available


  513. DE BRITO RANGEL J, Giglio AG, Cardozo CL, Bergmann A, et al
    Prognostic factors for brain metastasis in women presenting cervical cancer.
    J Neurooncol. 2022 Jul 14. pii: 10.1007/s11060-022-04082.
    PubMed     Abstract available


  514. RECKER MJ, Kuo CC, Prasad D, Attwood K, et al
    Incidence trends and survival analysis of atypical meningiomas: a population-based study from 2004 to 2018.
    J Neurooncol. 2022 Jul 11. pii: 10.1007/s11060-022-04085.
    PubMed     Abstract available


  515. FUJITA Y, Nunez-Rubiano L, Dono A, Bellman A, et al
    IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.
    J Neurooncol. 2022 Jul 11. pii: 10.1007/s11060-022-04060.
    PubMed     Abstract available


  516. KAWASHIMA M, Akabane A, Noda R, Segawa M, et al
    Interfractional change of tumor volume during fractionated stereotactic radiotherapy using gamma knife for brain metastases.
    J Neurooncol. 2022 Jul 9. pii: 10.1007/s11060-022-04075.
    PubMed     Abstract available


  517. MASSIMINO M, Vennarini S, Barretta F, Colombo F, et al
    How ten-years of reirradiation for paediatric high-grade glioma may shed light on first line treatment.
    J Neurooncol. 2022 Jul 9. pii: 10.1007/s11060-022-04079.
    PubMed     Abstract available


  518. SCHLOMER S, Felsberg J, Pertz M, Hentschel B, et al
    Mid-term treatment-related cognitive sequelae in glioma patients.
    J Neurooncol. 2022 Jul 7. pii: 10.1007/s11060-022-04044.
    PubMed     Abstract available


  519. PEI YY, Zhang Y, Liu ZR, He Y, et al
    Lactate dehydrogenase as promising marker for prognosis of brain metastasis.
    J Neurooncol. 2022 Jul 7. pii: 10.1007/s11060-022-04070.
    PubMed     Abstract available


  520. TOBOCHNIK S, Lapinskas E, Vogelzang J, Ligon KL, et al
    Correction to: Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma.
    J Neurooncol. 2022 Jul 6. pii: 10.1007/s11060-022-04086.
    PubMed    


  521. BUNEVICIUS A, Donovan L, Sheehan J
    Health related quality of life trajectories after stereotactic radiosurgery for brain metastases: a systematic review.
    J Neurooncol. 2022 Jul 4. pii: 10.1007/s11060-022-04067.
    PubMed     Abstract available


  522. SUZUKI H, Ono T, Koyota S, Takahashi M, et al
    Clinical, histopathological, and molecular features of IDH-wildtype indolent diffuse glioma: comparison with typical glioblastoma.
    J Neurooncol. 2022 Jul 2. pii: 10.1007/s11060-022-04074.
    PubMed     Abstract available


  523. MALDAR AN, Pattankar S, Misra BK, Chauhan PH, et al
    Long-term hormonal and imaging outcomes of adjunctive gamma knife radiosurgery in non-functioning pituitary adenomas: a single center experience.
    J Neurooncol. 2022;158:423-433.
    PubMed     Abstract available


  524. BANDER ED, Knisely JPS, Schwartz TH
    Brachytherapy for central nervous system tumors.
    J Neurooncol. 2022;158:393-403.
    PubMed     Abstract available


    June 2022
  525. DE LAURENTIS C, Cristaldi PMF, Rebora P, Valsecchi MG, et al
    Posterior fossa syndrome in a population of children and young adults with medulloblastoma: a retrospective, multicenter Italian study on incidence and pathophysiology in a histologically homogeneous and consecutive series of 136 patients.
    J Neurooncol. 2022 Jun 29. pii: 10.1007/s11060-022-04072.
    PubMed     Abstract available


  526. WANG F, Cathcart SJ, DiMaio DJ, Zhao N, et al
    Comparison of tumor immune environment between newly diagnosed and recurrent glioblastoma including matched patients.
    J Neurooncol. 2022 Jun 26. pii: 10.1007/s11060-022-04053.
    PubMed     Abstract available


  527. PALMER JD, Perlow HK, Matsui JK, Ho C, et al
    Fractionated pre-operative stereotactic radiotherapy for patients with brain metastases: a multi-institutional analysis.
    J Neurooncol. 2022 Jun 25. pii: 10.1007/s11060-022-04073.
    PubMed     Abstract available


  528. GREER HR, Miller K, Samay S, Nellan A, et al
    Investigation of white blood cell characteristics in cerebrospinal fluid samples at pediatric brain tumor diagnosis.
    J Neurooncol. 2022 Jun 22. pii: 10.1007/s11060-022-04065.
    PubMed     Abstract available


  529. PETERSON R, Kandregula S, Jee E, Guthikonda B, et al
    Utility of hospital frailty risk score for predicting postoperative outcomes in craniopharyngioma.
    J Neurooncol. 2022 Jun 20. pii: 10.1007/s11060-022-04056.
    PubMed     Abstract available


  530. WIJAYA JH, Arjuna YYE, July J
    The role of stereotactic radiosurgery in the management of petroclival meningioma: a systematic review.
    J Neurooncol. 2022 Jun 18. pii: 10.1007/s11060-022-04041.
    PubMed     Abstract available


  531. BRACCI PM, Rice T, Hansen HM, Francis SS, et al
    Pre-surgery immune profiles of adult glioma patients.
    J Neurooncol. 2022 Jun 18. pii: 10.1007/s11060-022-04047.
    PubMed     Abstract available


  532. WERNER JM, Wolf L, Tscherpel C, Bauer EK, et al
    Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas.
    J Neurooncol. 2022 Jun 18. pii: 10.1007/s11060-022-04066.
    PubMed     Abstract available


  533. SPECKTER H, Radulovic M, Trivodaliev K, Vranes V, et al
    MRI radiomics in the prediction of the volumetric response in meningiomas after gamma knife radiosurgery.
    J Neurooncol. 2022 Jun 17. pii: 10.1007/s11060-022-04063.
    PubMed     Abstract available


  534. TOBOCHNIK S, Lapinskas E, Vogelzang J, Ligon KL, et al
    Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma.
    J Neurooncol. 2022 Jun 17. pii: 10.1007/s11060-022-04059.
    PubMed     Abstract available


  535. PRADHAN A, Mozaffari K, Ghodrati F, Everson RG, et al
    Modern surgical management of incidental gliomas.
    J Neurooncol. 2022 Jun 15. pii: 10.1007/s11060-022-04045.
    PubMed     Abstract available


  536. WELLER J, Schafer N, Schaub C, Potthoff AL, et al
    Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
    J Neurooncol. 2022 Jun 15. pii: 10.1007/s11060-022-04046.
    PubMed     Abstract available


  537. RAMOS-FRESNEDO A, Domingo RA, Perez-Vega C, Pullen MW, et al
    The early infiltrative phase of GBM hypothesis: are molecular glioblastomas histological glioblastomas in the making? A preliminary multicenter study.
    J Neurooncol. 2022 Jun 14. pii: 10.1007/s11060-022-04040.
    PubMed     Abstract available


  538. PALMISCIANO P, Haider AS, Balasubramanian K, D'Amico RS, et al
    The role of cesium-131 brachytherapy in brain tumors: a scoping review of the literature and ongoing clinical trials.
    J Neurooncol. 2022 Jun 13. pii: 10.1007/s11060-022-04050.
    PubMed     Abstract available


  539. AUTRY AW, Lafontaine M, Jalbert L, Phillips E, et al
    Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas.
    J Neurooncol. 2022 Jun 8. pii: 10.1007/s11060-022-04042.
    PubMed     Abstract available


  540. MICHEL A, Dinger TF, Santos AN, Pierscianek D, et al
    Time interval between the diagnosis of breast cancer and brain metastases impacts prognosis after metastasis surgery.
    J Neurooncol. 2022 Jun 7. pii: 10.1007/s11060-022-04043.
    PubMed     Abstract available


  541. AMER RG, Ezz El Arab LR, Abd El Ghany D, Saad AS, et al
    Prognostic utility of lncRNAs (LINC00565 and LINC00641) as molecular markers in glioblastoma multiforme (GBM).
    J Neurooncol. 2022 Jun 6. pii: 10.1007/s11060-022-04030.
    PubMed     Abstract available


  542. BERGER A, Bernstein K, Alzate JD, Mullen R, et al
    Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?
    J Neurooncol. 2022 Jun 4. pii: 10.1007/s11060-022-04036.
    PubMed     Abstract available


  543. CHEN ZH, Zhang XH, Lin FH, Li C, et al
    The application of fluorescein sodium for the resection of medulloblastoma.
    J Neurooncol. 2022 Jun 3. pii: 10.1007/s11060-022-04035.
    PubMed     Abstract available


  544. SHAH HA, Mishra A, Gouzoulis MJ, Ben-Shalom N, et al
    Analysis of factors leading to early termination in glioblastoma-related clinical trials.
    J Neurooncol. 2022 Jun 1. pii: 10.1007/s11060-022-04039.
    PubMed     Abstract available


  545. GOODMAN AL, Velazquez Vega JE, Glenn C, Olson JJ, et al
    Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults.
    J Neurooncol. 2022 Jun 1. pii: 10.1007/s11060-022-04005.
    PubMed     Abstract available


    May 2022
  546. LE A, Mohammadi H, Mohammed T, Burney H, et al
    Local and distant brain control in melanoma and NSCLC brain metastases with concurrent radiosurgery and immune checkpoint inhibition.
    J Neurooncol. 2022 May 31. pii: 10.1007/s11060-022-04038.
    PubMed     Abstract available


  547. OBERHEIM-BUSH NA, Shi W, McDermott MW, Grote A, et al
    The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts.
    J Neurooncol. 2022 May 31. pii: 10.1007/s11060-022-04033.
    PubMed     Abstract available


  548. PEREIRA ELR, Feio DCA, Tavares JPL, Morikawa NM, et al
    Uptake of lipid core nanoparticles by fragments of tissues collected during cerebral tumor excision surgeries: hypotheses for use in drug targeting therapy.
    J Neurooncol. 2022 May 25. pii: 10.1007/s11060-022-04028.
    PubMed     Abstract available


  549. REN L, Hua L, Bao Z, Deng J, et al
    Distinct clinical outcome of microcystic meningioma as a WHO grade 1 meningioma subtype.
    J Neurooncol. 2022 May 25. pii: 10.1007/s11060-022-04034.
    PubMed     Abstract available


  550. VUONG HG, Ngo TNM, Le HT, Dunn IF, et al
    The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
    J Neurooncol. 2022 May 23. pii: 10.1007/s11060-022-04027.
    PubMed     Abstract available


  551. DADEY DYA, Rodrigues A, Haider G, Pollom EL, et al
    Impact of socio-economic factors on radiation treatment after resection of metastatic brain tumors: trends from a private insurance database.
    J Neurooncol. 2022 May 21. pii: 10.1007/s11060-022-04031.
    PubMed     Abstract available


  552. BREEN WG, Youland RS, Giri S, Jacobson SB, et al
    Initial results of a phase II trial of (18)F-DOPA PET-guided re-irradiation for recurrent high-grade glioma.
    J Neurooncol. 2022 May 18. pii: 10.1007/s11060-022-04011.
    PubMed     Abstract available


  553. STRONG MJ, Koduri S, Allison JA, Pesavento CM, et al
    Bone metastasis from glioblastoma: a systematic review.
    J Neurooncol. 2022 May 17. pii: 10.1007/s11060-022-04025.
    PubMed     Abstract available


  554. LOPEZ-PEREZ CA, Franco-Mojica X, Villanueva-Gaona R, Diaz-Alba A, et al
    Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
    J Neurooncol. 2022 May 14. pii: 10.1007/s11060-022-04024.
    PubMed     Abstract available


  555. RAMMOHAN N, Ho A, Saxena M, Bajaj A, et al
    Tumor-associated alterations in white matter connectivity have prognostic significance in MGMT-unmethylated glioblastoma.
    J Neurooncol. 2022 May 7. pii: 10.1007/s11060-022-04018.
    PubMed     Abstract available


  556. SHAO N, Mao J, Xue L, Wang R, et al
    Correction to: Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma.
    J Neurooncol. 2022 May 4. pii: 10.1007/s11060-022-04006.
    PubMed    


  557. RIVERA PERLA KM, Tang OY, Durfey SNM, Vivas-Buitrago T, et al
    Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI).
    J Neurooncol. 2022 May 3. pii: 10.1007/s11060-022-04020.
    PubMed     Abstract available


  558. MCTHENIA SS, Pandit-Taskar N, Grkovski M, Donzelli MA, et al
    Quantifying intraventricular drug delivery utilizing programmable ventriculoperitoneal shunts as the intraventricular access device.
    J Neurooncol. 2022;157:457-463.
    PubMed     Abstract available


  559. LIU KX, Shang HH, Cacciotti C, Everdell E, et al
    DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis.
    J Neurooncol. 2022;157:499-510.
    PubMed     Abstract available


  560. WICKENHAUSER ME, Khan RB, Raches D, Ashford JM, et al
    The posterior fossa syndrome questionnaire: using science to inform practice.
    J Neurooncol. 2022;157:465-473.
    PubMed     Abstract available


  561. LIU ZM, Han Z, Wang JM, Sun T, et al
    Treatment and outcome of pediatric intracranial ependymoma after first relapse.
    J Neurooncol. 2022;157:385-396.
    PubMed     Abstract available


  562. HERSH AM, Antar A, Pennington Z, Aygun N, et al
    Predictors of survival and time to progression following operative management of intramedullary spinal cord astrocytomas.
    J Neurooncol. 2022;158:117-127.
    PubMed     Abstract available


  563. KAVOURIDIS VK, Ligon KL, Wen PY, Iorgulescu JB, et al
    Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
    J Neurooncol. 2022;158:111-116.
    PubMed     Abstract available


  564. IRONSIDE N, Snyder H, Xu Z, Schlesinger D, et al
    Effect of distance from target on hypopituitarism after stereotactic radiosurgery for pituitary adenomas.
    J Neurooncol. 2022;158:41-50.
    PubMed     Abstract available


  565. DEATKINE AB, Abdelrashid M, Tucker Z, Mehta A, et al
    High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.
    J Neurooncol. 2022;158:33-40.
    PubMed     Abstract available


    April 2022
  566. PARK DY, Tom MC, Chen Y, Tewari S, et al
    Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas.
    J Neurooncol. 2022 Apr 29. pii: 10.1007/s11060-022-04019.
    PubMed     Abstract available


  567. ZEITLBERGER AM, Putora PM, Hofer S, Schucht P, et al
    Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.
    J Neurooncol. 2022 Apr 29. pii: 10.1007/s11060-022-04022.
    PubMed     Abstract available


  568. CHANG L, Wang J, Zhou F, Wang D, et al
    Retraction Note to: LncRNA RP11-84E24.3 drives tumorigenesis and epithelial-to-mesenchymal transition of glioma cells by promoting TFAP2C-mediated activation of SNAI1.
    J Neurooncol. 2022 Apr 28. pii: 10.1007/s11060-022-04023.
    PubMed    


  569. KLINGENSCHMID J, Krigers A, Pinggera D, Kerschbaumer J, et al
    The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma.
    J Neurooncol. 2022 Apr 25. pii: 10.1007/s11060-022-04001.
    PubMed     Abstract available


  570. NEMATI H, Fakhre-Taha M, Javanmard AR, Jahanbakhshi A, et al
    LINC02381-ceRNA exerts its oncogenic effect through regulation of IGF1R signaling pathway in glioma.
    J Neurooncol. 2022 Apr 23. pii: 10.1007/s11060-022-03992.
    PubMed     Abstract available


  571. WALSH LE, Polacek LC, Panageas K, Reiner A, et al
    Coping with glioblastoma: prognostic communication and prognostic understanding among patients with recurrent glioblastoma, caregivers, and oncologists.
    J Neurooncol. 2022 Apr 18. pii: 10.1007/s11060-022-04010.
    PubMed     Abstract available


  572. LOUGHAN AR, Willis KD, Braun SE, Rodin G, et al
    Managing cancer and living meaningfully (CALM) in adults with malignant glioma: a proof-of-concept phase IIa trial.
    J Neurooncol. 2022 Apr 18. pii: 10.1007/s11060-022-03988.
    PubMed     Abstract available


  573. AOYAMA M, Masukawa K, Sugiyama I, Morita T, et al
    Comparison of the quality of death between primary malignant brain tumor patients and other cancer patients: results from a nationwide bereavement survey in Japan.
    J Neurooncol. 2022 Apr 18. pii: 10.1007/s11060-022-04013.
    PubMed     Abstract available


  574. CAI Q, Wu Y, Wang S, Huang T, et al
    Preoperative antiepileptic drug prophylaxis for early postoperative seizures in supratentorial meningioma: a single-center experience.
    J Neurooncol. 2022 Apr 17. pii: 10.1007/s11060-022-04009.
    PubMed     Abstract available


  575. SINGH DK, Shivalingappa PKM, Sharma A, Mondal A, et al
    NSG-70, a new glioblastoma cell line with mixed proneural-mesenchymal features, associates NOTCH1-WNT5A signaling with stem cell maintenance and angiogenesis.
    J Neurooncol. 2022 Apr 17. pii: 10.1007/s11060-022-04002.
    PubMed     Abstract available


  576. KERSCHBAUMER J, Krigers A, Demetz M, Pinggera D, et al
    The Clinical Frailty Scale as useful tool in patients with brain metastases.
    J Neurooncol. 2022 Apr 13. pii: 10.1007/s11060-022-04008.
    PubMed     Abstract available


  577. HOSOYA T, Takahashi M, Honda-Kitahara M, Miyakita Y, et al
    MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas.
    J Neurooncol. 2022 Apr 10. pii: 10.1007/s11060-022-03999.
    PubMed     Abstract available


  578. HALKETT GKB, Berg MN, Daudu D, Dhillon HM, et al
    Supportive care of patients diagnosed with high grade glioma and their carers in Australia.
    J Neurooncol. 2022 Apr 9. pii: 10.1007/s11060-022-03991.
    PubMed     Abstract available


  579. MO F, Meletti S, Belcastro V, Quadri S, et al
    Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study.
    J Neurooncol. 2022 Apr 9. pii: 10.1007/s11060-022-03998.
    PubMed     Abstract available


  580. LOUGHAN AR, Reid M, Willis KD, Davies A, et al
    The burden of a brain tumor: guiding patient centric care in neuro-oncology.
    J Neurooncol. 2022 Apr 8. pii: 10.1007/s11060-022-03993.
    PubMed     Abstract available


  581. STOYANOV GS, Lyutfi E, Georgieva R, Georgiev R, et al
    Diaph3 underlines tumor cell heterogeneity in glioblastoma with implications for treatment modalities resistance.
    J Neurooncol. 2022 Apr 5. pii: 10.1007/s11060-022-03996.
    PubMed     Abstract available


  582. STOYANOV GS
    Comment on "The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study".
    J Neurooncol. 2022 Apr 5. pii: 10.1007/s11060-022-04000.
    PubMed    


  583. MARCHETTI M, Pinzi V, Iezzoni C, Morlino S, et al
    Multisession radiosurgery for grade 2 (WHO), high risk meningiomas. A phase II clinical trial.
    J Neurooncol. 2022 Apr 4. pii: 10.1007/s11060-022-03978.
    PubMed     Abstract available


  584. MESNY E, Barritault M, Izquierdo C, Poncet D, et al
    Gyriform infiltration as imaging biomarker for molecular glioblastomas.
    J Neurooncol. 2022 Apr 1. pii: 10.1007/s11060-022-03995.
    PubMed     Abstract available


  585. GIANTINI-LARSEN AM, Garton ALA, Villamater FN, Kuzan-Fischer CM, et al
    Familial colloid cysts: not a chance occurrence.
    J Neurooncol. 2022;157:321-332.
    PubMed     Abstract available


  586. KIM C, Lim M, Woodworth GF, Arvanitis CD, et al
    The roles of thermal and mechanical stress in focused ultrasound-mediated immunomodulation and immunotherapy for central nervous system tumors.
    J Neurooncol. 2022;157:221-236.
    PubMed     Abstract available


  587. HART M, Anderson-Mellies A, Beltrami A, Gilani A, et al
    Population-based analysis of CNS tumor diagnoses, treatment, and survival in congenital and infant age groups.
    J Neurooncol. 2022;157:333-344.
    PubMed     Abstract available


  588. METZGER S, Weiser A, Gerber NU, Otth M, et al
    Central nervous system tumors in children under 5 years of age: a report on treatment burden, survival and long-term outcomes.
    J Neurooncol. 2022;157:307-317.
    PubMed     Abstract available


    March 2022
  589. BERTHOLD D, Carrasco AP, Uhl E, Muller H, et al
    Palliative care of older glioblastoma patients in neurosurgery.
    J Neurooncol. 2022 Mar 24. pii: 10.1007/s11060-022-03985.
    PubMed     Abstract available


  590. WEI Z, Niranjan A, Abou-Al-Shaar H, Deng H, et al
    A volume matched comparison of survival after radiosurgery in non-small cell lung cancer patients with one versus more than twenty brain metastases.
    J Neurooncol. 2022 Mar 22. pii: 10.1007/s11060-022-03981.
    PubMed     Abstract available


  591. GRITSCH D, Castro LNG
    Relevant pharmacologic interactions in the concurrent management of brain tumor-related epilepsy and venous thromboembolism: a systematic review.
    J Neurooncol. 2022 Mar 21. pii: 10.1007/s11060-022-03984.
    PubMed     Abstract available


  592. NIDAMANURI P, Drappatz J
    Immune checkpoint inhibitor therapy for recurrent meningiomas: a retrospective chart review.
    J Neurooncol. 2022 Mar 17. pii: 10.1007/s11060-022-03979.
    PubMed     Abstract available


  593. BIN ALAMER O, Palmisciano P, Mallela AN, Labib MA, et al
    Stereotactic radiosurgery in the management of petroclival meningiomas: a systematic review and meta-analysis of treatment outcomes of primary and adjuvant radiosurgery.
    J Neurooncol. 2022 Mar 17. pii: 10.1007/s11060-021-03934.
    PubMed     Abstract available


  594. RUTENBERG MS, Holtzman AL, Indelicato DJ, Huh S, et al
    Disease Control after Radiotherapy for Adult Craniopharyngioma: Clinical Outcomes from a Large Single-Institution Series.
    J Neurooncol. 2022 Mar 12. pii: 10.1007/s11060-022-03983.
    PubMed     Abstract available


  595. VANHAUWAERT D, Pinson H, Sweldens C, Du Four S, et al
    Quality indicators in neuro-oncology: Review of the literature and development of a new quality indicator set for glioma care through a two-round Delphi survey.
    J Neurooncol. 2022 Mar 11. pii: 10.1007/s11060-022-03971.
    PubMed     Abstract available


  596. MOON HH, Park JE, Kim YH, Kim JH, et al
    Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment.
    J Neurooncol. 2022 Mar 11. pii: 10.1007/s11060-022-03980.
    PubMed     Abstract available


  597. ROBERTS JW, Powlovich L, Sheybani N, LeBlang S, et al
    Focused ultrasound for the treatment of glioblastoma.
    J Neurooncol. 2022 Mar 10. pii: 10.1007/s11060-022-03974.
    PubMed     Abstract available


  598. BARRAGAN-PEREZ EJ, Alvarez-Amado DE, Dies-Suarez P, Tobon SH, et al
    Compassionate use of Quantum Magnetic Resonance Therapy for treatment of children with Diffuse Brainstem Glioma in Mexico City: a single institutional experience.
    J Neurooncol. 2022 Mar 10. pii: 10.1007/s11060-022-03972.
    PubMed     Abstract available


  599. MILLS MN, King W, Soyano A, Pina Y, et al
    Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease.
    J Neurooncol. 2022 Mar 4. pii: 10.1007/s11060-022-03977.
    PubMed     Abstract available


  600. PATRICK HH, Sherman JH, Elder JB, Olson JJ, et al
    Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of cytoreductive surgery in the management of progressive glioblastoma in adults.
    J Neurooncol. 2022 Mar 4. pii: 10.1007/s11060-021-03881.
    PubMed     Abstract available


  601. DE MARCELLUS C, Tauziede-Espariat A, Cuinet A, Pasqualini C, et al
    The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.
    J Neurooncol. 2022 Mar 3. pii: 10.1007/s11060-022-03970.
    PubMed     Abstract available


  602. BROGGI G, Gianno F, Shemy DT, Massimino M, et al
    Atypical teratoid/rhabdoid tumor in adults: a systematic review of the literature with meta-analysis and additional reports of 4 cases.
    J Neurooncol. 2022;157:1-14.
    PubMed     Abstract available


  603. DIAZ M, Singh P, Kotchetkov IS, Skakodub A, et al
    Quantitative assessment of circulating tumor cells in cerebrospinal fluid as a clinical tool to predict survival in leptomeningeal metastases.
    J Neurooncol. 2022;157:81-90.
    PubMed     Abstract available


  604. PECIU-FLORIANU I, Legrand V, Monfilliette-Djelad A, Maurage CA, et al
    Frameless robot-assisted stereotactic biopsies for lesions of the brainstem-a series of 103 consecutive biopsies.
    J Neurooncol. 2022;157:109-119.
    PubMed     Abstract available


    February 2022
  605. GROGAN D, Bray DP, Cosgrove M, Boucher A, et al
    Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review.
    J Neurooncol. 2022 Feb 25. pii: 10.1007/s11060-022-03961.
    PubMed     Abstract available


  606. BYRNE E, Abel S, Yu A, Shepard M, et al
    Trends in radiation dose for low grade gliomas across the United States.
    J Neurooncol. 2022 Feb 23. pii: 10.1007/s11060-022-03962.
    PubMed     Abstract available


  607. GERMANO IM, Ziu M, Wen P, Ormond DR, et al
    Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults.
    J Neurooncol. 2022 Feb 23. pii: 10.1007/s11060-021-03900.
    PubMed     Abstract available


  608. VALLEJO FA, Eichberg DG, Morell AA, Shah AH, et al
    Same-day discharge after brain tumor resection: a prospective pilot study.
    J Neurooncol. 2022 Feb 22. pii: 10.1007/s11060-022-03969.
    PubMed     Abstract available


  609. OBRECHT D, Mynarek M, Hagel C, Kwiecien R, et al
    Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies.
    J Neurooncol. 2022 Feb 21. pii: 10.1007/s11060-021-03913.
    PubMed     Abstract available


  610. LIN R, Xu Y, Xie S, Zhang Y, et al
    Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
    J Neurooncol. 2022 Feb 21. pii: 10.1007/s11060-022-03964.
    PubMed     Abstract available


  611. RAMOS-FRESNEDO A, Pullen MW, Perez-Vega C, Domingo RA, et al
    The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.
    J Neurooncol. 2022 Feb 17. pii: 10.1007/s11060-022-03960.
    PubMed     Abstract available


  612. MORENO DA, da Silva LS, Zanon MF, Bonatelli M, et al
    Single nCounter assay for prediction of MYCN amplification and molecular classification of medulloblastomas: a multicentric study.
    J Neurooncol. 2022 Feb 15. pii: 10.1007/s11060-022-03965.
    PubMed     Abstract available


  613. ABDULHALEEM M, Johnston H, D'Agostino R Jr, Lanier C, et al
    Local control outcomes for combination of stereotactic radiosurgery and immunotherapy for non-small cell lung cancer brain metastases.
    J Neurooncol. 2022 Feb 15. pii: 10.1007/s11060-022-03951.
    PubMed     Abstract available


  614. SOLANO-PAEZ P, Fonseca A, Baroni LV, Amayiri N, et al
    Clinical and molecular characteristics of pediatric low-grade glioma complicated with ventriculo-peritoneal shunt related ascites.
    J Neurooncol. 2022 Feb 5. pii: 10.1007/s11060-022-03956.
    PubMed     Abstract available


  615. HAIM O, Abramov S, Shofty B, Fanizzi C, et al
    Predicting EGFR mutation status by a deep learning approach in patients with non-small cell lung cancer brain metastases.
    J Neurooncol. 2022 Feb 4. pii: 10.1007/s11060-022-03946.
    PubMed     Abstract available


  616. FATIMA N, Maxwell AK, La Dine A, Barnard ZR, et al
    Predictors of hearing functional outcome following surgery for cerebellopontine angle meningioma.
    J Neurooncol. 2022 Feb 3. pii: 10.1007/s11060-022-03958.
    PubMed     Abstract available


  617. HAQUE W, Teh C, Butler EB, Teh BS, et al
    Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma.
    J Neurooncol. 2022 Feb 1. pii: 10.1007/s11060-022-03955.
    PubMed     Abstract available


  618. SHEPARD MJ, Haider AS, Prabhu SS, Sawaya R, et al
    Long term outcomes following surgery for pineal region tumors.
    J Neurooncol. 2022;156:491-498.
    PubMed     Abstract available


  619. LUKAS RV, Thakkar JP, Cristofanilli M, Chandra S, et al
    Leptomeningeal metastases: the future is now.
    J Neurooncol. 2022;156:443-452.
    PubMed     Abstract available


  620. WOLFF JE, Van Gool SW, Kutluk T, Diez B, et al
    Final results of the Choroid Plexus Tumor study CPT-SIOP-2000.
    J Neurooncol. 2022;156:599-613.
    PubMed     Abstract available


    January 2022
  621. LEE YP, Jung HA, Lee MS, Choi JW, et al
    Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.
    J Neurooncol. 2022 Jan 30. pii: 10.1007/s11060-021-03930.
    PubMed     Abstract available


  622. YANG K, Landry AP, Aljoghaiman M, Gutierrez E, et al
    Postoperative CT scans after resection of brain metastases: neurosurgical routine or added value?
    J Neurooncol. 2022 Jan 29. pii: 10.1007/s11060-022-03957.
    PubMed     Abstract available


  623. CHIANG JA, Feghali PT, Saavedra A, Whitaker AM, et al
    Effects of sleep disturbance on neuropsychological functioning in patients with pediatric brain tumor.
    J Neurooncol. 2022 Jan 29. pii: 10.1007/s11060-022-03954.
    PubMed     Abstract available


  624. PIKIS S, Mantziaris G, Islim AI, Peker S, et al
    Stereotactic radiosurgery versus active surveillance for incidental, convexity meningiomas: a matched cohort analysis from the IMPASSE study.
    J Neurooncol. 2022 Jan 29. pii: 10.1007/s11060-022-03953.
    PubMed     Abstract available


  625. MARKU M, Rasmussen BK, Belmonte F, Andersen EAW, et al
    Postoperative epilepsy and survival in glioma patients: a nationwide population-based cohort study from 2009 to 2018.
    J Neurooncol. 2022 Jan 28. pii: 10.1007/s11060-022-03948.
    PubMed     Abstract available


  626. NETH BJ, Balakrishnan SN, Carabenciov ID, Uhm JH, et al
    Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
    J Neurooncol. 2022 Jan 25. pii: 10.1007/s11060-022-03950.
    PubMed     Abstract available


  627. GERRITSEN JKW, Broekman MLD, De Vleeschouwer S, Schucht P, et al
    Decision making and surgical modality selection in glioblastoma patients: an international multicenter survey.
    J Neurooncol. 2022 Jan 24. pii: 10.1007/s11060-021-03894.
    PubMed     Abstract available


  628. MANTZIARIS G, Pikis S, Samanci Y, Peker S, et al
    Stereotactic radiosurgery versus active surveillance for asymptomatic, skull-based meningiomas: an international, multicenter matched cohort study.
    J Neurooncol. 2022 Jan 24. pii: 10.1007/s11060-021-03923.
    PubMed     Abstract available


  629. NORONHA C, Ribeiro AS, Taipa R, Leitao D, et al
    PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma.
    J Neurooncol. 2022 Jan 23. pii: 10.1007/s11060-021-03907.
    PubMed     Abstract available


  630. PARK DY, Tom MC, Wei W, Tewari S, et al
    Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.
    J Neurooncol. 2022 Jan 22. pii: 10.1007/s11060-021-03920.
    PubMed     Abstract available


  631. NAZEM A, Guiry SC, Pourfathi M, Ware JB, et al
    MR susceptibility imaging for detection of tumor-associated macrophages in glioblastoma.
    J Neurooncol. 2022 Jan 19. pii: 10.1007/s11060-022-03947.
    PubMed     Abstract available


  632. MOITRA P, Chatterjee A, Kota PK, Epari S, et al
    Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study.
    J Neurooncol. 2022 Jan 17. pii: 10.1007/s11060-022-03944.
    PubMed     Abstract available


  633. LAMBA N, Groves A, Torre M, Yeo KK, et al
    The epidemiology of primary and metastatic brain tumors in infancy through childhood.
    J Neurooncol. 2022 Jan 17. pii: 10.1007/s11060-021-03927.
    PubMed     Abstract available


  634. DADARIO NB, Zaman A, Pandya M, Dlouhy BJ, et al
    Endoscopic-assisted surgical approach for butterfly glioma surgery.
    J Neurooncol. 2022 Jan 15. pii: 10.1007/s11060-022-03945.
    PubMed     Abstract available


  635. TANG OY, Clarke RA, Rivera Perla KM, Corcoran Ruiz KM, et al
    Brain tumor craniotomy outcomes for dual-eligible medicare and medicaid patients: a 10-year nationwide analysis.
    J Neurooncol. 2022 Jan 13. pii: 10.1007/s11060-021-03922.
    PubMed     Abstract available


  636. AFTAB K, Aamir FB, Mallick S, Mubarak F, et al
    Radiomics for precision medicine in glioblastoma.
    J Neurooncol. 2022 Jan 12. pii: 10.1007/s11060-021-03933.
    PubMed     Abstract available


  637. MASSARWEH A, Tschernichovsky R, Stemmer A, Benouaich-Amiel A, et al
    Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study.
    J Neurooncol. 2022 Jan 12. pii: 10.1007/s11060-021-03911.
    PubMed     Abstract available


  638. PERLOW HK, Yaney A, Yang M, Klamer B, et al
    Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma.
    J Neurooncol. 2022 Jan 11. pii: 10.1007/s11060-021-03925.
    PubMed     Abstract available


  639. PENA PINO I, Ma J, Hori YS, Fomchenko E, et al
    Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (cSRS) as treatment for brain metastasis that recurred locally after initial radiosurgery (BMRS): a multi-institutional experience.
    J Neurooncol. 2022 Jan 10. pii: 10.1007/s11060-021-03893.
    PubMed     Abstract available


  640. DONO A, Zhu P, Holmes E, Takayasu T, et al
    Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma.
    J Neurooncol. 2022 Jan 8. pii: 10.1007/s11060-021-03917.
    PubMed     Abstract available


  641. KILIAN A, Aigner A, Simon M, Salchow DJ, et al
    Tumor load rather than contrast enhancement is associated with the visual function of children and adolescents with optic pathway glioma - a retrospective Magnetic Resonance Imaging study.
    J Neurooncol. 2022 Jan 7. pii: 10.1007/s11060-021-03941.
    PubMed     Abstract available


  642. GRIMALDI S, Harlay V, Appay R, Bequet C, et al
    Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.
    J Neurooncol. 2022 Jan 7. pii: 10.1007/s11060-022-03943.
    PubMed     Abstract available


  643. EATZ TA, Eichberg DG, Lu VM, Di L, et al
    Intraoperative 5-ALA fluorescence-guided resection of high-grade glioma leads to greater extent of resection with better outcomes: a systematic review.
    J Neurooncol. 2022 Jan 6. pii: 10.1007/s11060-021-03901.
    PubMed     Abstract available


  644. KAWAUCHI D, Ohno M, Honda-Kitahara M, Miyakita Y, et al
    The clinical characteristics and outcomes of incidentally discovered glioblastoma.
    J Neurooncol. 2022 Jan 5. pii: 10.1007/s11060-021-03931.
    PubMed     Abstract available


  645. MAGANA SM, Peterson TE, Evans JE, Decker PA, et al
    Pediatric brain tumor cell lines exhibit miRNA-depleted, Y RNA-enriched extracellular vesicles.
    J Neurooncol. 2022 Jan 5. pii: 10.1007/s11060-021-03914.
    PubMed     Abstract available


  646. CHEN JS, Clarke R, Haddad AF, Wang EJ, et al
    The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis.
    J Neurooncol. 2022 Jan 4. pii: 10.1007/s11060-021-03940.
    PubMed     Abstract available


  647. GERAGHTY BJ, Dasgupta A, Sandhu M, Malik N, et al
    Predicting survival in patients with glioblastoma using MRI radiomic features extracted from radiation planning volumes.
    J Neurooncol. 2022 Jan 3. pii: 10.1007/s11060-021-03939.
    PubMed     Abstract available


  648. ZUO J, Liu C, Ni H, Yu Z, et al
    WDR34 affects PI3K/Akt and Wnt/beta-catenin pathways to regulates malignant biological behaviors of glioma cells.
    J Neurooncol. 2022 Jan 3. pii: 10.1007/s11060-021-03932.
    PubMed     Abstract available


  649. KIM N, Lim DH, Yoon SE, Kim SJ, et al
    Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma.
    J Neurooncol. 2022;156:307-316.
    PubMed     Abstract available


  650. LOIZIDOU M, Sefcikova V, Ekert JO, Bone M, et al
    Reforming support systems of newly diagnosed brain cancer patients: a systematic review.
    J Neurooncol. 2022;156:61-71.
    PubMed     Abstract available


  651. NAKAJIMA R, Kinoshita M, Okita H, Nakada M, et al
    Quality of life following awake surgery depends on ability of executive function, verbal fluency, and movement.
    J Neurooncol. 2022;156:173-183.
    PubMed     Abstract available


    December 2021
  652. ROBERT SM, Vetsa S, Nadar A, Vasandani S, et al
    Correction to: The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications.
    J Neurooncol. 2021 Dec 30. pii: 10.1007/s11060-021-03937.
    PubMed    


  653. KLEMENT RJ, Popp I, Kaul D, Ehret F, et al
    Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis.
    J Neurooncol. 2021 Dec 23. pii: 10.1007/s11060-021-03926.
    PubMed     Abstract available


  654. TESKE N, Karschnia P, Weller J, Siller S, et al
    Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
    J Neurooncol. 2021 Dec 13. pii: 10.1007/s11060-021-03912.
    PubMed     Abstract available


  655. JIMENEZ AE, Khalafallah AM, Botros D, Horowitz MA, et al
    The role of anticoagulation for superior sagittal sinus thrombosis following craniotomy for resection of parasagittal/parafalcine meningiomas.
    J Neurooncol. 2021 Dec 2. pii: 10.1007/s11060-021-03916.
    PubMed     Abstract available


  656. JOHNSON KJ, Wang X, Barnes JM, Delavar A, et al
    Residential distance from the reporting hospital and survival among adolescents, and young adults diagnosed with CNS tumors.
    J Neurooncol. 2021;155:353-361.
    PubMed     Abstract available


  657. HAINC N, Alsafwani N, Gao A, O'Halloran PJ, et al
    The centrally restricted diffusion sign on MRI for assessment of radiation necrosis in metastases treated with stereotactic radiosurgery.
    J Neurooncol. 2021;155:325-333.
    PubMed     Abstract available


    November 2021
  658. ROBERT SM, Vetsa S, Nadar A, Vasandani S, et al
    The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications.
    J Neurooncol. 2021 Nov 30. pii: 10.1007/s11060-021-03874.
    PubMed     Abstract available


  659. YOUNG M, Delaney A, Jurbergs N, Pan H, et al
    Radiotherapy alone for pediatric patients with craniopharyngioma.
    J Neurooncol. 2021 Nov 30. pii: 10.1007/s11060-021-03908.
    PubMed     Abstract available


  660. SOLER DC, Kerstetter-Fogle A, McCormick TS, Sloan AE, et al
    Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments.
    J Neurooncol. 2021 Nov 26. pii: 10.1007/s11060-021-03902.
    PubMed     Abstract available


  661. GARCIA CR, Myint ZW, Jayswal R, Wang C, et al
    Hematological adverse events in the management of glioblastoma.
    J Neurooncol. 2021 Nov 24. pii: 10.1007/s11060-021-03891.
    PubMed     Abstract available


  662. WEFEL JS, Zhou R, Sulman EP, Boehling NS, et al
    Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients.
    J Neurooncol. 2021 Nov 24. pii: 10.1007/s11060-021-03905.
    PubMed     Abstract available


  663. BARAK T, Vetsa S, Nadar A, Jin L, et al
    Correction to: Surgical strategies for older patients with glioblastoma.
    J Neurooncol. 2021 Nov 23. pii: 10.1007/s11060-021-03888.
    PubMed    


  664. ROH TH, Lee JH, Kim SJ, Shim JK, et al
    A novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres.
    J Neurooncol. 2021 Nov 22. pii: 10.1007/s11060-021-03903.
    PubMed     Abstract available


  665. YUSUF M, Rattani A, Gaskins J, Oliver AL, et al
    Stereotactic radiosurgery for melanoma brain metastases: dose-size response relationship in the era of immunotherapy.
    J Neurooncol. 2021 Nov 22. pii: 10.1007/s11060-021-03899.
    PubMed     Abstract available


  666. HENDERSON F JR, Schwartz TH
    Update on management of craniopharyngiomas.
    J Neurooncol. 2021 Nov 22. pii: 10.1007/s11060-021-03906.
    PubMed     Abstract available


  667. BEHLING F, Fodi C, Wang S, Hempel JM, et al
    Increased proliferation is associated with CNS invasion in meningiomas.
    J Neurooncol. 2021 Nov 20. pii: 10.1007/s11060-021-03892.
    PubMed     Abstract available


  668. PAOLI C, Segard S, Burel-Vandenbos F
    Is H3 K27M mutation testing relevant in the diagnostic routine of WHO grade 4 gliomas exclusively located in the corpus callosum in adults?
    J Neurooncol. 2021 Nov 20. pii: 10.1007/s11060-021-03884.
    PubMed    


  669. BUNEVICIUS A, Pikis S, Kondziolka D, Patel DN, et al
    Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study.
    J Neurooncol. 2021 Nov 19. pii: 10.1007/s11060-021-03883.
    PubMed     Abstract available


  670. PALMISCIANO P, El Ahmadieh TY, Haider AS, Bin Alamer O, et al
    Thalamic gliomas in adults: a systematic review of clinical characteristics, treatment strategies, and survival outcomes.
    J Neurooncol. 2021 Nov 19. pii: 10.1007/s11060-021-03898.
    PubMed     Abstract available


  671. YANG K, Luan L, Li X, Sun X, et al
    ERK inhibition in glioblastoma is associated with autophagy activation and tumorigenesis suppression.
    J Neurooncol. 2021 Nov 19. pii: 10.1007/s11060-021-03896.
    PubMed     Abstract available


  672. VUONG HG, Le HT, Ngo TNM, Fung KM, et al
    H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients.
    J Neurooncol. 2021 Nov 18. pii: 10.1007/s11060-021-03890.
    PubMed     Abstract available


  673. SARAN F, Welsh L, James A, McBain C, et al
    Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
    J Neurooncol. 2021 Nov 17. pii: 10.1007/s11060-021-03877.
    PubMed     Abstract available


  674. PATIL N, Somasundaram E, Waite KA, Lathia JD, et al
    Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
    J Neurooncol. 2021 Nov 10. pii: 10.1007/s11060-021-03886.
    PubMed     Abstract available


  675. ZIU M, Goyal S, Olson JJ
    Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of radiation therapy in the management of progressive and recurrent glioblastoma in adults.
    J Neurooncol. 2021 Nov 8. pii: 10.1007/s11060-021-03857.
    PubMed     Abstract available


  676. SHEYBANI ND, Witter AR, Garrison WJ, Miller GW, et al
    Profiling of the immune landscape in murine glioblastoma following blood brain/tumor barrier disruption with MR image-guided focused ultrasound.
    J Neurooncol. 2021 Nov 3. pii: 10.1007/s11060-021-03887.
    PubMed     Abstract available


  677. YOULDEN DR, Henshaw C, Gottardo NG, Hassall T, et al
    Incidence and survival for childhood central nervous system tumours in Australia, 1983-2016.
    J Neurooncol. 2021;155:203-213.
    PubMed     Abstract available


  678. ADOLPH JE, Fleischhack G, Gaab C, Mikasch R, et al
    Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies.
    J Neurooncol. 2021;155:193-202.
    PubMed     Abstract available


  679. WANG S, Sun MZ, Abecassis IJ, Weil AG, et al
    Predictors of mortality and tumor recurrence in desmoplastic infantile ganglioglioma and astrocytoma-and individual participant data meta-analysis (IPDMA).
    J Neurooncol. 2021;155:155-163.
    PubMed     Abstract available


  680. LU VM, Luther EM, Eichberg DG, Morell AA, et al
    Prognosticating survival of pineal parenchymal tumors of intermediate differentiation (PPTID) by grade.
    J Neurooncol. 2021;155:165-172.
    PubMed     Abstract available


    October 2021
  681. KANAZAWA T, Ohara K, Kitamura Y, Nakaya M, et al
    Histopathological investigation of the 1p/19q-codeleted gliomas resected following alkylating agent chemotherapy.
    J Neurooncol. 2021 Oct 31. pii: 10.1007/s11060-021-03855.
    PubMed     Abstract available


  682. JAMAN E, Zhang X, Sandlesh P, Habib A, et al
    History of atopy confers improved outcomes in IDH mutant and wildtype lower grade gliomas.
    J Neurooncol. 2021 Oct 29. pii: 10.1007/s11060-021-03854.
    PubMed     Abstract available


  683. HASEGAWA H, Vakharia K, Link MJ, Stafford SL, et al
    The role of single-fraction stereotactic radiosurgery for atypical meningiomas (WHO grade II): treatment results based on a 25-year experience.
    J Neurooncol. 2021 Oct 27. pii: 10.1007/s11060-021-03882.
    PubMed     Abstract available


  684. WINOGRAD E, Germano I, Wen P, Olson JJ, et al
    Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma.
    J Neurooncol. 2021 Oct 25. pii: 10.1007/s11060-021-03876.
    PubMed     Abstract available


  685. OLSON JJ
    Congress of neurological surgeons systematic review and evidence-based guidelines for the treatment of adults with progressive glioblastoma update: introduction and methods.
    J Neurooncol. 2021 Oct 25. pii: 10.1007/s11060-021-03850.
    PubMed     Abstract available


  686. JOHNSON DR, Glenn CA, Javan R, Olson JJ, et al
    Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of imaging in the management of progressive glioblastoma in adults.
    J Neurooncol. 2021 Oct 25. pii: 10.1007/s11060-021-03853.
    PubMed     Abstract available


  687. MALIK N, Geraghty B, Dasgupta A, Maralani PJ, et al
    MRI radiomics to differentiate between low grade glioma and glioblastoma peritumoral region.
    J Neurooncol. 2021 Oct 25. pii: 10.1007/s11060-021-03866.
    PubMed     Abstract available


  688. DIXIT KS, Sachdev S, Amidei C, Kumthekar P, et al
    A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
    J Neurooncol. 2021 Oct 24. pii: 10.1007/s11060-021-03875.
    PubMed     Abstract available


  689. GIRARD A, Le Reste PJ, Metais A, Carsin Nicol B, et al
    Combining (18)F-DOPA PET and MRI with perfusion-weighted imaging improves delineation of high-grade subregions in enhancing and non-enhancing gliomas prior treatment: a biopsy-controlled study.
    J Neurooncol. 2021 Oct 22. pii: 10.1007/s11060-021-03873.
    PubMed     Abstract available


  690. SAMANIC CM, Teer JK, Thompson ZJ, Creed JH, et al
    Mitochondrial DNA sequence variation and risk of meningioma.
    J Neurooncol. 2021 Oct 20. pii: 10.1007/s11060-021-03878.
    PubMed     Abstract available


  691. WILCOX JA, Brown S, Reiner AS, Young RJ, et al
    Salvage resection of recurrent previously irradiated brain metastases: tumor control and radiation necrosis dependency on adjuvant re-irradiation.
    J Neurooncol. 2021 Oct 16. pii: 10.1007/s11060-021-03872.
    PubMed     Abstract available


  692. YERRABOTHALA S, Gourley BL, Ford JC, Ahmed SR, et al
    Systemic coagulation is activated in patients with meningioma and glioblastoma.
    J Neurooncol. 2021 Oct 15. pii: 10.1007/s11060-021-03865.
    PubMed     Abstract available


  693. SOHN B, An C, Kim D, Ahn SS, et al
    Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant.
    J Neurooncol. 2021 Oct 14. pii: 10.1007/s11060-021-03870.
    PubMed     Abstract available


  694. FANG S, Liang Y, Li L, Wang L, et al
    Correction to: Tumor location-based classification of surgery-related language impairments in patients with glioma.
    J Neurooncol. 2021 Oct 12. pii: 10.1007/s11060-021-03871.
    PubMed    


  695. BARAK T, Vetsa S, Nadar A, Jin L, et al
    Surgical strategies for older patients with glioblastoma.
    J Neurooncol. 2021 Oct 9. pii: 10.1007/s11060-021-03862.
    PubMed     Abstract available


  696. AKMAL S, Ginalis EE, Patel NV, Aiken R, et al
    Leptomeningeal disease in glioblastoma: endgame or opportunity?
    J Neurooncol. 2021 Oct 8. pii: 10.1007/s11060-021-03864.
    PubMed     Abstract available


  697. RINCON-TORROELLA J, Khela H, Bettegowda A, Bettegowda C, et al
    Biomarkers and focused ultrasound: the future of liquid biopsy for brain tumor patients.
    J Neurooncol. 2021 Oct 6. pii: 10.1007/s11060-021-03837.
    PubMed     Abstract available


  698. PATEL NV, Wong T, Fralin SR, Li M, et al
    Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial.
    J Neurooncol. 2021 Oct 3. pii: 10.1007/s11060-021-03851.
    PubMed     Abstract available


  699. ALDRICH KD, Horne VE, Bielamowicz K, Sonabend RY, et al
    Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma.
    J Neurooncol. 2021 Oct 1. pii: 10.1007/s11060-021-03847.
    PubMed     Abstract available


  700. FANG S, Liang Y, Li L, Wang L, et al
    Tumor location-based classification of surgery-related language impairments in patients with glioma.
    J Neurooncol. 2021 Oct 1. pii: 10.1007/s11060-021-03858.
    PubMed     Abstract available


  701. ORT J, Hamou HA, Kernbach JM, Hakvoort K, et al
    (18)F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III/IV glioma: moving towards a multimodal imaging-guided resection.
    J Neurooncol. 2021 Oct 1. pii: 10.1007/s11060-021-03844.
    PubMed     Abstract available


  702. CABRAL DE CARVALHO CORREA D, Tesser-Gamba F, Dias Oliveira I, Saba da Silva N, et al
    Molecular profiling of pediatric and adolescent ependymomas: identification of genetic variants using a next-generation sequencing panel.
    J Neurooncol. 2021;155:13-23.
    PubMed     Abstract available


  703. BROWNE-FARMER C, Hazrati LN, Mamatjan Y, Zadeh G, et al
    Paediatric atypical choroid plexus papilloma: is adjuvant therapy necessary?
    J Neurooncol. 2021;155:63-70.
    PubMed     Abstract available


    September 2021
  704. FUJITA Y, Nagashima H, Tanaka K, Hashiguchi M, et al
    Hyperintense signal on diffusion-weighted imaging for monitoring the acute response and local recurrence after photodynamic therapy in malignant gliomas.
    J Neurooncol. 2021 Sep 22. pii: 10.1007/s11060-021-03845.
    PubMed     Abstract available


  705. CACHO-DIAZ B, Cuapatencatl LD, Rodriguez JA, Garcilazo-Reyes YJ, et al
    Identification of a high-risk group for brain metastases in non-small cell lung cancer patients.
    J Neurooncol. 2021 Sep 21. pii: 10.1007/s11060-021-03849.
    PubMed     Abstract available


  706. ROGERS S, Stauffer A, Lomax N, Alonso S, et al
    Five fraction stereotactic radiotherapy after brain metastasectomy: a single-institution experience and literature review.
    J Neurooncol. 2021 Sep 21. pii: 10.1007/s11060-021-03840.
    PubMed     Abstract available


  707. CARDONA AF, Jaramillo-Velasquez D, Ruiz-Patino A, Polo C, et al
    Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation.
    J Neurooncol. 2021 Sep 9. pii: 10.1007/s11060-021-03834.
    PubMed     Abstract available


  708. BARONI LV, Freytes C, Fernandez Ponce N, Oller A, et al
    Craniospinal irradiation as part of re-irradiation for children with recurrent medulloblastoma.
    J Neurooncol. 2021 Sep 9. pii: 10.1007/s11060-021-03842.
    PubMed     Abstract available


  709. DICPINIGAITIS AJ, Kazim SF, Schmidt MH, Couldwell WT, et al
    Association of baseline frailty status and age with postoperative morbidity and mortality following intracranial meningioma resection.
    J Neurooncol. 2021 Sep 8. pii: 10.1007/s11060-021-03841.
    PubMed     Abstract available


  710. BRAUN SE, Aslanzadeh FJ, Lanoye A, Fountain-Zaragoza S, et al
    Working memory training for adult glioma patients: a proof-of-concept study.
    J Neurooncol. 2021 Sep 7. pii: 10.1007/s11060-021-03839.
    PubMed     Abstract available


  711. VAN DER LINDEN SD, Rutten GM, Dirven L, Taphoorn MJB, et al
    eHealth cognitive rehabilitation for brain tumor patients: results of a randomized controlled trial.
    J Neurooncol. 2021 Sep 6. pii: 10.1007/s11060-021-03828.
    PubMed     Abstract available


  712. PENG G, Su J, Xiao S, Liu Q, et al
    LINC00152 acts as a potential marker in gliomas and promotes tumor proliferation and invasion through the LINC00152/miR-107/RAB10 axis.
    J Neurooncol. 2021 Sep 3. pii: 10.1007/s11060-021-03836.
    PubMed     Abstract available


  713. LUO T, Ding K, Ji J, Zhang X, et al
    Cytoskeleton-associated protein 4 (CKAP4) promotes malignant progression of human gliomas through inhibition of the Hippo signaling pathway.
    J Neurooncol. 2021 Sep 2. pii: 10.1007/s11060-021-03831.
    PubMed     Abstract available


  714. AHMETI H, Borzikowsky C, Hollander D, Rocken C, et al
    Risks and neurological benefits of meningioma surgery in elderly patients compared to young patients.
    J Neurooncol. 2021 Sep 1. pii: 10.1007/s11060-021-03832.
    PubMed     Abstract available


  715. NORMAN S, Ramos A, Giantini Larsen AM, Bander E, et al
    Impact of the COVID-19 pandemic on neuro-oncology outcomes.
    J Neurooncol. 2021;154:375-381.
    PubMed     Abstract available


  716. HUNTOON K, Makary MS, Damante M, Giglio P, et al
    Intraoperative 3 T MRI is more correlative to residual disease extent than early postoperative MRI.
    J Neurooncol. 2021;154:345-351.
    PubMed     Abstract available


  717. BANDER ED, Yuan M, Reiner AS, Garton ALA, et al
    Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes.
    J Neurooncol. 2021;154:301-313.
    PubMed     Abstract available


  718. TANAKA R, Inoue K, Yamada Y, Yoshida M, et al
    A case of primary CNS embryonal rhabdomyosarcoma with PAX3-NCOA2 fusion and systematic meta-review.
    J Neurooncol. 2021;154:247-256.
    PubMed     Abstract available


  719. SANDHU MRS, Chiang VL, Tran T, Yu JB, et al
    Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis.
    J Neurooncol. 2021;154:197-203.
    PubMed     Abstract available


  720. KIM N, Lim DH, Yoon SE, Kim SJ, et al
    Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
    J Neurooncol. 2021;154:207-217.
    PubMed     Abstract available


  721. OTANI R, Mukasa A, Uzuka T, Higuchi F, et al
    Gene expression profiling of 19q-loss astrocytomas suggest a specific pattern associated with the better prognosis.
    J Neurooncol. 2021;154:221-228.
    PubMed     Abstract available


    August 2021
  722. PERAGALLO JH, Bruce BB, Vasseneix C, Jariyakosol S, et al
    Vision-related quality-of-life in pediatric primary brain tumor patients.
    J Neurooncol. 2021 Aug 30. pii: 10.1007/s11060-021-03835.
    PubMed     Abstract available


  723. NOFFSINGER B, Witter A, Sheybani N, Xiao A, et al
    Technical choices significantly alter the adaptive immune response against immunocompetent murine gliomas in a model-dependent manner.
    J Neurooncol. 2021 Aug 25. pii: 10.1007/s11060-021-03822.
    PubMed     Abstract available


  724. SEARS TK, Horbinski CM, Woolard KD
    IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
    J Neurooncol. 2021 Aug 23. pii: 10.1007/s11060-021-03829.
    PubMed     Abstract available


  725. APRA C, Guillemot D, Frouin E, Bouvier C, et al
    Molecular description of meningeal solitary fibrous tumors/hemangiopericytomas compared to meningiomas: two completely separate entities.
    J Neurooncol. 2021 Aug 20. pii: 10.1007/s11060-021-03830.
    PubMed     Abstract available


  726. XIAO B, Lv SG, Wu MJ, Shen XL, et al
    Circ_CLIP2 promotes glioma progression through targeting the miR-195-5p/HMGB3 axis.
    J Neurooncol. 2021 Aug 6. pii: 10.1007/s11060-021-03814.
    PubMed     Abstract available


  727. JIN L, Youngblood MW, Gupte TP, Vetsa S, et al
    Type of bony involvement predicts genomic subgroup in sphenoid wing meningiomas.
    J Neurooncol. 2021 Aug 4. pii: 10.1007/s11060-021-03819.
    PubMed     Abstract available


  728. SCHNEIDER M, Schafer N, Apallas S, Potthoff AL, et al
    Red blood cell distribution width to platelet ratio substantiates preoperative survival prediction in patients with newly-diagnosed glioblastoma.
    J Neurooncol. 2021 Aug 4. pii: 10.1007/s11060-021-03817.
    PubMed     Abstract available


  729. TAKAMI H, Graffeo CS, Perry A, Ohno M, et al
    Histopathology and prognosis of germ cell tumors metastatic to brain: cohort study.
    J Neurooncol. 2021;154:121-130.
    PubMed     Abstract available


  730. GAZZERI R, Telera S, Galarza M, Callovini GM, et al
    Surgical treatment of solitary intradural extramedullary spinal cord metastases from solid cancers of non-neurogenic origin. A multicenter study.
    J Neurooncol. 2021;154:101-112.
    PubMed     Abstract available


  731. DHAWAN S, Venteicher AS, Butler WE, Carter BS, et al
    Clinical outcomes as a function of the number of samples taken during stereotactic needle biopsies: a meta-analysis.
    J Neurooncol. 2021;154:1-11.
    PubMed     Abstract available


  732. ALEKSONIS HA, Krishnamurthy LC, King TZ
    White matter hyperintensity volumes are related to processing speed in long-term survivors of childhood cerebellar tumors.
    J Neurooncol. 2021;154:63-72.
    PubMed     Abstract available


  733. SAITO M, Wages NA, Schiff D
    Incidence, risk factors and management of venous thromboembolism in patients with primary CNS lymphoma.
    J Neurooncol. 2021;154:41-47.
    PubMed     Abstract available


    July 2021
  734. TAKIGAWA K, Hata N, Michiwaki Y, Hiwatashi A, et al
    Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.
    J Neurooncol. 2021 Jul 28. pii: 10.1007/s11060-021-03812.
    PubMed     Abstract available


  735. LIN MR, Chen PY, Wang HC, Lin PC, et al
    Prevalence of sleep disturbances and their effects on quality of life in adults with untreated pituitary tumor and meningioma.
    J Neurooncol. 2021 Jul 24. pii: 10.1007/s11060-021-03811.
    PubMed     Abstract available


  736. OGINO A, Niranjan A, Kano H, Flickinger JC, et al
    Optimizing stereotactic radiosurgery in patients with recurrent or residual craniopharyngiomas.
    J Neurooncol. 2021 Jul 20. pii: 10.1007/s11060-021-03806.
    PubMed     Abstract available


  737. LEE EJ, Choi KS, Park ES, Cho YH, et al
    Single- and hypofractionated stereotactic radiosurgery for large (> 2 cm) brain metastases: a systematic review.
    J Neurooncol. 2021 Jul 15. pii: 10.1007/s11060-021-03805.
    PubMed     Abstract available


  738. BUNEVICIUS A, Pikis S, Padilla F, Prada F, et al
    Sonodynamic therapy for gliomas.
    J Neurooncol. 2021 Jul 12. pii: 10.1007/s11060-021-03807.
    PubMed     Abstract available


  739. PALMISCIANO P, Haider AS, Nwagwu CD, Wahood W, et al
    Bevacizumab vs laser interstitial thermal therapy in cerebral radiation necrosis from brain metastases: a systematic review and meta-analysis.
    J Neurooncol. 2021 Jul 3. pii: 10.1007/s11060-021-03802.
    PubMed     Abstract available


  740. LIU IC, Holtzman AL, Rotondo RL, Indelicato DJ, et al
    Correction to: Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes.
    J Neurooncol. 2021 Jul 1. pii: 10.1007/s11060-021-03798.
    PubMed    


  741. VAN OPIJNEN MP, van der Meer PB, Dirven L, Fiocco M, et al
    The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide.
    J Neurooncol. 2021 Jul 1. pii: 10.1007/s11060-021-03800.
    PubMed     Abstract available


  742. MEHTA GU, Barone AK, Bradford D, Larkins E, et al
    US Food and Drug Administration regulatory updates in neuro-oncology.
    J Neurooncol. 2021;153:375-381.
    PubMed     Abstract available


  743. BUSH NAO, Young JS, Zhang Y, Dalle Ore CL, et al
    A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma.
    J Neurooncol. 2021;153:447-454.
    PubMed     Abstract available


  744. JOHNSON RA, Do TH, Palzer EF, Cramer SW, et al
    Pattern of technology diffusion in the adoption of stereotactic laser interstitial thermal therapy (LITT) in neuro-oncology.
    J Neurooncol. 2021;153:417-424.
    PubMed     Abstract available


    June 2021
  745. AHN SS, An C, Park YW, Han K, et al
    Identification of magnetic resonance imaging features for the prediction of molecular profiles of newly diagnosed glioblastoma.
    J Neurooncol. 2021 Jun 30. pii: 10.1007/s11060-021-03801.
    PubMed     Abstract available


  746. MAREIKE M, Franziska SB, Julia E, Daniel H, et al
    Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
    J Neurooncol. 2021 Jun 29. pii: 10.1007/s11060-021-03794.
    PubMed     Abstract available


  747. VAN RUITENBEEK NJ, Ho VKY, Westgeest HM, Beerepoot LV, et al
    Validation of the updated renal graded prognostic assessment (GPA) for patients with renal cancer brain metastases treated with gamma knife radiosurgery.
    J Neurooncol. 2021 Jun 25. pii: 10.1007/s11060-021-03793.
    PubMed     Abstract available


  748. PORPER K, Shpatz Y, Plotkin L, Pechthold RG, et al
    A Phase I clinical trial of dose-escalated metabolic therapy combined with concomitant radiation therapy in high-grade glioma.
    J Neurooncol. 2021 Jun 21. pii: 10.1007/s11060-021-03786.
    PubMed     Abstract available


  749. CHO A, Untersteiner H, Fitschek F, Khalaveh F, et al
    The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumor.
    J Neurooncol. 2021 Jun 20. pii: 10.1007/s11060-021-03788.
    PubMed     Abstract available


  750. BETTAG C, Hussein A, Sachkova A, Bock HC, et al
    Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system.
    J Neurooncol. 2021 Jun 20. pii: 10.1007/s11060-021-03792.
    PubMed     Abstract available


  751. NEWMAN WC, Goldberg J, Guadix SW, Brown S, et al
    The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes.
    J Neurooncol. 2021 Jun 19. pii: 10.1007/s11060-021-03790.
    PubMed     Abstract available


  752. ROSSO DA, Rosato M, Iturrizaga J, Gonzalez N, et al
    Glioblastoma cells potentiate the induction of the Th1-like profile in phosphoantigen-stimulated gammadelta T lymphocytes.
    J Neurooncol. 2021 Jun 14. pii: 10.1007/s11060-021-03787.
    PubMed     Abstract available


  753. LIU IH, Holtzman AL, Rotondo RL, Indelicato DJ, et al
    Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes.
    J Neurooncol. 2021 Jun 8. pii: 10.1007/s11060-021-03783.
    PubMed     Abstract available


  754. CASTRO M, Pampana A, Alam A, Parashar R, et al
    Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit.
    J Neurooncol. 2021 Jun 8. pii: 10.1007/s11060-021-03780.
    PubMed     Abstract available


  755. CHEN YL, Huang AP, Wang CC, Chen HY, et al
    Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis.
    J Neurooncol. 2021 Jun 7. pii: 10.1007/s11060-021-03782.
    PubMed     Abstract available


  756. ADELON J, Dufour C, Foulon S, Masliah Planchon J, et al
    What does a non-response to induction chemotherapy imply in high-risk medulloblastomas?
    J Neurooncol. 2021 Jun 2. pii: 10.1007/s11060-021-03777.
    PubMed     Abstract available


  757. LEE MH, Hur KY, Hong SD, Seol HJ, et al
    Early hormonal recovery following endoscopic transsphenoidal surgery for silent non-functioning pituitary adenomas with hormone dysfunction.
    J Neurooncol. 2021;153:343-350.
    PubMed     Abstract available


  758. RODRIGUES A, Bhambhvani H, Medress ZA, Malhotra S, et al
    Differences in treatment patterns and overall survival between grade II and anaplastic pleomorphic xanthoastrocytomas.
    J Neurooncol. 2021;153:321-330.
    PubMed     Abstract available


  759. SHEEHAN D, Sheehan K, Sheehan J
    Sonodynamic therapy for metastatic melanoma to the brain.
    J Neurooncol. 2021;153:373-374.
    PubMed    


  760. WELLER J, Katzendobler S, Karschnia P, Lietke S, et al
    PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.
    J Neurooncol. 2021;153:283-291.
    PubMed     Abstract available


    May 2021
  761. EICHBERG DG, Slepak TI, Pascoini AL, Komotar RJ, et al
    Genetic manipulation of adhesion GPCR CD97/ADGRE5 modulates invasion in patient-derived glioma stem cells.
    J Neurooncol. 2021 May 24. pii: 10.1007/s11060-021-03778.
    PubMed     Abstract available


  762. DIJKSTRA BM, de Jong M, Stroet MCM, Andreae F, et al
    Correction to: Evaluation of Ac-Lys(0)(IRDye800CW)Tyr(3)-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma.
    J Neurooncol. 2021 May 20. pii: 10.1007/s11060-021-03769.
    PubMed    


  763. MOTOMURA K, Chalise L, Ohka F, Aoki K, et al
    Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping.
    J Neurooncol. 2021 May 19. pii: 10.1007/s11060-021-03776.
    PubMed     Abstract available


  764. OYA S, Ikawa F, Ichihara N, Wanibuchi M, et al
    Effect of adjuvant radiotherapy after subtotal resection for WHO grade I meningioma: a propensity score matching analysis of the Brain Tumor Registry of Japan.
    J Neurooncol. 2021 May 17. pii: 10.1007/s11060-021-03775.
    PubMed     Abstract available


  765. ZHONG J, Huang V, Gurbani SS, Ramesh K, et al
    3D whole-brain metabolite imaging to improve characterization of low-to-intermediate grade gliomas.
    J Neurooncol. 2021 May 13. pii: 10.1007/s11060-021-03770.
    PubMed     Abstract available


  766. FATIMA N, Shin JH, Curry WT, Chang SD, et al
    Microsurgical resection of foramen magnum meningioma: multi-institutional retrospective case series and proposed surgical risk scoring system.
    J Neurooncol. 2021 May 10. pii: 10.1007/s11060-021-03773.
    PubMed     Abstract available


  767. KRAUSS WE, Yolcu YU, Alvi MA, Moinuddin FM, et al
    Clinical characteristics and management differences for grade II and III spinal meningiomas.
    J Neurooncol. 2021 May 10. pii: 10.1007/s11060-021-03771.
    PubMed     Abstract available


  768. CROTTY EE, Smith SMC, Brasel K, Pakiam F, et al
    Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival.
    J Neurooncol. 2021 May 8. pii: 10.1007/s11060-021-03767.
    PubMed     Abstract available


  769. EL-KHOULY FE, Veldhuijzen van Zanten SEM, Jansen MHA, Bakker DP, et al
    A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma.
    J Neurooncol. 2021 May 7. pii: 10.1007/s11060-021-03763.
    PubMed     Abstract available


  770. CORONA AM, Di L, Shah AH, Crespo R, et al
    Current experimental therapies for atypical and malignant meningiomas.
    J Neurooncol. 2021 May 5. pii: 10.1007/s11060-021-03759.
    PubMed     Abstract available


  771. RUTTENS D, Messiaen J, Ferster A, Piette C, et al
    Retrospective study of diffuse intrinsic pontine glioma in the Belgian population: a 25 year experience.
    J Neurooncol. 2021 May 3. pii: 10.1007/s11060-021-03766.
    PubMed     Abstract available


  772. SANDLER CX, Matsuyama M, Jones TL, Bashford J, et al
    Physical activity and exercise in adults diagnosed with primary brain cancer: a systematic review.
    J Neurooncol. 2021;153:1-14.
    PubMed     Abstract available


  773. BENDER K, Perez E, Chirica M, Onken J, et al
    High-grade astrocytoma with piloid features (HGAP): the Charite experience with a new central nervous system tumor entity.
    J Neurooncol. 2021;153:109-120.
    PubMed     Abstract available


  774. ELTOBGY M, Huntoon K, Musgrave N, Shaikhouni A, et al
    Impact of cerebrospinal fluid flow study in patients undergoing intrathecal chemotherapy via ventricular catheter reservoir.
    J Neurooncol. 2021;153:161-167.
    PubMed     Abstract available


  775. RAUCH M, Tausch D, Stera S, Blanck O, et al
    MRI characteristics in treatment for cerebral melanoma metastasis using stereotactic radiosurgery and concomitant checkpoint inhibitors or targeted therapeutics.
    J Neurooncol. 2021;153:79-87.
    PubMed     Abstract available


  776. NIEBLAS-BEDOLLA E, Christophers B, Williams JR, Power-Hays A, et al
    Racial and ethnic disparities among children with primary central nervous system tumors in the US.
    J Neurooncol. 2021;152:451-466.
    PubMed     Abstract available


  777. LEE CY, Soliman H, Bragagnolo ND, Sahgal A, et al
    Predicting response to radiotherapy of intracranial metastases with hyperpolarized [Formula: see text]C MRI.
    J Neurooncol. 2021;152:551-557.
    PubMed     Abstract available


  778. MONTERO AS, Tran S, Amelot A, Berriat F, et al
    Clinical characteristics and long-term surgical outcome of spinal myxopapillary ependymoma: a French cohort of 101 patients.
    J Neurooncol. 2021;152:491-499.
    PubMed     Abstract available


    April 2021
  779. DASGUPTA A, Geraghty B, Maralani PJ, Malik N, et al
    Quantitative mapping of individual voxels in the peritumoral region of IDH-wildtype glioblastoma to distinguish between tumor infiltration and edema.
    J Neurooncol. 2021 Apr 27. pii: 10.1007/s11060-021-03762.
    PubMed     Abstract available


  780. AVADIAPPAN S, Morrison MA, Jakary A, Felton E, et al
    Relationship between 7T MR-angiography features of vascular injury and cognitive decline in young brain tumor patients treated with radiation therapy.
    J Neurooncol. 2021 Apr 24. pii: 10.1007/s11060-021-03753.
    PubMed     Abstract available


  781. SONG J, Aljabab S, Abduljabbar L, Tseng YD, et al
    Radiation-induced brain injury in patients with meningioma treated with proton or photon therapy.
    J Neurooncol. 2021 Apr 22. pii: 10.1007/s11060-021-03758.
    PubMed     Abstract available


  782. GILLESPIE CS, Islim AI, Taweel BA, Millward CP, et al
    The growth rate and clinical outcomes of radiation induced meningioma undergoing treatment or active monitoring.
    J Neurooncol. 2021 Apr 22. pii: 10.1007/s11060-021-03761.
    PubMed     Abstract available


  783. DONO A, Mitra S, Shah M, Takayasu T, et al
    PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.
    J Neurooncol. 2021 Apr 21. pii: 10.1007/s11060-021-03755.
    PubMed     Abstract available


  784. CHO YA, Kim D, Lee B, Shim JH, et al
    Incidence, clinicopathologic, and genetic characteristics of mismatch repair gene-mutated glioblastomas.
    J Neurooncol. 2021 Apr 17. pii: 10.1007/s11060-021-03710.
    PubMed     Abstract available


  785. O'KEEFFE D, Bambury RM, O'Reilly S
    High grade glioma and caregiver burden.
    J Neurooncol. 2021 Apr 15. pii: 10.1007/s11060-021-03754.
    PubMed    


  786. SCHEURING UJ, Ritter S, Martin D, Schackert G, et al
    GliPR1 knockdown by RNA interference exerts anti-glioma effects in vitro and in vivo.
    J Neurooncol. 2021 Apr 15. pii: 10.1007/s11060-021-03737.
    PubMed     Abstract available


  787. RUSTE V, Sunyach MP, Tanguy R, Jouanneau E, et al
    Synchronous brain metastases as a poor prognosis factor in clear cell renal carcinoma: a strong argument for systematic brain screening.
    J Neurooncol. 2021 Apr 10. pii: 10.1007/s11060-021-03751.
    PubMed     Abstract available


  788. VAN DER MEER PB, Koekkoek JAF, van den Bent MJ, Dirven L, et al
    Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints.
    J Neurooncol. 2021 Apr 6. pii: 10.1007/s11060-021-03747.
    PubMed     Abstract available


  789. RUTENBERG MS, Rotondo RL, Rao D, Holtzman AL, et al
    Correction to: Clinical outcomes following proton therapy for adult craniopharyngioma: a singleinstitution cohort study.
    J Neurooncol. 2021;152:415.
    PubMed    


  790. BARONI LV, Oller A, Freytes CS, Sampor CV, et al
    Intracranial germ cells tumour: a single institution experience in Argentina.
    J Neurooncol. 2021;152:363-372.
    PubMed     Abstract available


  791. ZHANG L, Chen W, Ding C, Hu Y, et al
    Gamma Knife radiosurgery as the initial treatment for elderly patients with nonfunctioning pituitary adenomas.
    J Neurooncol. 2021;152:257-264.
    PubMed     Abstract available


  792. CHIBA K, Aihara Y, Kawamata T
    Precise detection of the germinomatous component of intracranial germ cell tumors of the basal ganglia and thalamus using placental alkaline phosphatase in cerebrospinal fluid.
    J Neurooncol. 2021;152:405-413.
    PubMed     Abstract available


  793. VAN DER MEULEN M, Dirven L, Bakunina K, van den Bent MJ, et al
    MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma.
    J Neurooncol. 2021;152:357-362.
    PubMed     Abstract available


  794. TORDJMAN M, Madelin G, Gupta PK, Cordova C, et al
    Functional connectivity of the default mode, dorsal attention and fronto-parietal executive control networks in glial tumor patients.
    J Neurooncol. 2021;152:347-355.
    PubMed     Abstract available


  795. ASHER AL, Alvi MA, Bydon M, Pouratian N, et al
    Local failure after stereotactic radiosurgery (SRS) for intracranial metastasis: analysis from a cooperative, prospective national registry.
    J Neurooncol. 2021;152:299-311.
    PubMed     Abstract available


    March 2021
  796. BRENNAN PM, Borchert R, Coulter C, Critchley GR, et al
    Second surgery for progressive glioblastoma: a multi-centre questionnaire and cohort-based review of clinical decision-making and patient outcomes in current practice.
    J Neurooncol. 2021 Mar 31. pii: 10.1007/s11060-021-03748.
    PubMed     Abstract available


  797. LE VAN T, Graillon T, Jacob J, Vauleon E, et al
    Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort.
    J Neurooncol. 2021 Mar 28. pii: 10.1007/s11060-021-03741.
    PubMed     Abstract available


  798. MARTINEZ-PEREZ R, Florez-Perdomo W, Freeman L, Ung TH, et al
    Long-term disease control and treatment outcomes of stereotactic radiosurgery in cavernous sinus meningiomas.
    J Neurooncol. 2021 Mar 27. pii: 10.1007/s11060-021-03732.
    PubMed     Abstract available


  799. DIJKSTRA BM, de Jong M, Stroet MCM, Andreae F, et al
    Evaluation of Ac-Lys(0)(IRDye800CW)Tyr(3)-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma.
    J Neurooncol. 2021 Mar 26. pii: 10.1007/s11060-021-03739.
    PubMed     Abstract available


  800. ARUN S, Ravisankar S, Vanisree AJ
    Correction to: Implication of connexin30 on the stemness of glioma: connexin30 reverses the malignant phenotype of glioma by modulating IGF-1R, CD133 and cMyc.
    J Neurooncol. 2021 Mar 24. pii: 10.1007/s11060-021-03743.
    PubMed    


  801. OSTROM QT, Krebs HL, Patil N, Cioffi G, et al
    Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US.
    J Neurooncol. 2021 Mar 23. pii: 10.1007/s11060-021-03736.
    PubMed     Abstract available


  802. RITTERBUSCH R, Halasz LM, Graber JJ
    Distinct imaging patterns of pseudoprogression in glioma patients following proton versus photon radiation therapy.
    J Neurooncol. 2021 Mar 22. pii: 10.1007/s11060-021-03734.
    PubMed     Abstract available


  803. TABOR JK, Bonda D, LeMonda BC, D'Amico RS, et al
    Neuropsychological outcomes following supratotal resection for high-grade glioma: a review.
    J Neurooncol. 2021 Mar 21. pii: 10.1007/s11060-021-03731.
    PubMed     Abstract available


  804. VERMANDEL M, Dupont C, Lecomte F, Leroy HA, et al
    Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial.
    J Neurooncol. 2021 Mar 20. pii: 10.1007/s11060-021-03718.
    PubMed     Abstract available


  805. FULBERT C, Chabardes S, Ratel D
    Adjuvant therapeutic potential of moderate hypothermia for glioblastoma.
    J Neurooncol. 2021 Mar 19. pii: 10.1007/s11060-021-03704.
    PubMed     Abstract available


  806. MILLS MN, Thawani C, Figura NB, Oliver DE, et al
    Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases.
    J Neurooncol. 2021 Mar 19. pii: 10.1007/s11060-021-03735.
    PubMed     Abstract available


  807. SHIRVALILOU S, Khoei S, Esfahani AJ, Kamali M, et al
    Magnetic Hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: a systematic review.
    J Neurooncol. 2021 Mar 13. pii: 10.1007/s11060-021-03729.
    PubMed     Abstract available


  808. MALLA RR, Gopinath S, Gondi CS, Alapati K, et al
    Retraction Note to: uPAR and cathepsin B downregulation induces apoptosis by targeting calcineurin A to BAD via Bcl-2 in glioma.
    J Neurooncol. 2021 Mar 12. pii: 10.1007/s11060-021-03722.
    PubMed    


  809. TATEKAWA H, Uetani H, Hagiwara A, Yao J, et al
    Preferential tumor localization in relation to (18)F-FDOPA uptake for lower-grade gliomas.
    J Neurooncol. 2021 Mar 11. pii: 10.1007/s11060-021-03730.
    PubMed     Abstract available


  810. NAUNG H, Cohen KJ
    An intrathecal limited postoperative chemotherapy regimen for the treatment of young children with nodular/desmoplastic medulloblastoma and medulloblastoma with extensive nodularity.
    J Neurooncol. 2021 Mar 10. pii: 10.1007/s11060-021-03727.
    PubMed     Abstract available


  811. AHN J, Bunevicius A, Sheehan J
    Spontaneous pneumocephalus associated with a melanoma brain metastasis: a Case Report.
    J Neurooncol. 2021 Mar 9. pii: 10.1007/s11060-021-03728.
    PubMed    


  812. BURTH S, Ohmann M, Kronsteiner D, Kieser M, et al
    Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?
    J Neurooncol. 2021 Mar 5. pii: 10.1007/s11060-021-03716.
    PubMed     Abstract available


  813. PATEL SH, Batchala PP, Muttikkal TJE, Ferrante SS, et al
    Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.
    J Neurooncol. 2021 Mar 4. pii: 10.1007/s11060-021-03720.
    PubMed     Abstract available


  814. KURDI M, Butt NS, Baeesa S, Alghamdi B, et al
    Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
    J Neurooncol. 2021 Mar 4. pii: 10.1007/s11060-021-03723.
    PubMed     Abstract available


  815. MAIR MJ, Kiesel B, Feldmann K, Widhalm G, et al
    LAG-3 expression in the inflammatory microenvironment of glioma.
    J Neurooncol. 2021 Mar 2. pii: 10.1007/s11060-021-03721.
    PubMed     Abstract available


  816. LIM-FAT MJ, Song KW, Iorgulescu JB, Andersen BM, et al
    Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.
    J Neurooncol. 2021 Mar 1. pii: 10.1007/s11060-021-03719.
    PubMed     Abstract available


  817. DEWIRE M, Erker C, Hummel TR, Chow LML, et al
    Overcoming barriers to establishing autopsy procurement programs in pediatric patients with central nervous system tumors: a call to develop regional centers.
    J Neurooncol. 2021;152:107-114.
    PubMed     Abstract available


  818. AMER N, Taha H, Hesham D, Al-Shehaby N, et al
    Aggresomes predict poor outcomes and implicate proteostasis in the pathogenesis of pediatric choroid plexus tumors.
    J Neurooncol. 2021;152:67-78.
    PubMed     Abstract available


    February 2021
  819. UNTERBERGER A, Nguyen T, Duong C, Kondajji A, et al
    Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas.
    J Neurooncol. 2021 Feb 26. pii: 10.1007/s11060-020-03674.
    PubMed     Abstract available


  820. KRAFT J, Mayinger M, Willmann J, Brown M, et al
    Management of multiple brain metastases: a patterns of care survey within the German Society for Radiation Oncology.
    J Neurooncol. 2021 Feb 23. pii: 10.1007/s11060-021-03714.
    PubMed     Abstract available


  821. MOMIN AA, Shao J, Soni P, Almeida JP, et al
    Outcomes of salvage radiation for recurrent world health organization grade II meningiomas: a retrospective cohort study.
    J Neurooncol. 2021 Feb 15. pii: 10.1007/s11060-021-03711.
    PubMed     Abstract available


  822. HOLUB K, Louvel G
    Poor performance status and brain metastases treatment: who may benefit from the stereotactic radiotherapy?
    J Neurooncol. 2021 Feb 15. pii: 10.1007/s11060-021-03712.
    PubMed     Abstract available


  823. CIFARELLI CP, Jacques A, Bobko A
    Heterogeneity of radiation response in mesenchymal subtype glioblastoma: molecular profiling and reactive oxygen species generation.
    J Neurooncol. 2021 Feb 10. pii: 10.1007/s11060-021-03707.
    PubMed     Abstract available


  824. BORGER V, Hamed M, Ilic I, Potthoff AL, et al
    Seizure outcome in temporal glioblastoma surgery: lobectomy as a supratotal resection regime outclasses conventional gross-total resection.
    J Neurooncol. 2021 Feb 7. pii: 10.1007/s11060-021-03705.
    PubMed     Abstract available


  825. PRZYBYLOWSKI CJ, Hervey-Jumper SL, Sanai N
    Surgical strategy for insular glioma.
    J Neurooncol. 2021;151:491-497.
    PubMed     Abstract available


  826. ROGERS CM, Jones PS, Weinberg JS
    Intraoperative MRI for Brain Tumors.
    J Neurooncol. 2021;151:479-490.
    PubMed     Abstract available


  827. KARIMI S, Mansouri S, Nassiri F, Bunda S, et al
    Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status.
    J Neurooncol. 2021;151:443-449.
    PubMed     Abstract available


  828. D'AMICO RS, Aghi MK, Vogelbaum MA, Bruce JN, et al
    Convection-enhanced drug delivery for glioblastoma: a review.
    J Neurooncol. 2021;151:415-427.
    PubMed     Abstract available


  829. HOLLON T, Orringer DA
    Label-free brain tumor imaging using Raman-based methods.
    J Neurooncol. 2021;151:393-402.
    PubMed     Abstract available


  830. CHAN HY, Choi J, Jackson C, Lim M, et al
    Combination immunotherapy strategies for glioblastoma.
    J Neurooncol. 2021;151:375-391.
    PubMed     Abstract available


  831. MARTINEZ-PEREZ R, Requena LC, Carrau RL, Prevedello DM, et al
    Modern endoscopic skull base neurosurgery.
    J Neurooncol. 2021;151:461-475.
    PubMed     Abstract available


  832. CHEN C, Lee I, Tatsui C, Elder T, et al
    Laser interstitial thermotherapy (LITT) for the treatment of tumors of the brain and spine: a brief review.
    J Neurooncol. 2021;151:429-442.
    PubMed     Abstract available


  833. LAKOMKIN N, Van Gompel JJ, Post KD, Cho SS, et al
    Fluorescence guided surgery for pituitary adenomas.
    J Neurooncol. 2021;151:403-413.
    PubMed     Abstract available


  834. VOGELBAUM MA, Parney IF, Elder JB, Cahill D, et al
    Neurosurgical involvement in clinical trials for CNS tumors.
    J Neurooncol. 2021;151:367-373.
    PubMed     Abstract available


  835. BANDER ED, Sherman JH, Bettegowda C, Aghi MK, et al
    Beyond guidelines: analysis of current practice patterns of AANS/CNS tumor neurosurgeons.
    J Neurooncol. 2021;151:361-366.
    PubMed     Abstract available


  836. REDJAL N, Venteicher AS, Dang D, Sloan A, et al
    Guidelines in the management of CNS tumors.
    J Neurooncol. 2021;151:345-359.
    PubMed     Abstract available


  837. GERMANO IM, Heth J, Jones PS, Aghi MK, et al
    Introduction to special issue dedicated to the 35th anniversary of the joint section on tumors.
    J Neurooncol. 2021;151:341-343.
    PubMed     Abstract available


    January 2021
  838. VAIDYA KS, Mitten MJ, Zelaya-Lazo AL, Oleksijew A, et al
    Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
    J Neurooncol. 2021 Jan 30. pii: 10.1007/s11060-021-03703.
    PubMed     Abstract available


  839. MEDIKONDA R, Srivastava S, Kim T, Xia Y, et al
    Development of new brain metastases in triple negative breast cancer.
    J Neurooncol. 2021 Jan 29. pii: 10.1007/s11060-021-03702.
    PubMed     Abstract available


  840. KOMMERS I, Ackermans L, Ardon H, van den Brink WA, et al
    Between-hospital variation in rates of complications and decline of patient performance after glioblastoma surgery in the dutch Quality Registry Neuro Surgery.
    J Neurooncol. 2021 Jan 28. pii: 10.1007/s11060-021-03697.
    PubMed     Abstract available


  841. SAUNDERS JT, Holmes B, Benavides-Serrato A, Kumar S, et al
    Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
    J Neurooncol. 2021 Jan 28. pii: 10.1007/s11060-021-03699.
    PubMed     Abstract available


  842. KEBIR S, Rauschenbach L, Weber M, Lazaridis L, et al
    Machine learning-based differentiation between multiple sclerosis and glioma WHO II degrees -IV degrees using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography.
    J Neurooncol. 2021 Jan 27. pii: 10.1007/s11060-021-03701.
    PubMed     Abstract available


  843. DONO A, Amsbaugh M, Martir M, Smilie RH, et al
    Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma.
    J Neurooncol. 2021 Jan 25. pii: 10.1007/s11060-020-03689.
    PubMed     Abstract available


  844. BU L, Hameed NUF, Luo C, Hong P, et al
    Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.
    J Neurooncol. 2021 Jan 24. pii: 10.1007/s11060-020-03676.
    PubMed     Abstract available


  845. SHARMA A, Fruth B, Barrera C, Farfour HN, et al
    How much time do we have? Longitudinal perception of prognosis in newly-diagnosed high grade glioma patients and caregivers compared to clinicians.
    J Neurooncol. 2021 Jan 23. pii: 10.1007/s11060-021-03700.
    PubMed     Abstract available


  846. PATRIZZ A, Dono A, Zhu P, Tandon N, et al
    Tumor recurrence or treatment-related changes following chemoradiation in patients with glioblastoma: does pathology predict outcomes?
    J Neurooncol. 2021 Jan 22. pii: 10.1007/s11060-020-03690.
    PubMed     Abstract available


  847. HAEREN RHL, Rautalin I, Schwartz C, Korja M, et al
    Surgery on giant meningiomas in very old patients entails frequent postoperative intracranial hemorrhages and atypical histopathology.
    J Neurooncol. 2021 Jan 21. pii: 10.1007/s11060-020-03693.
    PubMed     Abstract available


  848. MALAIZE H, Samoyeau T, Zanello M, Roux A, et al
    Evolution of the neurosurgical management of progestin-associated meningiomas: a 23-year single-center experience.
    J Neurooncol. 2021 Jan 15. pii: 10.1007/s11060-021-03696.
    PubMed     Abstract available


  849. WEGNER RE, Abel S, D'Amico RS, Mehta GU, et al
    Time from stereotactic radiosurgery to immunotherapy in patients with melanoma brain metastases and impact on outcome.
    J Neurooncol. 2021 Jan 11. pii: 10.1007/s11060-020-03663.
    PubMed     Abstract available


  850. NOWAK-CHOI K, Palmer JD, Casey J, Chitale A, et al
    Resected WHO grade I meningioma and predictors of local control.
    J Neurooncol. 2021 Jan 9. pii: 10.1007/s11060-020-03688.
    PubMed     Abstract available


  851. FUJIOKA Y, Hata N, Akagi Y, Kuga D, et al
    Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
    J Neurooncol. 2021 Jan 8. pii: 10.1007/s11060-020-03682.
    PubMed     Abstract available


  852. ZHANG M, Rodrigues AJ, Pollom EL, Gibbs IC, et al
    Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
    J Neurooncol. 2021 Jan 7. pii: 10.1007/s11060-020-03686.
    PubMed     Abstract available


  853. GOMES I, Moreno DA, Dos Reis MB, da Silva LS, et al
    Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
    J Neurooncol. 2021 Jan 5. pii: 10.1007/s11060-020-03675.
    PubMed     Abstract available


  854. SHI W, Blumenthal DT, Bush NAO, Kebir S, et al
    Correction to: Global postmarketing safety surveillance of Tumor Treating Fields (TTFields) in patients with highgrade glioma in clinical practice.
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03681.
    PubMed    


  855. OLIVA MA, Staffieri S, Castaldo S, Giangaspero F, et al
    Characterization of primary glioma cell lines derived from the patients according to 2016 CNS tumour WHO classification and comparison with their parental tumours.
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03673.
    PubMed     Abstract available


  856. BRAHMBHATT N, Stupp R, Bushara O, Bachman E, et al
    Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy.
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03664.
    PubMed     Abstract available


  857. WUMMER B, Woodworth D, Flores C
    Brain stem gliomas and current landscape.
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03655.
    PubMed     Abstract available


  858. HABIB A, Pease M, Kodavali CV, Amankulor N, et al
    A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care.
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03671.
    PubMed     Abstract available


  859. CHAMPEAUX-DEPOND C, Weller J, Froelich S, Sartor A, et al
    Cyproterone acetate and meningioma: a nationwide-wide population based study.
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03672.
    PubMed     Abstract available


  860. CLAVREUL A, Aubin G, Delion M, Lemee JM, et al
    What effects does awake craniotomy have on functional and survival outcomes for glioblastoma patients?
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03666.
    PubMed     Abstract available


  861. VANMARCKE D, Menten J, Defraene G, Van Calenbergh F, et al
    Stroke rate after external fractionated radiotherapy for benign meningioma.
    J Neurooncol. 2021 Jan 4. pii: 10.1007/s11060-020-03678.
    PubMed     Abstract available


  862. SAMARUT E, Lugat A, Amelot A, Scharbarg E, et al
    Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma.
    J Neurooncol. 2021 Jan 3. pii: 10.1007/s11060-020-03683.
    PubMed     Abstract available


  863. NIMBALKAR VP, Kruthika BS, Sravya P, Rao S, et al
    Differential gene expression in peritumoral brain zone of glioblastoma: role of SERPINA3 in promoting invasion, stemness and radioresistance of glioma cells and association with poor patient prognosis and recurrence.
    J Neurooncol. 2021 Jan 3. pii: 10.1007/s11060-020-03685.
    PubMed     Abstract available


  864. BUNK EC, Wagner A, Stummer W, Senner V, et al
    5-ALA kinetics in meningiomas: analysis of tumor fluorescence and PpIX metabolism in vitro and comparative analyses with high-grade gliomas.
    J Neurooncol. 2021 Jan 3. pii: 10.1007/s11060-020-03680.
    PubMed     Abstract available


  865. HADDAD AF, Young JS, Mummaneni NV, Kasahara N, et al
    Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies.
    J Neurooncol. 2021 Jan 3. pii: 10.1007/s11060-020-03684.
    PubMed     Abstract available


  866. LEE D, Riestenberg RA, Haskell-Mendoza A, Bloch O, et al
    Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.
    J Neurooncol. 2021 Jan 3. pii: 10.1007/s11060-020-03677.
    PubMed     Abstract available


  867. LO YT, Ang YLS, Yang VS, Kanavathy DT, et al
    Motor deficits at presentation and predictors of overall survival in central nervous system lymphomas.
    J Neurooncol. 2021;151:295-306.
    PubMed     Abstract available


  868. SONI P, Shao J, Momin A, Lopez D, et al
    Clear cell histology portends a worse prognosis than other WHO grade II histologies.
    J Neurooncol. 2021;151:307-312.
    PubMed     Abstract available


  869. BONM AV, Gibson AW, Holmberg LA, Mielcarek M, et al
    A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
    J Neurooncol. 2021;151:193-200.
    PubMed     Abstract available


  870. SAMUEL N, Trifiletti DM, Quinones-Hinojosa A, Lunsford LD, et al
    Stereotactic radiosurgery training patterns across neurosurgical programs: a multi-national survey.
    J Neurooncol. 2021;151:325-330.
    PubMed     Abstract available


  871. SAVOOR R, Sita TL, Dahdaleh NS, Helenowski I, et al
    Long-term outcomes of spinal ependymomas: an institutional experience of more than 60 cases.
    J Neurooncol. 2021;151:241-247.
    PubMed     Abstract available


  872. SARID N, Bokstein F, Blumenthal DT, Weiss-Meilik A, et al
    Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients.
    J Neurooncol. 2021;151:211-220.
    PubMed     Abstract available


  873. BUTENSCHOEN VM, Hubertus V, Janssen IK, Onken J, et al
    Surgical treatment and neurological outcome of infiltrating intramedullary astrocytoma WHO II-IV: a multicenter retrospective case series.
    J Neurooncol. 2021;151:181-191.
    PubMed     Abstract available


  874. BECCARIA K, Sabbagh A, de Groot J, Canney M, et al
    Blood-brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors.
    J Neurooncol. 2021;151:65-73.
    PubMed     Abstract available


    November 2020
  875. FAN KY, Lalani N, LeVasseur N, Krauze A, et al
    Type and timing of systemic therapy use predict overall survival for patients with brain metastases treated with radiation therapy.
    J Neurooncol. 2020 Nov 18. pii: 10.1007/s11060-020-03657.
    PubMed     Abstract available


  876. POETSCH L, Bronnimann C, Loiseau H, Frenel JS, et al
    Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
    J Neurooncol. 2020 Nov 17. pii: 10.1007/s11060-020-03662.
    PubMed     Abstract available


  877. SONI P, Davison MA, Shao J, Momin A, et al
    Extent of resection and survival outcomes in World Health Organization grade II meningiomas.
    J Neurooncol. 2020 Nov 17. pii: 10.1007/s11060-020-03632.
    PubMed     Abstract available


  878. CHAN RW, Chen H, Myrehaug S, Atenafu EG, et al
    Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation.
    J Neurooncol. 2020 Nov 16. pii: 10.1007/s11060-020-03661.
    PubMed     Abstract available


  879. CHO A, Untersteiner H, Hirschmann D, Fitschek F, et al
    Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients.
    J Neurooncol. 2020 Nov 11. pii: 10.1007/s11060-020-03660.
    PubMed     Abstract available


  880. NAKADA M, Nakajima R, Okita H, Nakade Y, et al
    Awake surgery for right frontal lobe glioma can preserve visuospatial cognition and spatial working memory.
    J Neurooncol. 2020 Nov 2. pii: 10.1007/s11060-020-03656.
    PubMed     Abstract available


  881. FARRELL C, Shi W, Bodman A, Olson JJ, et al
    Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.
    J Neurooncol. 2020;150:269-359.
    PubMed     Abstract available


  882. ZIU M, Kim BYS, Jiang W, Ryken T, et al
    The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
    J Neurooncol. 2020;150:215-267.
    PubMed     Abstract available


  883. REDJAL N, Nahed BV, Dietrich J, Kalkanis SN, et al
    Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults.
    J Neurooncol. 2020;150:165-213.
    PubMed     Abstract available


  884. VELAZQUEZ VEGA JE, Brat DJ, Ryken TC, Olson JJ, et al
    The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.
    J Neurooncol. 2020;150:143-164.
    PubMed     Abstract available


  885. DOMINO JS, Ormond DR, Germano IM, Sami M, et al
    Cytoreductive surgery in the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update.
    J Neurooncol. 2020;150:121-142.
    PubMed     Abstract available


  886. LUNDY P, Domino J, Ryken T, Fouke S, et al
    The role of imaging for the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update.
    J Neurooncol. 2020;150:95-120.
    PubMed     Abstract available


  887. OLSON JJ, Ryken TC
    Congress of neurological surgeons systematic review and evidence-based clinical practice parameter guidelines for the treatment of adults with newly diagnosed glioblastoma: Introduction and Methods.
    J Neurooncol. 2020;150:87-93.
    PubMed     Abstract available


    October 2020
  888. CHANG L, Wang J, Zhou F, Wang D, et al
    LncRNA RP11-84E24.3 drives tumorigenesis and epithelial-to-mesenchymal transition of glioma cells by promoting TFAP2C-mediated activation of SNAI1.
    J Neurooncol. 2020 Oct 30. pii: 10.1007/s11060-020-03624.
    PubMed     Abstract available


  889. RAHMAN M, Parney I
    Journal of Neuro Oncology: immunotherapy for brain tumors.
    J Neurooncol. 2020 Oct 20. pii: 10.1007/s11060-020-03589.
    PubMed    


  890. ZAMANIPOOR NAJAFABADI AH, van der Meer PB, Boele FW, Taphoorn MJB, et al
    Determinants and predictors for the long-term disease burden of intracranial meningioma patients.
    J Neurooncol. 2020 Oct 19. pii: 10.1007/s11060-020-03650.
    PubMed     Abstract available


  891. HE W, Liu Z, Teng H, Tang L, et al
    Pediatric meningiomas: 10-year experience with 39 patients.
    J Neurooncol. 2020 Oct 16. pii: 10.1007/s11060-020-03649.
    PubMed     Abstract available


  892. MCABEE JH, Degorre-Kerbaul C, Valdez K, Wendler A, et al
    Detection of glioblastoma intratumor heterogeneity in radiosensitivity using patient-derived neurosphere cultures.
    J Neurooncol. 2020 Oct 15. pii: 10.1007/s11060-020-03643.
    PubMed     Abstract available


  893. HIPP SJ, Goldman S, Kaushal A, Krauze A, et al
    A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas.
    J Neurooncol. 2020 Oct 11. pii: 10.1007/s11060-020-03627.
    PubMed     Abstract available


  894. DEWIRE M, Fuller C, Hummel TR, Chow LML, et al
    A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
    J Neurooncol. 2020 Oct 9. pii: 10.1007/s11060-020-03641.
    PubMed     Abstract available


  895. SONG Y, Hu Z, Long H, Peng Y, et al
    Correction to: A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.
    J Neurooncol. 2020 Oct 8. pii: 10.1007/s11060-020-03644.
    PubMed     Abstract available


  896. SELT F, van Tilburg CM, Bison B, Sievers P, et al
    Response to trametinib treatment in progressive pediatric low-grade glioma patients.
    J Neurooncol. 2020 Oct 7. pii: 10.1007/s11060-020-03640.
    PubMed     Abstract available


  897. MOROKOFF A, Jones J, Nguyen H, Ma C, et al
    Correction to: Serum microRNA is a biomarker for post-operative monitoring in glioma.
    J Neurooncol. 2020 Oct 7. pii: 10.1007/s11060-020-03630.
    PubMed     Abstract available


  898. DE TOMMASI C, Richardson E, Reale M, Jordan J, et al
    Evaluation of a novel application of a mindfulness phone application for patients with brain tumours: a feasibility study.
    J Neurooncol. 2020 Oct 6. pii: 10.1007/s11060-020-03638.
    PubMed     Abstract available


  899. DONO A, Vu J, Anapolsky M, Hines G, et al
    Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.
    J Neurooncol. 2020 Oct 3. pii: 10.1007/s11060-020-03634.
    PubMed     Abstract available


    September 2020
  900. SCHNEIDER M, Ilic I, Potthoff AL, Hamed M, et al
    Safety metric profiling in surgery for temporal glioblastoma: lobectomy as a supra-total resection regime preserves perioperative standard quality rates.
    J Neurooncol. 2020 Sep 29. pii: 10.1007/s11060-020-03629.
    PubMed     Abstract available


  901. SCHNEIDER M, Potthoff AL, Scharnbock E, Heimann M, et al
    Newly diagnosed glioblastoma in geriatric (65 +) patients: impact of patients frailty, comorbidity burden and obesity on overall survival.
    J Neurooncol. 2020 Sep 29. pii: 10.1007/s11060-020-03625.
    PubMed     Abstract available


  902. RAMOS-FRESNEDO A, Domingo RA, Vivas-Buitrago T, Lundy L, et al
    Multiple meningiomas: does quantity matter? a population-based survival analysis with underlined age and sex differences.
    J Neurooncol. 2020 Sep 28. pii: 10.1007/s11060-020-03620.
    PubMed     Abstract available


  903. DI PERRI D, Tanguy R, Malet C, Robert A, et al
    Risk of radiation necrosis after hypofractionated stereotactic radiotherapy (HFSRT) for brain metastases: a single center retrospective study.
    J Neurooncol. 2020 Sep 26. pii: 10.1007/s11060-020-03628.
    PubMed     Abstract available


  904. WEISS SA, Zito C, Tran T, Heishima K, et al
    Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases.
    J Neurooncol. 2020 Sep 24. pii: 10.1007/s11060-020-03619.
    PubMed     Abstract available


    June 2020
  905. SENEVIRATNE DS, Hadley AR, Peterson JL, Malouff TD, et al
    Assessment of unintended shifts during frame-based stereotactic radiosurgery using cone beam computed tomography image guidance.
    J Neurooncol. 2020;148:273-279.
    PubMed     Abstract available


  906. LIN YY, Wu HM, Yang HC, Chen CJ, et al
    Repeated gamma knife radiosurgery enables longer tumor control in cases of highly-recurrent intracranial ependymoma.
    J Neurooncol. 2020;148:363-372.
    PubMed     Abstract available


  907. BERTAUX M, Houillier C, Edeline V, Habert MO, et al
    Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study.
    J Neurooncol. 2020;148:343-352.
    PubMed     Abstract available


    May 2020
  908. SULEIMAN M, Bunevicius A, Sheehan J
    Stereotactic radiosurgery for management of recurring Choroid Plexus Metastases from Non-Small Cell Lung Carcinoma.
    J Neurooncol. 2020;148:207-209.
    PubMed    


  909. MICHAIEL G, Strother D, Gottardo N, Bartels U, et al
    Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature.
    J Neurooncol. 2020;147:721-730.
    PubMed     Abstract available


  910. WEIDMAN DR, Palasamudram S, Zak M, Whitney R, et al
    The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    J Neurooncol. 2020;147:731-736.
    PubMed     Abstract available


  911. YEUNG JT, Vesely MD, Miyagishima DF
    In silico analysis of the immunological landscape of pituitary adenomas.
    J Neurooncol. 2020;147:595-598.
    PubMed     Abstract available


  912. KANNO H, Yoshizumi T, Shinonaga M, Kubo A, et al
    Role of VHL-JAK-STAT signaling pathway in central nervous system hemangioblastoma associated with von Hippel-Lindau disease.
    J Neurooncol. 2020;148:29-38.
    PubMed     Abstract available


  913. MORSHED RA, Reihl SJ, Molinaro AM, Kakaizada S, et al
    The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment.
    J Neurooncol. 2020;148:131-139.
    PubMed     Abstract available


  914. CHEN TW, Jan IS, Chang DY, Lin CH, et al
    Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival.
    J Neurooncol. 2020;148:165-172.
    PubMed     Abstract available


  915. NATHAN NH, Connor M, Sizdahkhani S, Ding L, et al
    Increased 30-day readmission rate after craniotomy for tumor resection at safety net hospitals in small metropolitan areas.
    J Neurooncol. 2020;148:141-154.
    PubMed     Abstract available


  916. THOMAS C, Metrock K, Kordes U, Hasselblatt M, et al
    Epigenetics impacts upon prognosis and clinical management of choroid plexus tumors.
    J Neurooncol. 2020;148:39-45.
    PubMed     Abstract available


  917. MAIR MJ, Wohrer A, Furtner J, Simonovska A, et al
    Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma.
    J Neurooncol. 2020;148:187-198.
    PubMed     Abstract available


  918. WANG H, Wang R, Hu T, Wang Z, et al
    Nonfunctioning pituitary adenomas in pediatric and adolescent patients: a clinical analysis of a series of 14 patients.
    J Neurooncol. 2020;148:179-186.
    PubMed     Abstract available


    April 2020
  919. SHIN DW, Kim JH, Kim YH, Cho YH, et al
    Primary central nervous system lymphoma involving the hypothalamic-pituitary axis: a case series and pooled analysis.
    J Neurooncol. 2020;147:339-349.
    PubMed     Abstract available


  920. GUO Y, He X, Zhang M, Qu Y, et al
    Reciprocal control of ADAM17/EGFR/Akt signaling and miR-145 drives GBM invasiveness.
    J Neurooncol. 2020;147:327-337.
    PubMed     Abstract available


  921. WILLEKE VM, Anderson MP, Mahadevan A, Rojas R, et al
    Epstein Barr virus associated smooth muscle tumors in the central nervous system: a case report and systematic review of the literature.
    J Neurooncol. 2020;147:247-260.
    PubMed     Abstract available


  922. PATEL MP, Kirkpatrick JP, Johnson MO, Healy P, et al
    Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
    J Neurooncol. 2020;147:477-483.
    PubMed     Abstract available


  923. PALMER JD, Bhamidipati D, Shukla G, Epperla N, et al
    Outcomes after stereotactic radiosurgery for CNS lymphoma.
    J Neurooncol. 2020;147:465-476.
    PubMed     Abstract available


  924. D'AMICO RS, Khatri D, Reichman N, Patel NV, et al
    Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.
    J Neurooncol. 2020;147:261-278.
    PubMed     Abstract available


  925. GUPTA T, Maitre M, Gupta P, Krishnatry R, et al
    Extent of re-excision, sequence/timing of salvage re-irradiation, and disease-free interval impact upon clinical outcomes in recurrent/progressive ependymoma.
    J Neurooncol. 2020;147:405-415.
    PubMed     Abstract available


    March 2020
  926. AMBADY P, Fu R, Szidonya L, Peereboom DM, et al
    Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma.
    J Neurooncol. 2020;147:171-176.
    PubMed     Abstract available


  927. BETTE S, Gradtke CV, Cammardella JH, Albertshauser J, et al
    Perioperative neurocognitive functions in patients with neuroepithelial intracranial tumors.
    J Neurooncol. 2020;147:77-89.
    PubMed     Abstract available


  928. FERREIRA MSV, Sorensen MD, Pusch S, Beier D, et al
    Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    J Neurooncol. 2020;147:1-14.
    PubMed     Abstract available


    January 2020
  929. LUTHER EM, McCarthy D, Berry KM, Rajulapati N, et al
    Hospital teaching status associated with reduced inpatient mortality and perioperative complications in surgical neuro-oncology.
    J Neurooncol. 2020;146:389-396.
    PubMed     Abstract available


  930. NG S, Fomekong F, Delabar V, Jacquesson T, et al
    Current status and treatment modalities in metastases to the pituitary: a systematic review.
    J Neurooncol. 2020;146:219-227.
    PubMed     Abstract available


  931. AHSAN SA, Chendeb K, Briggs RG, Fletcher LR, et al
    Beyond eloquence and onto centrality: a new paradigm in planning supratentorial neurosurgery.
    J Neurooncol. 2020;146:229-238.
    PubMed     Abstract available


  932. UMEMURA Y, Wang D, Peck KK, Flynn J, et al
    DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy.
    J Neurooncol. 2020;146:339-346.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.